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Introduction: Military training environments are rigorous requiring service men and women to 
endure not only physical and psychological stress but also sleep deprivation, caloric restrictions, 
and severe thermic challenges. Exposure to these layered stressors are thought to improve human 
performance by acclimating the individuals to “real-world” operational stressors. It is difficult 
for scientists to identify pertinent immunoendocrine interactions occurring in layered stress 
environments because of considerable logistical constraints involving location of and access to 
affected personnel. The convention has been to use immunoendocrine responses induced by 
various exercise regimens as platforms to generalize results to the layered, and more exaggerated 
stress environments of military training. Methods: Three distinct experiments were conducted to 
understand immunoendocrine interactions resulting from layered stress environments. The first 
project investigated T cell proliferation following concurrent aerobic and resistance training as 
well as assessing changes in measures of proliferation following delayed cell isolation protocols. 
The second project examined whether the exercise models we use to generalize to military 
experiences are accurate. Eight healthy males underwent a high intensity training session 
combining physical and psychological stress similar to that experience in military operational 
training. A control group of 8 subjects participated in a moderate intensity session as 
comparison. Blood parameters were measured at Pre, Post, 1 hr, 4hr, and 6hr. The third project 
was an observational study examining immunoendocrine responses to the Marine Corps Martial 
Arts Training Program (MCMAP). Thirty-six newly enlisted, male Marines were observed three 
times over a nine-week period at Fort Leonard Wood, MO. Blood parameters were measured 
prior to training, Post training and at 15 min intervals out to 1 hr after training cessation. 
Conclusions: Immunoendocrine alterations following MCMAP sessions are in line with current 
laboratory findings that examine response to paired physical and psychological stressors 
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suggesting MCMAP may be a good real world analogue of laboratory based layered stress 
experiments. The higher intensity training sessions utilized in study two generated an enhanced 
proliferative response similar to that observed from exercise in competitive settings suggestive of 
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Acute bouts of moderate and high-intensity exercise induce transient shifts in peripheral 
blood biomarkers resulting from the combined physical and psychological demands of the given 
effort. Exercise-induced alterations of specific immune cell populations and hormonal 
concentrations are some of, if not the most, commonly reported effects in the field of exercise 
immunology. The most consistent of these effects is the rapid mobilization of leukocytes and 
lymphocytes into peripheral circulation during exercise (1-4). Disruptions in leukocyte 
trafficking are thought to result from multiple stimuli including shear forces and hydrostatic 
pressure from surges in cardiac output (5, 6), additional lymphatic fluid pushed out by forceful 
muscle contractions (5) and as a response to increased concentrations of catecholamines (7) and 
glucocorticoids (1) in the blood.  
Exercise-associated increases (lymphocytosis) and decreases (lymphocytopenia) in 
peripheral immune cell concentrations have been reported on extensively (8-10). Information 
regarding alterations in cell trafficking, however, offers little information about the overall 
immunocompetence of an individual following exercise. Upon encountering cognate antigen, a 
lymphocyte undergoes clonal expansion to increase the number of lymphocytes present with 
identical antigen specificity and defend the host from the threat (11). This proliferative capacity 
is a crucial feature of the adaptive immune response and a failure to do so in response to foreign 
antigen is indicative of impaired immune function (12). Because lymphocytes play a pivotal role 
in the immune response, it is important that investigations of susceptibility to infection following 
exercise be conducted within the context of proliferative capacity. 
Accumulated evidence indicates that singular encounters of a physically or 
psychologically stressful nature lead to increased concentrations of catecholamines and 
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glucocorticoids, both of which can suppress immune function. While interpreting data of this sort 
it is important to remember that in the everyday environment it is rare that an individual is 
exposed to only a physical or psychological challenge alone. Whether it is psychological stress 
as part of competition (i.e. competitive triathlon or marathon) or stress related to occupational 
hazards (i.e. firefighting or military operations), there are a variety of ways individuals 
experience simultaneous psychological and physical stress in practical scenarios. This 
combination of stressors will, for the purposes of this review, be referred to as a dual stress 
challenge. Recently, scientists have begun investigating the role of dual stress challenges on 
endocrine physiology and they are finding enhanced sympathetic activation and adrenal 
responses following dual stress challenges (13-16). The mechanism(s) for this type of 
exacerbated response are unknown but the response itself indicates there may be a synergistic 
interaction in the dual stress response. Quantification of the functional immune response to dual 
stress challenges can potentially improve our understanding and development of wellness 
interventions for high-stress occupations (i.e. firefighter, law enforcement, and military) that, by 
the very nature of the job, are repeatedly exposed to combined physical and psychological stress. 
Therefore, the aim of these studies is to provide a better understanding of changes in 
immunocompetence following exposure to dual stress challenges in humans.  
 
1.2 Specific Aims 
 
Immunoendocrine interactions derived from the physiological stress response have profound 
effects on performance, cognitive processes, and organismal health. Improved understanding of 
how immune function is altered in response to single and dual stress events of moderate and high 
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intensities will advance the field of exercise immunology, particularly in terms of the practical 
application of results.  
 This proposal consists of three separate projects. Study One investigates changes in 
immunocompetence following either an exercise or control condition. The emphasis will be 
placed on measuring T cell activation through cluster of differentiation (CD) 25, a surface 
marker specific to T cell activation. Study Two examines acute stress-induced changes in 
immune markers, including in vitro lymphocyte proliferation, following either a moderate 
intensity exercise trial or a vigorous layered stress challenge delivered in a military style 
environment. Study Three examines perturbations in immunoendocrine markers following 
Marine Corps Martial Arts training. 
 
1.2.1 Study 1: T cell Activation Following an Acute Bout of Concurrent Aerobic and 
Resistance Exercise 
 
T cell proliferation is a sequential process and few exercise-driven studies have 
investigated discrete elements of this sequence (17, 18). CD25, also known as the interleukin 2 
receptor (IL-2R), is linked to immune activation by way of its interaction with IL-2, a potent T 
cell growth factor (19, 20). CD25 has relatively low expression in resting T cells but is quickly 
upregulated in response to IL-2 mediated signaling (21, 22). IL-2 signaling is crucial for T cell 
expansion and, consequently, any change in CD25 expression potentially disrupts the 
proliferative response.  
 
Specific Aim 1: Determine how CD25 expression in T cells is altered following 30 min of a 
combined moderate aerobic and anaerobic exercise protocol. 
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 Hypotheses: We hypothesized that CD25 expression would be upregulated following an 
exercise protocol consisting of 15 min of aerobic exercise and 15 min of resistance exercise. 
Intensity of exercise was modified to maintain a rate of perceived exertion (RPE) of 
approximately 15. Approach: To test this hypothesis total T cells were isolated from peripheral 
blood by negative selection using a Human T cell enrichment kit. T cell proliferation was 
analyzed in response to either co-stimulation through CD3+CD28 using plate-bound antibodies, 
phytohaemagglutinin (PHA), or no simulation. Cells were incubated for 7 d at 37˚ C in a 
humidified incubator with 5% CO2 and then analyzed by flow cytometry. 
 
Specific Aim 2: Determine if changes in T cell proliferative ability and surface marker 
expression of CD25 following exercise are stable when blood processing is delayed 24 h. 
 Hypotheses: We hypothesized that CD25 expression and measures of proliferation 
following exercise would be decreased if T cell isolation from whole blood is delayed by 24 h. 
Approach:  Two extra vials of blood were collected at both the baseline and post-training time 
points in addition to the vials used to address Aim# 1. One vial rested overnight at room 
temperature prior to T cell isolation and the other rested overnight at 4˚C. T cell isolation 
procedures were the same as those utilized for Aim 1.  
 
1.2.2 Study 2: Do Military and Tactical Experiences Model the Characteristic Exercise 
Response 
 
Military physical training programs are generally rigorous in nature and involve periods 
of intense physical activity, psychological stress, sleep deprivation, and exposure to extreme 
environments (23). The combined effects of these layered stressors on a trainee’s immune system 
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are complex in nature and may be deleterious as evidenced by wartime immunosuppression in 
active-duty military personnel (24). Recently, it has been reported that the combination of 
physical and psychological stressors leads to enhanced sympathetic activation and adrenal 
responses following combined stress challenges (13-16). 
A study investigating immunoendocrine responses to combined physical and 
psychological stressors in professional firefighters found a greater increase of norepinephrine 
(NE), epinephrine (EPI), and IL-2 in a dual challenge condition when compared to exercise alone 
(13). The authors did not, however, utilize a functional measurement of immunocompetence. 
This study will clarify whether a tactical experience is similar in scale and nature to current 
exercise and dual challenge stress designs. 
 
Specific Aim 1: Determine whether T cell proliferative capacity is differentially effected by 
exposure to a high intensity, dual stress environment relative to a moderate intensity, single 
stress challenge. 
 Hypothesis: We hypothesized that T cell proliferative capacity would be significantly 
suppressed in the high stress condition compared to the moderate intensity controls. Approach: 
T cell proliferation was analyzed in response to co-stimulation through CD3+CD28 using plate-
bound antibodies, PHA treatment, or no simulation. 
 
Specific Aim 2: Determine whether immunomodulatory cytokines and/or damage associated 




 Hypothesis: We hypothesized that oxidative stress following exercise would modulate T 
cell activity through immunomodulatory cytokines and DAMPs. Approach: Peripheral 
concentrations of the major cytokines IFN-, IL-10, IL-17a, IL-1, IL-2, IL-4, IL-5, IL-6, and 
TNF- were determined using a human cytokine magnetic bead panel kit. High mobility group 
box 1 protein (HMGB1) was assessed by ELISA. 
 
Specific Aim 3: Determine if high intensity stress causes greater perturbations in leukocyte 
concentrations in peripheral blood versus moderate intensity stress condition. 
 Hypothesis: We hypothesized that the leukocyte trafficking in the peripheral blood 
would be greater in the high intensity stress group and that these changes would be associated 
with endocrine measures. Approach: We measured these differences using commercially 
available ELISA kits. 
 
1.2.3 Study 3: Immunoendocrine responses to the Marine Corps Martial Arts Program 
 
The focus of the Marine Corps Martial Arts Program (MCMAP) is the personal 
development of each Marine in a team framework using a standardized, trainable, and 
sustainable close-combat fighting system that will both prepare and acclimate them to the rigors 
of training and deployments. The MCMAP is intentionally delivered in an environment 
characterized by periods of intense physical activity and psychological stress and is intended to 
develop the physical skills and character necessary for the Modern Marine. Our goal within the 
context of this training environment is to quantify immunoendocrine recovery profiles following 




Specific Aim 1: Quantify the immunoendocrine profiles over a one-hour recovery period 
following acute bouts of MCMAP training. 
 Hypothesis: We hypothesized that all immunoendocrine parameters would be 
significantly altered with respect to time post-training. Approach: Peripheral concentrations of 
both catecholamines and cortisol along with leukocyte and lymphocyte subsets were assessed as 
part of this protocol. These differences were measured using commercially available assays. 
 
Specific Aim 2: Develop a battery of visualized trend lines equations and predictive regression 
equations for how individual immunoendocrine parameters interact within Marines in the 
MCMAP program.  
 Hypotheses: We hypothesized that fluctuations in immunoendocrine parameters would 
vary slightly over repeated exposures to training. Approach: Physiological biomarkers were 
measured through commercially available assays. Analyses of effects were performed using 











































The immune system is a complex system of multiple cell-types that communicate to 
protect and repair the body. One of the many ways the immune system maintains organismal 
homeostasis is through direct and continuous communication with the endocrine and central 
nervous systems (CNS). Chronic dysregulation of the immune system can be problematic and 
lead to attenuated immune responses and increased rates of sickness. One of the major insults to 
the immune system is stress. Stressors, both physical and psychological, can impair the immune 
response via dysregulation of the endocrine system and CNS. The sympathetic-adrenal 
medullary (SAM) and the hypothalamic-pituitary-adrenal (HPA) axes are direct pathways by 
which immune disruptions occur in response to stressful conditions. A variety of immune cells 
express receptors for SAM and HPA hormones and their responses range from disruptions in cell 
trafficking to suppression of lymphocyte proliferative capacity. The proliferative response of 
lymphocytes to mitogens following exercise-specific stress has been extensively reported but the 
results have been inconsistent. Methodological issues related to mitogen selection and cell 
culture methods have hampered the ability to make adequate conclusions regarding the role of 
intense exercise in suppressing immune function. This review will address the role of acute 
exercise, a major physical stress, on the systemic interactions of the immune system, with a 
particular focus on understanding of the mechanisms underlying the functional immune response 
as measured through lymphocyte proliferative capacity.  
 
2.2 The Immune System 
 
Humans are constantly exposed to foreign pathogens that either lie on the skin or are 
exposed to the lumen by the normal physiological duties of the respiratory and digestive tracts. 
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Most pathogens fail to breach the organismal system due to immediate barriers like the skin, 
mucosal membranes, and membrane and peptide breakdown by the low pH environment of the 
stomach. These protective mechanisms are generally enough to prevent infection but pathogens 
that ultimately enter the system are often quickly eliminated by phagocytic cells or soluble 
factors like lysozymes or interferons. Beyond these simple barriers, the immune system is an 
adaptive and highly complex network of lymphoid organs, differing cell types, humoral factors, 
chemokines and cytokines that identify and target potentially harmful substances. The two major 
components of the immune response are the ability to target specific antigens (e.g. antibodies) 
and the ability to differentiate between self and non-self. The ability to discriminate between self 
and target invading pathogens allows for rapid removal of specific foreign objects while 
protecting the ‘self’ from unwarranted attack. Molecular recognition of this sort is a result of 
intricate interactions between cellular ligands and/or signaling proteins with surface receptors on 
the involved cells (11).  
The immune system is composed of the innate immune system and the acquired immune 
system. The innate immune system is comprised of monocytes, granulocytes (neutrophils, 
basophils, eosinophils) and dendritic cells. These cells circulate in the blood to identify pathogen 
associated molecular patterns (PAMPs) on microbes using toll-like receptors (TLR) and other 
pattern recognition receptors [PRR; (11)].  PRRs allow cells to accurately identify structural 
patterns common to microbial agents for purposes of opsonization, complement activation, 
phagocytosis, and activation of inflammatory processes (25, 26). The innate immune system acts 
as a fast and aggressive response for detection and elimination of foreign pathogens and can be 
characterized as the inflammatory response. It is not, however, particularly specific or adaptive. 
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This inflammation response is generated from detection of shared structural motifs, not specific 
antigens, and there is no institutional memory to improve the response to repeated exposures.  
Acquired immunity is the result of repeated exposure and institutional memory and, as a 
result, has a slower and more specific response. Acquired immunity takes advantage of antigen 
specificity, the diversity of recognition molecules, immunological memory of pathogens and the 
ability to differentiate between self and non-self (11). Unlike leukocytes of the innate immune 
system, the lymphocytes of acquired immunity are capable of identifying single amino acid 
differences in protein structures, allowing for tremendous diversity in antigenic specificity. 
Moreover, acquired immune cells are able to learn and retain information from the first exposure 




Primary lymphocytes originate from stem cells in the bone marrow and are classified as T 
cells or B cells. T cells mature in the thymus while B cells remain in the bone marrow until 
maturation (11). Together T and B cells are the primary effector cells of humoral and cell-
mediated immunity. Humoral immunity is driven through the production and secretion of 
antibodies which, when bound to their specific antigen, facilitate immune responses such as 
phagocytosis. The cell-mediated immune response is a function of direct cell-to-cell contact with 
T cells binding and attacking specific virus-infected or otherwise dangerous (i.e. neoplastic) cells 
(11). 
 




B cells are antibody producing lymphoid cells and mediators of the humoral immune 
response typically identified by the clusters of differentiation (CD) 19 surface marker and 
account for ~5-15% of circulating lymphocytes (27). B cell activation occurs predominately 
through T cell dependent (TD) and T cell independent (TI) antigens (28). TD antigens are first 
bound by dendritic cells and processed through endocytic pathways to present peptides of the 
class II major histocompatibility complex (MHC) to antigen specific T cells. Once activated, T 
cells upregulate expression of CD40L which binds to a CD40 receptor on B cells to stimulate 
further B cell activation (27-30). Activated T cells can further stimulate B cells through secretion 
of interferon- (IFN-), interleukin (IL)-2, IL-4 and IL-6. IL-4 and IL-6 are of note as they can 
stimulate B cell activation and plasma cell differentiation, respectively (27).  
TI antigens do not require degradation and presentation on class II MHC. TI antigens are 
further classified as type 1 (TI-1) and type 2 (TI-2). TI-1 are polyclonal activators of B cells that 
bind to TLR on the surface of cells (30). TI-2 antigens tend to be of large molecular weight with 
repeating antigenic epitopes that cross-link B cell receptors (BCR) directly (28). The BCR is a 
membrane-embedded antibody on the B cell surface that functions as the specific antigen 
binding site (11). TI-2 antigens do not require direct contact with T cells to generate B cell 
activation but appear to require T cell dependent cytokine secretions (27).  
 
2.2.3 T Cells 
 
T cells are identified by the CD3 surface marker and make up 60-85% of circulating 
lymphocytes (11). These lymphocytes are further differentiated based on expression of CD4 or 
CD8 surface markers, markers that define antigen recognition abilities through either class II 
(CD4) or class I MHC restrictions (CD8). CD4+ T cells are commonly referred to as T-helper 
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(TH) cells and provide assistance in activation of B cells and macrophages. CD8
+ T cells are also 
known as cytotoxic T cells (CTL) and can directly kill infected cells. TH cells also help mediate 
the CTL response.  
Both CD4 and CD8 T cells can be subdivided into functional subsets classified as naïve, 
effector, memory, and regulatory cells. The subsets are typically classified by their cytokine 
production with several major subsets of CD4+ cells having been clearly identified to include 
TH1, TH2, TH17, and regulatory T cells (TREG) (31-35). TH1 cells are associated with cell-
mediated immunity (i.e. inflammatory response and cytotoxicity) and TH2 cells with humoral 
immunity. Both cell types have relatively distinct cytokine production patterns with TH1 cells 
producing IFN-, and IL-2 and TH2 cells secreting IL-4, IL-5, IL-10, and IL-13 (33, 34). 
Additionally, these subsets are capable of downregulating each other with IFN- inhibiting the 
differentiation of TH2 cells and IL-4 and IL-10 inhibiting TH1 cell development (33, 36). TH17 
cells are a distinct cell line that can generate inflammatory reactions through secretion of IL-17 
(37).  Regulatory T cells have the ability to suppress a variety of immune responses, including 
TH1 and TH2 cell differentiation, largely through secretion of IL-10 and transforming growth 
factor (TGF)-. While an in-depth discussion of the mechanisms of actions for each 
functional cell subset is beyond the scope of this review, it is important to note that each subset 
has the ability to regulate the immune response as a result of their specific cytokine profile. 
 
2.2.5 T Cell Activation: the Immune Synapse 
 
When mature T cells are exposed to a target antigen, it initiates a complex process of 
proliferation and differentiation critical for a proper immune response. This process begins when 
T cell receptors (TCR) bind peptides on antigen-presenting cells (APC) and form the 
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immunological synapse (39, 40). Initial TCR-antigen binding forms TCR microclusters 
composed of 30-300 TCR at the primary contact area (41, 42) and increase in number as contact 
regions increase. Once a maximal number of contact points have been established, these 
microclusters migrate to the center of the cell-cell interaction to form a central-supramolecular 
activation cluster (c-SMAC) (39, 40). The c-SMAC is protected and supported by peripheral-
SMAC (p-SMAC), leading to the characteristic “bulls-eye” structure of the immunological 
synapse that provides for a stable junction between the T cell and APC (40, 43). 
Optimal T cell activation requires a two-signal process. The first signal is engagement of 
the TCR-CD3 complex to mediate activation of numerous downstream signaling proteins (44). 
This engagement forms a temporary association between the surface marker CD4 and leukocyte-
specific tyrosine kinase (Lck) (40, 45). The association causes the phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAM) of the CD3 -, and -chains 
(43). Phosphorylated CD3 ITAM results in TCR translocation of the 70 kDa zeta-activated 
protein (ZAP-70), which phosphorylates multiple tyrosines in the linker domain, resulting in the 
activation of T cells (LAT) (46). When phosphorylated, the LAT provides an assembly platform 
base for the inner leaflet of the plasma membrane and recruits important scaffolding proteins 
(SLP-76, Grb2, Gads) (43) and kinases such as IL-2 tyrosine kinase (Itk), phospholipase C 1 
(PLC1) and phosphatydilinositol-3 kinase (PI3K) (47, 48).  
The second, or costimulatory, signal is the classical binding of a T cell CD28 receptor 
with an APC-bound B7-1 or B7-2 (43). Binding of CD28 in this manner leads to phosphorylation 
of tyrosine sequences in the cytoplasmic portion of the receptor. Additional phosphorylation 
furthers recruitment of downstream adapter proteins, such as PI3K and ITK, and expedites T cell 
activation (49).    
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The end product of TCR stimulation is transcription of the IL-2 gene, which has a 
primary role in supporting T cell proliferation (50, 51), and other cytokines that lead to cell 
differentiation and proliferation. This is facilitated by activator protein 1, nuclear factor of 
activated T cells (NFAT) and nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFB) (40, 43). Substantial amounts of clonal expansion are required for T cells to differentiate 
and mount an effective immune response. Accordingly, it is imperative that signal transduction 
occurring at the level of TCR microclusters and the immunological synapse occur without 
complication.  
 
2.2.6 Lymphocyte Proliferation 
 
 Upon encountering a target antigen, T cells must go through clonal expansion to increase 
the number of lymphocytes to defend the host from the threat (11). IL-2 induction has been 
investigated as a crucial point of T cell proliferation (50, 51). IL-2 is a principal growth factor for 
T cells and maintains activated T cells in the proliferative cycle (19, 20). In steady-state 
conditions, IL-2 is mainly produced by TH secondary lymphoid organs such as the lymph nodes 
(21, 52). Following activation by antigen, IL-2 and the IL-2 receptor (IL-2R), production is 
increased by CD4+ and CD8+ T cells (52, 53). 
 IL-2 binds to cells expressing either the high-affinity (trimeric) or low-affinity (dimeric) 
IL-2R (53). The low-affinity receptor consists of a common -chain cytokine receptor composed 
of CD122 and CD132. This dimeric complex has a weak affinity for IL-2 and needs to be 
expressed at a high level for sufficient ligand sensitivity. The trimeric form of IL-2R includes 
CD25, resulting in an increase in ligand binding affinity by 10-100 fold (53). CD25 expression 
on T cells is increased following TCR stimulation and also through a positive feedback loop 
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involving IL-2 (21). CD122 and the common cytokine receptor -chain are the signaling 
components of the quaternary IL-2/IL-2R complex with signal transduction occurring via several 
pathways including the Janus kinase (JAK)/signal transducer and activator of transcription 
(STAT) pathway, PI3K/AKT pathway and the mitogen activated protein kinase (MAPK) 
pathway (21, 52, 54).  
 Lymphocyte proliferation can also be induced by factors other than cognate antigen. 
Plant lectins are carbohydrate-binding glycoproteins that agglutinate cells (55). When added to a 
cell culture, lectins act as a mitogen to induce lymphocyte proliferation similarly to lymphocytes 
that have been stimulated by an antigen (56). Mitogens, however, will activate a large percentage 
of cells regardless of antigen specificity and are referred to as polyclonal activators (57).  
 The primary mitogens used for proliferative assays [phytohaemagglutinin (PHA), 
concanavalin A (ConA), pokeweed mitogen (PWM)] work through distinct mechanisms to 
stimulate different subsets of lymphocytes. PHA primarily acts as a T cell mitogen (58) and is 
considered a valid inducer of T cell proliferation as only a small percentage of B cells are 
concomitantly stimulated (57). ConA can stimulate both B and T cells (58) and may accurately 
describe total lymphocyte proliferation while PWM primarily induces proliferation of B cell 
mitogen (58). The different stimulating properties of the mitogens effectively dictate what 
lymphocytes are being activated and how study results should be interpreted. 
 
2.3 Neuroendocrine modulation of the immune system 
 
The biological response to stress is to maintain systemic homeostasis while 
simultaneously reacting to a physical or psychological stressor. This highly conserved response, 
also known as “fight or flight”, is a function of two neuroendocrine responses: a fast, CNS-
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driven adrenergic response by the sympathetic nervous system, and a parallel, but slower, 
response from the hypothalamic-pituitary-adrenal (HPA) axis. The sympathetic response occurs 
in a matter of seconds and manifests as increased heart rate (HR), blood pressure, and other 
physiologic responses that provide the body with resources to fight or flee (59). The HPA 
response begins with the release of corticotrophin releasing factor (CRF) from the hypothalamus 
(60). The release of CRF prompts the release of adrenocorticotropic hormone (ACTH) from the 
anterior pituitary gland, stimulating the release of glucocorticoids (GC) from the adrenal cortex. 
GC release results in the production of cortisol, a major hormone associated with stress and long-
duration exercise, from the adrenal glands (61). Systemic increases in cortisol lead to elevated 
blood sugar and free triglycerides while also interacting with the immune response (62). This 
chain of events occurs over a matter of minutes and GC function as their own negative feedback 
mechanism, suppressing the HPA axis (63).  
 
2.3.1 Sympathoadrenal Activation and Immune Function  
 
Epinephrine (EPI) and norepinephrine (NE) are catecholamines released by the 
sympathetic nervous system that modulate immune cell activities such as cell trafficking and 
proliferation (64). EPI, which is released mainly by the adrenal glands, has been shown to 
produce dose-dependent increases in HR, ventilation and sweating during exercise while 
increasing blood flow to exercising muscles (59). NE, which is mainly released from 
postganglionic fibers in both target organs and the blood stream, has also been shown to 
redistribute blood flow to working muscles during exercise (65). The magnitude of the 




Increases in catecholamines are observable within 30-60s after the initiation of high-
intensity exercise (67). Increased concentrations of plasma NE occur during exercise intensities 
greater than 50% VO2max (66) while EPI concentrations tend to occur at intensities  ≥60% 
VO2max (68). Both NE and EPI concentrations will peak at the end of exercise and return to 
baseline values within 20-30 min (69). The continued production of the catecholamines is 
necessary for their post-exercise immune function as free-circulating catecholamines are quickly 
degraded by either monoamine oxidase or catechol-O-methyltransferase, leading to a relatively 
short half-life of approximately 2-3min (70).  
The magnitude of the total catecholamine response appears to be mediated by fitness 
level. Endurance trained subjects have reduced responses compared to untrained individuals at 
sub-maximal exercise intensities (71, 72). However, at maximal work intensities, well-trained 
individuals have a greater capacity for total catecholamine secretion compared to untrained 
individuals (73). It is unclear if long-term exercise training has any effect on baseline 
catecholamine concentrations (74). 
The increased catecholamine concentrations after exercise correspond to a redistribution 
of inflammatory cells in the peripheral circulation (8-10). One of the principal characteristics of 
exercise is the increase of mononuclear cells in the blood, termed leukocytosis (10, 75). 
Neutrophil concentrations increase during exercise and continue to increase during the recovery 
period (8). Concentrations of natural killer (NK) cells and total lymphocytes increase quickly 
during exercise and fall below baseline values during the recovery period (8-10, 75, 76). Of the 
lymphocytes, NK cells show the greatest increases in concentration followed by CD8+ and CD4+ 
T cells (10, 77). NK cell counts can increase anywhere from 150-500% during or after high-
intensity exercise and are the strongest contributor to exercise induced lymphocytosis (78, 79). 
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This increase is noteworthy as NK cells account for only 10-15% of resting peripheral blood 
mononuclear cells but 20-30% during exercise (75). Concentrations of circulating T cells 
increase during exercise with a greater percentage of increase in CD8+ (50-100%) cells relative 
to CD4+ (40-50%) (77). The differential mobilization of T cells leads to a decline in the 
CD4:CD8 ratio during exercise. The ratio of CD4+ to CD8+ cells in a healthy person is 
approximately 2:1 (80). An inverted ratio between these cells is associated with viral infections 
or other impairments in immunocompetence (81). In regards to exercise, changes in this ratio are 
likely a result of the increased mobilization of CD8+ cells. CD19+ B cells exhibit moderate to no 
change in cell counts during exercise (76, 82).  
Catecholamine receptors are present on lymphocytes and leukocytes and are thought to 
be involved in altering immune cell distributions during stress (83, 84). Adrenergic 2-receptors 
(β2-r) primarily influence lymphocytes (85) while neutrophils are regulated by adrenergic -
receptors (α-r) (7). NK cells have the highest density of β2-r followed by CD8
+ and CD4+ cells, 
respectively (86, 87). Spikes in circulating EPI and NE seen during acute stress and exercise are 
associated with quick redistributions of granulocytes in circulation (6, 7). In vivo expression of 
β2-ron T and B cells have been shown to increase post-exercise and return to baseline levels 
after 30 min of recovery (88). Interestingly, an association has been shown between density of 
β2-ron lymphocyte subsets and cell trafficking patterns (NK>CD8
+>CD4+) following stress 
and/or exercise (87), suggesting that the role in inflammatory trafficking during exercise is 
controlled, at least partially, by β2-r. Furthermore, administration of physiological doses of EPI 
in human subjects has been shown to accurately mimic this leukocyte response to exercise (89).  
Stimulation of β2-rinhibits T cell proliferation (90) and down regulates IL-2R (91). 
Decreases in IL-2 secretion by T cells have been linked to increased intracellular levels of cyclic-
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AMP (cAMP), providing a mechanism in which β2-rmay regulate T cell proliferative capacity 
(92, 93). This is supported by evidence in which the proliferative response of CD8+ T cells was 




2.3.2 Hypothalamic-Pituitary-Adrenal Axis and Immune Function  
 
 Changes in circulating GC concentrations in response to exercise are similar to the 
catecholamine response and depend on exercise intensity and duration, even though cortisol has 
a half-life of close to an hour, compared to 2-3 min half-life of the catecholamines (95).  Cortisol 
concentrations increase at exercise intensities  ≥60% VO2max or during exercise lasting longer 
than 1 h (69). Conversely, the same study reports concentrations may decrease during low 
intensity exercise (≤50% VO2max) (69). Cortisol levels begin to increase after 10 min of high-
intensity exercise and peak around 20 min after exercise ends (96).  
GC are considered to be immunosuppressive in terms of both cell trafficking (97) and 
proliferation (98). GC reduce the number of eosinophils (99) and basophils (100) in circulation 
while increasing the number of neutrophils and facilitating opsonization and phagocytic 
processes (101, 102). In contrast to the catecholamine response, which recruits lymphocytes 
from the periphery, GC secretion may facilitate an egress of lymphocytes out of the peripheral 
circulation (1, 103). Cortisol concentrations have been directly correlated with circulating 
neutrophil counts but inversely correlated with lymphocyte and eosinophil numbers in blood 
serum taken immediately after a marathon race (104, 105). This finding is not uniform as other 
studies have found no significant relationship (106, 107) or conflicting results following an 
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exercise stimulus (76, 108-110), although a limitations in these latter studies are non-uniform 
exercise bouts. 
The anti-proliferative effects of GC on lymphocytes appear to be mediated through the 
inhibition of IFN-, IL-2, and IL-12 (98, 111), with evidence suggesting that a major component 
is dysregulation NFB signaling and decreased transcription of IL-2 (112). Determining the 
mechanistic processes in the dysregulation is difficult due to redundant inflammatory pathways 
and protein signaling “cross-talk”.   
As GC concentrations tend to peak later than catecholamines, it has been hypothesized  
that cortisol serves to maintain increased numbers of circulating neutrophils and signal for 
lymphocytes to exit the peripheral circulation following exercise (113). Schedlowski et al (103) 
provide compelling evidence supporting this hypothesis after examining lymphocyte trafficking 
and plasma hormone concentrations in parachutists. The study observed a significant increase in 
total T cell and NK cell counts immediately after the jump but a decrease to below baseline 
values at 1 h post-jump. The observed lymphocytosis was associated with increases in circulating 
catecholamines whereas the lymphopenia (clearing of peripheral lymphocytes) was inversely 
correlated with plasma cortisol concentrations (103).  
The biphasic hormone response represented by the relative increases in hormones of the 
sympathoadrenal and HPA axes most likely have differential effects on immune cell trafficking 
and function. This requires investigators to account for the combined effects of both 






 Cytokines are a diverse family of small glycoproteins that modulate many physiological 
processes but are highly relevant in controlling the intensity and duration of inflammatory 
responses. These peptides are often effective at small concentrations and can act in autocrine, 
paracrine, intracrine (within the same cell), or endocrine fashions. Cytokines are readily 
produced and secreted by endothelial cells, smooth muscle cells, fibroblasts, skeletal muscle, 
adipose tissue, and virtually all immune cells (114, 115). Cytokines often exhibit pleiotropic and 
redundant properties and can interact with other cytokines in antagonistic or synergistic 
capacities (114). The actions of cytokines are quickly induced following cellular activation as 
various feedback mechanisms rapidly regulate cytokine uptake and utilization (116). The aim of 
this section is to address cytokines important to functional T cell subsets following exercise.  
 The cytokine profiles of TH1 and TH2 cells are of interest due to their roles in moderating 
different components of the adaptive immune response. TH1 cells primarily secrete the pro-
inflammatory cytokines IFN-, IL-2, and IL-12, which are involved in facilitating cell-mediated 
immunity and delayed-type hypersensitivity (a secondary immune response appearing 48-72 hr 
after exposure to antigen). The TH1 cytokines also activate macrophages and NK cells, with IL-2 
specifically involved in proliferation of CD4+ and CD8+ T cells. 
 IL-4, IL-5, and IL-10 are derived primarily from TH2 cells and mediate humoral 
immunity. The cytokine profiles of Th1 and Th2 cells are interesting as they inhibit the function 
of each other. This is best observed in Th1-derived IFN-inhibiting Th2 and Th2-derived IL-10 
inhibiting TH1 cells. This cross-regulation is also observed at the level of IFN- which can be 
inhibited by IL-10 and upregulated by IL-12 (117). Cytokine concentrations in the 
microenvironment drive cell differentiation as well with IL-4 being a potent stimulus for 
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differentiation into a TH2cell and IL-12, and IFN- leading to TH1 cell development (118). The 
overall relationship between T cell and cytokine regulation can be seen below in Fig. 1. 
 
 
2.4.1 TH1 Cytokines and Exercise 
 
 Exercise likely has a role in altering the concentrations of principal effector cytokines 
from TH1 cells in the serum. Although no studies have observed increases of IFN- following 
acute exercise in vivo, studies examining ex vivo production of IFN- report decreased 
concentrations after acute bouts of exercise after isolation of peripheral blood monocytes and 
Fig. 1. Simplified diagram of cytokine interface with T cells. Cytokines are secreted by T cells with inhibitory 
and cross-regulatory effects. Arrowed lines indicate a stimulus in favor of differentiation/activation. Blocked 
lines indicate an inhibitory effect. M = macrophage; Ab = antibody.   
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lymphocytes and whole blood (119-121). This is not unexpected as IFN-production is 
suppressed by catecholamines and cortisol (122-124), which increase following exercise.  
 Accumulated evidence suggests IL-12, which induces the release of IFN-from TH1 
cells, does not increase following exercise (125, 126). Conversely, Rhind, et al. (127) observed 
increases following exercise in the heat (cycling at 65% VO2max for 40 min at 39˚C) although the 
observed changes were at concentrations ≤ 5 pg/ml and may not be physiologically relevant. One 
study investigating responses to maximal exercise using a modified Wingate protocol did find 
significant increases in IL-12 (128).  
 Plasma IL-2 concentrations have largely been shown to decrease or remain unchanged 
during exercise (115). Recently, however, Kakanis, et al. (129) found increased concentrations 
of IL-2 4-8 h after a 2 h bout of cycling at 90% of the subjects’ anaerobic threshold. This result 
may be indicative of T cell activation and suggests that previous investigations may have 
collected data at the wrong time points. Accordingly, future research should sample multiple 
time points to allow for the immune response to develop following exercise. 
 
2.4.2 TH2 Cytokines and Exercise 
 
 The IL-4 response to exercise is inconsistent within the literature and suggests circulating 
concentrations are largely unchanged following acute bouts of exercise (115, 130). Della Gatta, 
et al. (131) recently observed that while IL-4 either does not change, or may decrease following 
an acute bout of resistance exercise in untrained individuals after three months of supervised 
resistance training 3 times a week those same subjects reported increased IL-4 concentrations 
after an acute bout of exercise, indicating training status may affect the IL-4 response. 
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 There is little data for exercise effects on the secretion of IL-5. Chan et al. (132) looked 
at the role of carbohydrate supplementation and the IL-5 response to exercise. They found a 
resistance exercise session consisting of 5x10 back squats at 65% 1RM and 3x10 half squats at 
85% 1RM, with each set having 1 min rest interval, led to decreased post-exercise IL-5 
concentrations of 12% in the subjects given carbohydrate and 26% in those given placebo. This 
may indicate that carbohydrate supplementation minimizes the IL-5 response. 
 Circulating concentrations of IL-10 have consistently shown increases following 
exhaustive endurance exercise (115). Studies investigating short duration, high-intensity have 
had mixed results with some studies seeing significant elevations in IL-10 immediately post-
exercise (133) while others see a time delayed response (134). For example, Smith, et al. (134) 
observed significant elevations in IL-10 at 72 h, 96 h and 144 h post-exercise following a high-
intensity, eccentric loading protocol (4x12 eccentric bench press and leg extension with 2 min 
rest) which may be indicative of a delayed anti-inflammatory response following short duration, 
high-intensity events. 
 
2.5 Exercise Immunology 
 
Exercise-associated lymphocytosis and lymphocytopenia have been reported on 
extensively (8-10) and suggests the characteristic immune response to exercise involves an 
increase in lymphocytes mobilized from the marginal pools in the blood and other organs. This is 
followed by a decrease to below baseline levels as the mobilized cells move into areas like the 
skin, mucosa, and lymph nodes. These findings have produced ideas like the “Open Window” 
hypothesis whereby individuals are thought to have decreased immune function following 
intense physical activity. Epidemiological studies seem to support this as athletes participating in 
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sustained periods of high-intensity exercise are at increased risk for opportunistic infections (i.e. 
upper respiratory tract infection [URTI; (8, 135)]. The risk of infection in those that exercise 
follows a ‘J’ curve (Fig.2) with regular, moderate-intensity exercise improving immune function 
and sustained high-intensity exercise increasing risk of infection (136, 137). Efforts to identify 
how exercise intensity modulates immune function have largely focused on lymphocyte 
trafficking following exercise, which contribute little information about the overall functional 
capacity of a lymphocyte, termed immunocompetence, of an individual (8, 136). 
 
 
A better method of determining immunocompetence is investigating the proliferative 
ability of lymphocytes in response to cognate antigen. Lymphocytes undergo clonal expansion 
when they encounter cognate antigen (11) and this is a critical feature of the adaptive immune 
response (12). Any failure to proliferate in response to a foreign antigen is indicative of impaired 
immune function and attenuates the immune response of the host. The classical assay to measure 
T cell proliferation is to stimulate them with PHA, a T cell-specific mitogen. PHA assays are 
routinely used to monitor immune function in immunosuppressed patients such as recipients of 
organ transplants, individuals that are HIV-positive, and others at risk for immunosuppression. 
Fig. 2. The risk of infection relative to volume of 
exercise. Adapted from Nieman, et al. (1994) 
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Although proliferation assays are a mainstay of clinical diagnostics, they represent a small 
proportion of the literature comprising the field of exercise immunology (9, 138).   
 
2.5.1 Lymphocyte Proliferation Following Exercise 
 
Non-systematic review articles of lymphocyte proliferation report inconsistent findings 
regarding whether immune function is enhanced or suppressed by exercise [see reviews in (8-10, 
138)]. These inconsistencies are likely a result of varied subject populations, different exercise 
protocols and methods that evaluate lymphocyte proliferation. A systematic review of published 
studies involving measurements of lymphocyte proliferation immediately after acute exercise 
suggests that exercise does indeed suppress lymphocyte proliferation (ES: -.22, 95% CI:-.29, -
.24; Siedlik, et al. Unpublished Data). Follow up analyses in this same study found no 
appreciable differences between exercise of moderate and high intensity (ES = -0.17 vs. -0.27 
respectively), but did uncover a trend for a suppressive effect of long duration (≥60min) exercise 




While there was no statistically significant difference in suppression based on duration of 
exercise, there was a differential response for exercise intensity with long duration high-intensity 
exercise having a greater suppressive effect than long duration moderate-intensity (-0.55 vs. -
0.24; Fig. 4). Beyond the quantification of acute exercise-induced proliferative responses, the 
systematic review identified two different responses within the context of high-intensity exercise 
lasting longer than one hour. The first response is a greater suppressive effect following high 
intensity training intervals lasting over two hours and the second being enhanced proliferation 
following competitive events (Siedlik, et al. Unpublished Data).  
Fig. 3. Effect of short duration (a) and long duration (b) exercise on measures of lymphocyte proliferative 
capacity. Data are presented as mean effect size (boxes) for each study, 95% confidence intervals (horizontal 




 Two articles used in the comprehensive review had very large effect sizes due to their 
unique study designs. Bacurau et al. (139) investigated the immune response in trained cyclists 
participating in an exercise bout composed of cycling intervals (6x20 min with equal rest 
intervals) at 90% of their anaerobic threshold. Additionally, Nieman et al. (140) examined the 
proliferative responses of elite adolescent tennis athletes who maintained a mean HR of over 
80% of their predicted HRmax throughout 2 h of high-intensity tennis drills performed in 15 min 
intervals with 4-5 min rest. While these studies have work intervals greater than 60 min, they 
also had a higher sustained intensity level and their large changes in the proliferative response 
Fig. 4. Effect of long, moderate-intensity (a) and long, high-intensity (b) exercise on measures of 
lymphocyte proliferative capacity. Data are presented as mean effect size (boxes) for each study, 95% 
confidence intervals (horizontal lines), and summary of overall proliferative effect (diamonds). 
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may be unique to high intensity, long-duration activity. Thus, the data suggest an enhanced 
suppressive effect following events of this nature that needs to be accounted for in research 
designs.   
 The proliferative capacity, however, may increase immediately after competition. Bassit, 
et al. (119) examined immune responses after a competition of an Olympic distance triathlon (1.5 
km swim, 40 km bike, 10 km run) and noted an increase in lymphocyte proliferation 
immediately post-race. This is supported by a report that evaluated lymphocyte proliferation 
immediately after an Adventure Spring Race consisting of 12 km of hiking, 100 m of vertical 
skills, and 30 km of mountain biking (141). These studies contrast to the observed effects from 
long duration, high-intensity exercise in a non-competitive setting and suggest that the 
psychological stress unique to competition may regulate the immune response via a different 
mechanism (Fig. 3).  To further clarify this we conducted a sub group analysis examining 
whether the proliferative response to competition differed. We did identify a discordant result 
(p=0.02) with the long duration, high intensity competitive events being associated with an 
enhanced proliferative effect (SMD): 0.46, 95% CI: 0.03, 0.89) and long duration, high-intensity 
exercise outside of a competition having a large suppressive effect (SMD: -1.28, 95% CI: -1.61, -
0.96; Siedlik, et al. Unpublished Data). It should be noted that Henson, et al. (142) was included 
as a long duration, high-intensity event but not a competitive one as the average finish time was 
4.57 h which suggests the participants were mainly recreational runners.  
 The reason for the observed differences in proliferative responses in unclear at this time. 
It is known that exercise, particularly exercise of long duration, leads to increased circulating 
concentrations of hormones and cytokines that may modulate the immune response. Radom-
Aizik, et al. (143) observed that Jurkat cells, an immortalized T cell line, exhibited increased 
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proliferative ability following stimulation by proliferating nuclear cell antigen when treated with 
sera obtained from healthy donors following a bout of exercise (30 min cycling at 80% peak 
work rate). This supports the hypothesis that serum factors are able to modulate T cell function 
in vitro, and suggests that secreted soluble factors are at least partially accountable for changes in 
immunocompetence following exercise. The identification of these secretory factors and their 
mechanisms of action for the immunomodulatory responses has not yet been elucidated. 
 
2.5.2 Effect of Fitness 
 
Training status is likely another factor involved in the immune response to exercise. Few 
studies have attempted to quantify differences between trained and untrained subjects. In those 
that have, mixed results have been reported when comparing trained versus untrained subjects 
with studies finding trained individuals have either increased, decreased, or no change relative to 
untrained individuals of similar age. 
A study by Baj, et al. (144) examined competitive cyclists before and after a training 
season (6 months) and found that proliferative capacity at rest was improved following the 
intensive training/racing season and that those changes were associated with increases maximal 
oxygen consumption. Nieman, et al. (145) found a similar result with well-conditioned (actively 
competing in endurance events) elderly women exhibiting greater proliferative ability compared 
to age matched sedentary controls.  
Papa, et al. (146) found decreased proliferative ability in trained water polo players 
compared to untrained volunteers. PHA and PWM were used as mitogens in this study looking at 




Potteiger, et al. (147) undertook an elegant study examining the functional immune 
response to an acute bout of exercise in resistance-trained versus untrained-females. This study 
found that trained females (3 d/wk resistance training for at least 3 months prior to study start) 
did not see a significant reduction in T cell proliferative capacity after a bout of resistance 
exercise while untrained females exhibited suppressed proliferative ability up to 3 h post-
exercise. These data suggest high-intensity resistance training may influence T cell proliferative 
capacity following an exercise bout and that differences in training backgrounds may be a 
confounding variable and should be better controlled for in future studies. 
Other studies have found no difference in proliferative capacity between trained 
individuals and age matched controls. Oshida, et al. (148) found parallel suppressive effects 
immediately post-exercise in both untrained individuals and athletes (~20 km running, 6-7 d/wk) 
with no appreciable difference between groups. Similar results have been found in studies 
comparing resting levels of lymphocyte proliferative ability in athletes and non-athletes (VO2max: 
70.7 ± 1.3 vs. 47.6 ± 3.1) (149) and in marathon runners (minimum 4 y training/racing 
marathons) relative to sedentary controls (150). 
The major limitation of these studies, and the field of exercise immunology, is a non-
universal classification of a trained individual. In the literature, trained status often ranges from 
recreational to elite and researchers may not explicitly state how they qualified their subjects’ 
training status.  One can appreciate that there may be substantial variances in the outcomes due 
to these inconsistencies.  
 




The primary mitogens used for proliferative assays (PHA, ConA and PWM) work 
through functionally distinct mechanisms and allow for the stimulation and measurement of 
different subsets of lymphocytes. Pooled measurements, which combine studies using multiple 
mitogens into a single analysis, give an accurate representation of total proliferative capacity, but 
do not allow for a discussion regarding specific mechanisms of exercise-derived 
immunosuppression. As an example, the overall SMD in global suppressive effects of acute 
exercise observed in studies that used both PHA and ConA is trivial (-0.15 and -0.09 
respectively; Fig. 5). In Fig 5 all studies that used both PHA (5a) and ConA (5b) in the 
systematic review are listed and sorted according to effect size from largest to smallest. Note that 
while the overall SMD are very similar, the individual SMD differences between PHA and ConA 
are different even though the subjects and exercise stimuli are identical. These observations 
suggest a lack of agreement between variable measures, which is likely a result of the different 





While Fig. 5 allows for a direct comparison of effects, other studies that do not use both 
PHA and ConA limit the ability to compare results across study designs. Mitogen-specific 
suppression of long duration exercise provides an estimated SMD = -0.46 (95% CI: -0.56, -0.35) 
for PHA and a SMD = -0.21 (95% CI: -0.31, -0.12) for ConA (Siedlik, et al. Unpublished Data). 
This difference in estimated SMD, while not statistically significant, suggests a suppressive 
mechanism may be preferentially targeting the T cell compartment during exercise lasting 
greater than 60 min. We suggest that PHA is a more accurate assessment of T cell proliferation 
and research investigating proliferative responses to exercise should consider the mitogenic 
properties of possible lectins and target lymphocyte subsets. This is supported by existing 
literature (57, 58, 151, 152) and in agreement with clinical immunology practices. 
The question of which lymphocyte subpopulation is being activated is further 
complicated by cell culture techniques utilized for proliferation assays. The majority of studies 
Fig. 5. Lymphocyte proliferation following stimulation by either Phytohaemagglutinin (a) or 
Concanavalin A (b) stimulation following an acute bout of exercise. Data are presented as mean effect size 




use either peripheral blood mononuclear cells or whole blood cell. These may limit functional 
capacity measurements of specific cell type functional unless a cell specific mitogen (i.e. PHA) 
is utilized. For this reason, interpreting data pairing culture methods using ConA or PWM, both 
of which can activate B cells, must be done carefully. 
It has been argued that whole blood assays accurately represent in vivo conditions and are 
the best method in assessing proliferative responses (153). The primary concern with this method 
is the combination of lymphocytes, leukocytes, and immunomodulatory factors such as cytokines 
and hormones present in the blood, limit mechanistic analyses of proliferative capacity and make 
difficult the ability to measure a specific lymphocyte’s function in this manner. Peripheral blood 
mononuclear cell assays, on the other hand, isolate white blood cells for analysis but cannot 
differentiate between T and B cell responses. For these reasons, it is difficult to draw conclusions 
for clinical implications of these findings as they relate to increased risk of infection.  
 
2.6 Dual Stress Challenges 
 
As mentioned previously, it is generally accepted that a single exposure to a physical or 
psychological stress can lead to increased concentrations of catecholamines and GC and a 
resultant suppression of immune function. A meta-analysis examining the impact of 
psychological stress on immune parameters found increased numbers of circulating leukocytes 
and lymphocytes following mental challenges to a degree similar to acute physical stress (154). 
The same study found a decrease in mitogen-induced lymphocyte proliferation following timed 
events associated with psychological stress, such as public speaking and mental arithmetic, and 
this data is suggestive of a functional impairment in adaptive immunity (154). Stressful life 
events have also been linked to increased risk of viral respiratory infections in a dose-dependent 
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manner (155), further solidifying the current opinion that stressful encounters compromise 
immune function. 
It should be noted that in the everyday environment it is exceedingly rare for an 
individual to be exposed to only a physical or psychological challenge and there are a variety of 
ways individuals experience multifactorial stressors in practical scenarios. This can be seen in 
conditions where performers may experience state anxiety. Elevations in endocrine measures 
specific to a stress response have been observed in judoka (156) and ballroom dancers (157) 
prior to a competition when compared to these same individuals’ response to a time-matched 
training session. These results, which are anticipated to occur, represent a potential confounding 
variable in studies where participants are placed in anxiety-arousing situations due to the nature 
of the task they are asked to complete.  
Recent studies have compared paired physical & psychological dual stress models to 
physical stress alone (i.e. a bout of exercise) and have observed increased concentrations of 
circulating catecholamines and cortisol (16, 158) in the dual-challenge groups compared to the 
exercise only controls. Descriptive studies have reported the catecholamine responses in veteran 
firefighters undergoing laboratory based exercise alone (37 min cycling at 60% VO2max) and 
during dual stress conditions. These participants were subjected to the same exercise condition 
but underwent a 20 min computer based firefighting strategies and tactics decision-making 
challenge during minutes 12-32 of the exercise trial (13-15). These studies have repeatedly 
observed increased concentrations of EPI and NE relative to the exercise-alone controls (13-15) 




Increased activation of the HPA axis was also observed during one of the above 
referenced studies (15) but was not assessed in the other two (13, 14). Webb, et al. (16) utilized 
the same exercise stress (37 min cycling at 60% VO2max) but had civilian subjects undergo five 
consecutive cycles of a modified Stroop Color-Word task and mental arithmetic challenge during 
minutes 12-32 of the exercise protocol. They observed a resultant increase in circulating cortisol 
levels in the dual stress challenge compared to the exercise alone condition. In another study, 
Webb, et al. (158) found that a mental task (20 min of cycled Stroop Color-Word and mental 
arithmetic tasks) preceding 20 min of cycling at 35% VO2max enhanced the cortisol response to 
exercise above what would be expected from exercise at such a low intensity. The mechanism(s) 
for these types of exacerbated endocrine responses are unknown but indicate there may be a 
synergistic interaction in the multifactorial stress response. 
 In an effort to examine immune responses in this context, Huang et al. investigated the 
response of veteran firefighters to combined physical and psychological stressors and identified a 
greater increase of EPI, NE, and IL-2 in the dual challenge condition when compared to an 
exercise-alone trial (14). The same authors expanded their inquiry into the civilian population but 
did not observe increased concentrations of IL-2 (159). Although the results are seemingly 
contradictory the primary factor driving this disparity is most likely baseline aerobic fitness 
levels as the firefighters had roughly a 20% greater VO2max (45.13 ± 7.7 ml/kg/min) vs. the 
civilian subjects (36.9 ± 5.6 ml/kg/min) (14, 159). 
Aerobic fitness has been thought to mitigate the cardiovascular response to psychological 
stress (160, 161). Rimmele, et al. (162) examined how the physiologic stress response is 
mediated based on levels of physical activity. Participants were separated into untrained (no 
running), amateur (~2.43 h/wk running), and elite (~4.67 h/wk running) groups. These 
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participants underwent the Trier Social Stress Test to induce psychosocial stress. They found 
runners in the elite group had reduced heart rate and cortisol responses to the psychosocial 
stressor when compared to both the amateur and untrained subjects (162). These researchers 
were able to further define a graded relationship between physical activity level and anxiety 
management. They demonstrated that the greatest reductions in the anxiety response (physiologic 
and psychological) occurred at the highest levels of physical activity (162, 163). These findings 
are supported by observations in which subjects with low aerobic fitness exhibit exacerbated 
cardiorespiratory (164) and cortisol responses (16) compared to aerobically fit individuals 
following dual stress conditions. This is supportive of a role for anxiety in altering stress markers 
independent of the physiological response while also leading to differential immune activation 
between fit and unfit individuals.  
In a recent study attempting to assess immunoendocrine interactions in a real-world field 
testing environment during and after exposure to a dual stress intervention, Siedlik, et al. (165) 
testing aerobically fit male Marines using a standardized US Marine Corps Martial Arts Training 
protocol, a program encompassing training and teaching in a high-stress environment with 
constant feedback from senior officers, and found elevated circulating catecholamine 
concentrations and increases in circulating leukocytes and lymphocytes without activation of an 
adaptive immune response. Quantification of the functional immune response to combined stress 
challenges specific to real-world contexts can improve our understanding and development of 
wellness interventions for occupations that are consistently exposed to physical and 






 Lymphocyte proliferative ability is a crucial component of the adaptive immune 
response. Failure to proliferate in response to cognate antigen is indicative of impaired 
immunocompetence. The functional capacity of these cells, specifically T cells, is modulated by 
a variety of factors including changes in hormone and cytokine concentrations. 
 Exercise is a prominent way to activate and suppress lymphocyte function as the 
composition of the peripheral circulation changes in response to the exercise stimulus. These 
changes may be related to a convergence of interactions with soluble mediators generated by a 
physical stress, a psychological stress, or a combination of the two. Accordingly, the goal of the 
proposed studies is to illuminate how a physical stress such as exercise or a dual-stress challenge 
affects global measures of immunocompetence. Specifically, the aims are to investigate T cell 
proliferation and discern the discrete steps involved in T cell activation during multiple stress 





































































 Six healthy males volunteered for this study (age = 26 ± 5 yrs; height = 181 ± 9 cm; 
weight = 88 ± 14 kg). All subjects were recreationally trained individuals with a mix of aerobic 
and resistance training experience (average 1-mile run time: 5:58 ± 40 s; average 1-repetion 
maximum back squat: 167 ± 42 kg). The subjects’ self-reported time spent aerobic training each 
week was 2.5 ± 2.2 h with an average of 4.2 ± 2.5 h resistance training. Subjects provided 
informed consent and completed a medical history questionnaire prior to participation. At the 
time of recruitment, subjects were instructed to maintain their normal dietary patterns prior to 
participating in either session but to refrain from exercise in the period 24 hrs before data 
collection. The study was approved by the Institutional Review Board for Human Subjects at the 




 Subjects were tested on two occasions with each laboratory visit occurring between 0800-
0845 hours. During the treatment visit, subjects underwent 30 min of moderate exercise 
comprised of 15 min of treadmill running followed by three times through a resistance training 
circuit. Each circuit consisted of 10 repetitions of the back squat at 135 lbs, as many repetitions 
as possible (AMAP) body weight pull-ups (max 25), and AMAP of body weight dips (max 25). 
Rating of Perceived Exertion (RPE) was measured every 3 min (time points included were 3, 6, 
9, 12, and 15 min) during the treadmill portion with speed and grade adjusted to 
achieve/maintain an RPE of 15-16 on the 6-20 Borg Scale (166). Following the treadmill portion, 
subjects were given a 3 min rest break before beginning the first resistance training circuit. 
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Additional 3 min rest breaks were provided between each circuit with RPE assessed at the 
beginning of each rest period. 
 During the control visit, subjects sat quietly in a room for 30 min. Subjects were not 
allowed to read or use electronic devices during this time. Subjects were monitored at random 
intervals to ensure they remained awake. 
 
Physiological monitoring 
Participants were fitted with a Zephyr BioHarness 3 (Zephyr Technology, Annapolis, 
MD, USA) for heart rate (HR) measures. Continuous HR measures were recorded at 1 Hz 
intervals during the training session. HR data was downloaded using the Zephyr BioHarness Log 
Downloader (version 1.0.29.0). Five training zones were defined as follows: zone 1 <60% 
predicted maximum HR (HRmax); zone 2, 60%-70% HRmax; zone 3, 70%-80% HRmax; zone 4, 




Blood draws were performed by physician-approved allied health care providers using 
standard phlebotomy techniques. Venous blood samples were obtained by venipuncture of the 
antecubital fossa at baseline (Pre) and immediately post (Post) the testing sessions in sodium 
heparin Vacutainers.  
 
Antibodies and reagents 
 All antibodies used for flow cytometry were purchased from BioLegend (San Diego, CA) 
and include: anti-CD3-APC, anti-CD4-APC, and anti-CD25-PE. Cells were stained with 2.0 M 
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5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE, BioLegend, San Diego, CA) 
on day 0 of stimulation for proliferation assays. Flow cytometry was performed using an Accuri 
C6 (BD Accuri Cytometers, Ann Arbor, MI) and data analysis using CFlow Plus (Accuri).    
 
Cell purification and culture 
 Peripheral blood (30 ml into sodium heparin) was obtained at each time point for 
analyses of T cell proliferation. One pair of pre/post blood samples were processed immediately 
post exercise while the other two sets of blood samples were held overnight at room temperature 
or 4˚C. For all samples, total T cells were isolated from the peripheral blood by negative 
selection using a Human T cell enrichment kit (Stemcell Technologies, Vancouver, BC, Canada). 
Cells were cultured immediately at 37˚C with 5% CO2 in complete RPMI 1640 (Mediatech, 
Herndon, VA) containing 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 50 
U/ml each of penicillin and streptomycin (Life Technologies, Grand Island, NY), and 20 mM L-
glutamine (Life Technologies).  
 
T cell stimulation 
 T cell proliferation was analyzed in response to co-stimulation through CD3+CD28 using 
either plate-bound antibodies, PHA treatment, or no simulation. Each antibody was titrated to the 
lowest concentration that gave maximum T cell proliferation: anti-CD3 (OKT3) was used at 1 
g/ml (BioLegend, San Diego, CA) and anti-CD28 (CD28.2) at 2 g/ml (BioLegend, San Diego, 
CA). Antibodies were diluted to their indicated concentrations in sterile Dulbecco’s PBS (dPBS; 
Life Technologies) and incubated in 96 well plates overnight at 4˚ C; unbound antibodies were 
removed by washing 3X with dPBS immediately before cell plating. Total T cells were plated at 
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1.5 x 106 cells/ml in 200 l of complete RPMI 1640 directly after isolation. Stock 5 mg/ml PHA 
(Sigma-Aldrich, St. Louis, MO) was diluted into complete medium before use and added to 
appropriate wells immediately following cell plating to final concentration of 2.5 μg/mL. Cells 




Data were analyzed using a three-way mixed factorial ANOVA (trial [control x exercise] 
x time [pre x post] x delay condition [immediate (SP) x 24hrs room temperature (RT) x 24hrs 
4˚C (CH)]). When appropriate, follow-up analyses were performed using independent samples t-
tests and ANOVA models with Bonferroni corrections. The level of significance was set at  = 
0.05. All statistical analyses were performed using SPSS 22 (IBM Corporation, Armonk, New 
York, USA). 
 




Sixteen healthy, recreationally trained males (aerobic and/or resistance exercise 3-5 
d/wk) volunteered for this study. Participants were randomized to either a high-intensity (HI) 
(age = 21 ± 3 y; height = 178 ± 6 cm; weight = 82 ± 8 kg) or moderate-intensity (MOD) (age = 
20 ± 1 y; height = 182 ± 9 cm; weight = 84 ± 6 kg) group after study enrollment. There were no 
statistically significant differences between subject demographics between groups. Participants 
reported no recent use of non-steroidal anti-inflammatory drugs (NSAID), aspirin, or other over-
the-counter or prescription medications. Participants were instructed to refrain from exercise 24 
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h prior to data collection. This study was approved by the University of Kansas Institutional 
Review Board for Human Subjects at the University of Kansas, Lawrence, and all participants 
provided written informed consent and completed a Health & Exercise Status Questionnaire 
prior to participation.   
 
Dietary Controls 
 To ensure participants consumed a consistent diet, both in terms of energy content and 
macronutrition, food intake was standardized during data collection. Participants were instructed 
to abstain from caffeine and alcohol 12 h prior to data collection and to report in an 8 h fasted 
state. Each individual consumed a meal of commercially available food bars (Clif Bar & 
Company) and shakes (CytoSport, Inc) 1 h prior to baseline blood collection. The meal contained 
460 kcal, 17 g fat, 38 g carbohydrate, 22 g sugar, and 40 g protein. Sixty minutes into the 
training session subjects were provided with a commercially available electrolyte replacement 
beverage (Gatorade, Inc) containing 80 kcal, 21 g carbohydrates, and 21 g sugar. Upon training 
cessation participants were again provided food bars and shakes as well as a commercially 
available snack mix (Wal-Mart Stores, Inc.). The meal contained 600 kcal, 26 g fat, 52 g 
carbohydrate, 32 g sugar, and 44 g protein. At  2h post training participants consumed a 
standardized meal from a commercial location (Chipotle Mexican Grill) consisting of 1085 kcal, 
33 g fat, 107 g carbohydrates, 3 g sugar, and 84 g protein. All participants were allowed water ad 
libitum. Total food intake for the data collection period was: 2225 kcal, 76 g fat, 218 g 





 Subjects in the HI group participated in a single bout of training similar to what would be 
experienced in a military basic training environment. To achieve this effect the exercise session 
was led by senior members of the University of Kansas Army Reserve Officers’ Training Corps 
(ROTC) staff. During the session lead instructors would alternate, allowing for the physical 
intensity to remain at a high level throughout the training program. All exercises had been pre-
programmed prior to the session start with modification during the session to maintain intensity. 
Training consisted of a mix of aerobic activities (≤ 400 m), anaerobic body weight exercises, and 
anaerobic exercises utilizing 45 lbs weights with exercises quickly transitioning from one to the 
next to prevent recovery. The exercise bout lasted a total of 100 min. Scheduled 5 min rests were 
inserted at 30, 60, and 85 min after the initiation of the exercise session. During the scheduled 
rest periods, subjects were encouraged to consume water and a carbohydrate/electrolyte drink. 
 Subjects in the moderate-intensity group (MOD) participated in a 100 min bout of 
exercise training led by an exercise physiologist. Training consisted of similar activities as the HI 
group but performed at a pace allowing for in-session recovery. Scheduled 5 min rests were 
included at 30, 60, and 85 min after the initiation of the exercise session and MOD subjects were 
similarly encouraged to consume water and a carbohydrate/electrolyte drink. 
 
Physiological monitoring 
Participants were fitted with a Zephyr BioHarness 3 (Zephyr Technology, Annapolis, 
MD, USA) for HR measures. Continuous HR measures were recorded at 1 Hz intervals during 
the training session. HR data was downloaded using the Zephyr BioHarness Log Downloader 
(version 1.0.29.0). Five training zones were defined as follows: zone 1 <60% predicted 
maximum HR (HRmax); zone 2, 60%-70% HRmax; zone 3, 70%-80% HRmax; zone 4, 80%-90%; 
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and zone 5, >90% HRmax. HRmax was estimated using the methods of Tanaka et al. (167). HR, 
breathing rate and approximations of core temperature are logged by the Bioharness and 
interpreted using a proprietary Red/Orange/Green (ROG states) status indicator. Time in ROG 
states (Green: OK – vital signs within expected normal values. Orange: Alert – vital signs 
outside of “normal,” observation recommended. Red: Alert – vital signs significantly outside of 
normal range) were recorded at 1 Hz intervals for analysis.   
 
Blood collections 
Blood draws were performed by physician-approved allied health care providers using 
standard phlebotomy techniques. Venous blood samples were obtained by venipuncture of the 
antecubital fossa at baseline, immediately post-training (Post), 1 h post-training, 4 h post, and 6 h 
post-training and placed in sodium EDTA, sodium heparin, serum separator tubes, and no 
anticoagulant Vacutainers as indicated.  
 
Antibodies and reagents 
 Antibodies used for flow cytometry were: purchased from and include: anti-CD3-APC 
(BioLegend, San Diego, CA), and anti-CD152-PE (CTLA4 BioLegend, San Diego, CA). Cells 
were stained with 2.0 M 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE, 
BioLegend, San Diego, CA) on day 0 of stimulation for proliferation assays. Flow cytometry 
was performed using an Accuri C6 (BD Accuri Cytometers, Ann Arbor, MI) and data analysis 
using CFlow Plus (Accuri).    
 
Measurement of catecholamines, cortisol and complete blood counts 
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 Peripheral blood was collected in a serum separator tube (8 ml) for analyses of cortisol. 
Blood (6 ml) was collected in vials containing EDTA for analyses of complete blood counts 
(CBC) and catecholamines. Cortisol concentrations and CBC were assessed commercially by 
immunoassay and cytometry methods (Quest Diagnostics Laboratories, Lenexa, KS). Plasma for 
catecholamine (epinephrine and norepinephrine) analyses was obtained by centrifugation at 2000 
g for 10 min at 4˚ C and stored at -80˚C until analysis. Catecholamine concentrations were 
determined using BI-CAT ELISA kits according to the manufacturer’s instructions (Eagle 
Biosciences, Inc, Nashua, NH) using a Synergy microplate reader (BioTek, Winooski, VT, 
USA).  
 
Cell purification and culture 
 Peripheral blood (10 ml into sodium heparin) was obtained at each time point for 
analyses of T cell proliferation. Peripheral blood mononuclear cells (PBMC) were isolated using 
Ficoll-Paque PLUS (GE Healthcare, Piscataway, NJ) density gradient centrifugation. Total T 
cells were purified from washed PBMC by E-rosetting. Briefly, PBMC were incubated with 
AET-treated sheep red blood cells (RBC, Hemostat Laboratories) for 10 min at 37˚ C. Cells were 
pelleted and held on ice for 30 min, re-suspended in the same fluid, and centrifuged over a 
Ficoll-Paque PLUS density gradient. T cells from the pellet were cleared of red blood cells by 
lysis in ACT (17 mM Tris, 0.83% NH4Cl, pH 7.2), and washed three times. Cells were cultured 
immediately at 37˚ C with 5% CO2 in complete RPMI 1640 (Mediatech, Herndon, VA) 
containing 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 50 U/ml each of 
penicillin and streptomycin (Life Technologies, Grand Island, NY), and 20 mM L-glutamine 




T cell stimulation 
 T cell proliferation was analyzed in response to co-stimulation through CD3+CD28 using 
either plate-bound antibodies, phytohaemagglutinin (PHA) treatment, or no simulation. Each 
antibody was titrated to the lowest concentration that gave maximum T cell proliferation: anti-
CD3 (OKT3) used at 1 g/ml (BioLegend, San Diego, CA) and anti-CD28 (CD28.2) at 2 g/ml 
(BioLegend, San Diego, CA). Antibodies were diluted to indicated concentration in sterile 
Dulbecco’s PBS (Life Technologies) and incubated in 96 well plate overnight at 4˚C; unbound 
Antibodies were removed by washing 3X with dPBS immediately before cell plating. Total T 
cells were plated at 1.5 x 106 cells/ml in 200l complete RPMI 1640 directly after isolation. 
Stock 5 mg/ml PHA (Sigma-Aldrich, St. Louis, MO) was diluted into complete medium before 
use and added to appropriate wells immediately following cell plating to final concentration of 
2.5 ug/mL. . Cells were incubated for 6 d at 37˚ C in a humidified incubator with 5% CO2 and 
then analyzed by flow cytometry 
  
Serum cytokines, creatine kinase, and high mobility group box 1 protein 
Peripheral blood (8ml) was collected into at tube containing no anticoagulant. Serum for 
analyses was obtained after clotting by centrifugation at 2000g for 10 min at 4˚ C and stored at -
80˚ C until analysis.  Peripheral concentrations of IFN-, IL-10, IL-17a, IL-1, IL-2, IL-4, IL-5, 
IL-6, and TNF- were determined using a human cytokine magnetic bead panel kit 
(HCYTOMAG-60K-13) (Millipore, Billerica, MA, USA). The samples were detected and 
analyzed using a Luminex 200 System (Luminex Corp, Austin, TX). Creatine kinase (CK) 
enzyme concentrations were computed using a CK reagent kit (Pointe Scientific, Inc. Canton, 
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MI). The samples were measured using a Synergy microplate reader (BioTek, Winooski, VT) at 
340 nm at 1, 2 and 3 minutes. HMGB1 concentrations were measured using Human HMGB1 
Elisa kits (NeoBioLab, Cambridge, MA). The results were read at 450 nm using a Synergy 
microplate reader (BioTek, Winooski, VT, USA). All ELISA procedures were performed 
according to the manufacturer’s instruction.   
 
Statistical analysis 
Data were analyzed using two-way mixed factorial ANOVA (group [HI x MOD] x time 
[1 vs. 2 vs. 3 … vs. 5]). When appropriate, follow-up analyses were performed using 
independent samples t-tests and ANOVA models with Bonferroni corrections. The level of 
significance was set at  = 0.05. All statistical analyses were performed using SPSS 22 (IBM 
Corporation, Armonk, New York, USA). 
 
3.3 Study 3: Immunoendocrine responses to the Marine Corps Martial Arts Program 
 
Subjects 
Thirty-six male, active duty, newly enlisted U.S. Marines were recruited for this 
investigation (age = 19 ± 1 yrs; height = 175 ± 7 cm; weight = 74 ± 7 kg). Six cohorts were 
recruited over a period of 18 months with each cohort being observed 3 times with 3 weeks 
between each visit. All Marines had recently graduated Recruit Training and the School of 
Infantry and were reporting to the Marine Corps detachment based in Fort Leonard Wood, MO 
for formal training in their assigned Military Operational Skill (MOS).  Subjects provided 
informed consent and completed a medical history questionnaire prior to participation. At the 
time of recruitment, subjects were instructed to maintain their normal physical activity and 
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dietary patterns leading up to data collection. This implied that subjects would be in a non-fasted 
state at the time of data collection. This study was approved by the University Institutional 
Review Board for Human Subjects at the University of Kansas, Lawrence and the U.S. Marine 
Corps Human Research Protection Program in Washington D.C.  
 
Training Session 
The Marines arrived at the testing location at 0530 hours for baseline assessment and 
began the training session at 0600 hours. MCMAP training consists of approximately 30 min of 
Combative Conditioning (CC) involving a variety of exercises including but not limited to 
sprints, calisthenics and partner carries/drags. The CC component is followed by approximately 
30 min of Combative Arts (CA) under the supervision of a MCMAP instructor. The CA portion 
involves skill instruction and practice at varying intensities. In addition to the physical stress of 




Participants were fitted with a Zephyr BioHarness 3 (Zephyr Technology, Annapolis, 
MD, USA) for heart rate (HR) measures. Continuous HR measures were recorded at 1Hz 
intervals during the training session. HR data were downloaded using the Zephyr BioHarness 
Log Downloader (version 1.0.29.0). Five training zones were defined as follows: zone 1 <60% 
predicted maximum HR (HRmax); zone 2, 60%-70% HRmax; zone 3, 70%-80% HRmax; zone 4, 





Blood collections and analyses 
Blood draws were performed by physician-approved allied health care provider using 
standard phlebotomy techniques. Venous blood samples were obtained by venipuncture of the 
antecubital fossa at baseline. Following the training session, an intravenous catheter (Braun, 18 
g, 32 mm) was inserted into the antecubital vein, and a small bore extension set (Braun, 20 cm) 
was attached. Venous blood samples were collected immediately after training end (IP) and 
every 15 min for 1 h post-training (R15, R30, R45, and R60) in sodium EDTA, sodium heparin, 
serum separator tubes, and no anticoagulant Vacutainers as indicated. For each post-training 
blood collection, approximately 1 ml of blood (with saline from the extension set) was drawn 
into a discard tube prior to the sample draw. 
NE, EPI, CORT, immunoglobulin (Ig)-G, IgM, complete blood count (CBC), neutrophil 
oxidative burst and lymphocyte subsets were determined from blood samples obtained 
immediately after training end (IP) and every 15 min for 1 h post-training (R15, R30, R45, and 
R60). Peripheral blood was collected in a serum separator tube (16 ml) for analyses of cortisol 
and immunoglobulins. Blood (6 ml) was collected in vials containing EDTA for analyses of 
complete blood counts (CBC) and lymphocyte subsets. Peripheral blood (16 ml into sodium 
heparin) was obtained for analyses of catecholamines and neutrophil oxidative burst function. 
Cortisol levels, IgG, IgM, and CBC were assessed commercially by immunoassay, 
immunoturbidimetric, and cytometry methods respectively (Quest Diagnostics Laboratories, 
Lenexa, KS). Catecholamines (EPI and NE) were assessed commercially by high performance 
liquid chromatography (HPLC) with electrochemical detection (Quest Diagnostics Laboratories, 
Chantilly, VA). Lymphocyte subsets including absolute and percent CD3, CD4, CD8, CD19, 
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CD16/56 and total lymphocytes and neutrophil oxidative burst function were assessed 
commercially by flow cytometry (Quest Diagnostics Laboratories, St. Louis, MO; Quest 
Diagnostics Laboratories, San Juan Capistrano, CA).  
 
Statistical analysis 
The data were naturally arranged in a hierarchical structure (i.e. time nested within visits, 
nested within subjects). We performed three-level multilevel models with the repeated measures 
for time as the level 1 measurement, visit as the level 2, and subject as level 3. The main analysis 
focused on change over time for each parameter after controlling for baseline concentrations. 
Preliminary analyses found 1.4% missing data in our data set. Given the localization of the 
missing data and our knowledge of why it occurred, these data points were classified as missing 
completely at random and imputed (168). Missing data imputation was performed using the mice 
(169) package and the lme4 package in R version 3.0.1 (170) was used for model analyses. 
Random intercepts and slopes were specified for subjects as well as for time. Fixed effects for 
time (linear, quadratic, and cubic) were tested using nested model tests. Overall, significant 
predictors at p < 0 .05 were retained.  Ancillary analyses employed procedures for analyzing 
serial measurements (171). Specifically, variables were quantified using area-under-the-curve 

































4.1 Study 1: T Cell Proliferation and Activation Following Exercise 
 
4.1.1 Acute exercise induced substantial changes in heart rate and ratings of perceived 
exertion 
 
 The acute exercise trial elicited a substantial sympathetic stimulus as demonstrated by the 
summative time spent in heart rate zones. The mean predicted HRmax for all subjects was 190 ± 3 
bpm. Average HR during the EX trial was 150 ± 15 bpm compared to an average of 79 ± 7 bpm 
in the CT session. Summative time in HR zones for the EX trial were: zone 1: 4.6 ± 4.4 min; 
zone 2: 3.5 ± 2 min; zone 3: 7.8 ± 4.1 min; zone 4: 6.4 ± 3.6 min; and zone 5: 9.2 ± 6.7 min. 
Average RPE during the EX trial was 14. The entirety of the 30 min CT session was spent under 
the zone 1 threshold with an average RPE of 6.  
 
4.1.2 T cell proliferation responses to PHA increased post exercise  
 
 Acute exercise significantly increased T cell proliferation relative to the control trial with 
a significant trial x time interaction effect observed for both the percent of proliferating cells 
(p=0.026) and total number of divided cells (p=0.048) (Fig. 1). There were no significant 
changes in PHA stimulated proliferation measures pre-to-post CT session. It did not appear that 
T cell proliferation via PHA was adversely impacted when cells were rested in whole blood 
overnight suggesting it would be a fairly robust stimulant for delayed isolation protocols (Fig. 2). 
There were no significant differences in pre-trial PHA stimulated proliferation measures for the 







4.1.3 CD3+CD28 proliferation affected by isolation protocol 
 
 Exercise-induced T cell proliferation increased when cells were stimulated with 
CD3+CD28, but there were no significant trial x time interactions for either percent changes in 
proliferation (p=0.094) or cell count data (p=0.902). T cell delay protocols did significantly 
Fig. 2. PHA stimulated T cell proliferation measures are relatively stable across delayed isolation 
protocols. a) Control trial cell count measures. b) Exercise trial cell count measures. c) Control trial percent of 
cells dividing. d) Exercise trial percent of cells dividing. Values are presented as means ± SD. SP: Standard 
Protocol; RT: Overnight at Room Temperature; CH: Overnight at 4˚C.  
 
Fig. 1. PHA stimulated cell counts increased following the exercise condition. a) PHA stimulated cell count 
data. b) PHA stimulated percent data. All values have been normalized to baseline. Values are presented as 
means ± SD.  * indicates significant difference from Pre. 
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impact both measures, however, with trial x delay interaction effects observed for both percent 
(p=0.019) and count data (p=0.042). Follow up analyses uncovered no significant differences 
among delay conditions for the CT session, but did reveal significant differences in the EX trial.  
 The SP method had significantly higher proliferation values for both percent and cell 
counts when compared to the RT (percent: p=0.048; count: p=0.036) and CH (percent: p=0.026; 
count: p=0.085) delayed isolation protocols (Fig. 3). Proliferation increased following exercise 
relative to the control session using the SP method but failed to reach statistical significance for 
either percent (p=0.078) or count data (p=0.051). The lack of significance is likely a result of 
small sample size and future work will need to address whether this finding holds in larger 
studies.  
 Allowing cells to rest overnight in whole blood, whether at room temperature or 4˚ C, 
lessened the exercise-induced stimulus for proliferation rendering both the RT and CH samples 




Fig. 3. Proliferation measures for CD3+CD28 stimulated T cells were depressed when cells were rested 
overnight in whole blood. a) Cell count data. b) Percent data. Values are presented as means ± SD. SP: 
Standard Protocol; RT: Overnight at Room Temperature; CH: Overnight at 4˚C. * indicates statistically 






4.1.4 Activation of PHA stimulated T cells marginally increased with exercise 
 
Although the level of PHA induced proliferation increased significantly from pre-to-post 
exercise, the trial x time interaction effect did not remain significant when looking at CD4-
CD25+ (p=0.078) and CD4+CD25+ (p=0.057) cell counts (Fig. 5). There were no significant 




Fig. 4. Measures CD3+CD28 stimulated T cell proliferation post-exercise are negatively impacted by 
delayed cell isolation. a) Control trial cell count measures. b) Exercise trial cell count measures. c) Control trial 
percent of cells dividing. d) Exercise trial percent of cells dividing. Values are presented as means ± SD. SP: 




 There was a significant time x delay interaction for CD4-CD25+ cells (p=0.014). Follow-
up analyses indicated that while there were no differences within trial sessions, the SP and CH 
isolations both saw substantial increases in activated cell counts from pre-to-post (SP: p=0.076; 
CH: p=0.012). The RT isolation also had higher values for the post measure but did not reach a 
significant level (p=0.338). Figure 6 represents cell activation responses pre-to-post trial and by 
isolation protocol. 
Fig. 5. PHA stimulated cell activation in CD4- and CD4+ cells marginally increased post-exercise. a) PHA 
stimulated cell count data for CD4-CD25+ T cells. b) PHA stimulated cell count data for CD4+CD25+ T cells. 




4.1.5 Delay protocol affects markers of CD3+CD28 stimulated T cell activation 
 
 T cell activation following stimulation with CD3+CD28 was again disproportionately 
influenced by the delay protocol used for T cell isolation from whole blood. CD4-CD25+ cells 
had a significant trial x delay interaction for cell counts (p=0.019) as well as percent of cells 
activated (p=0.028). Examination of cell count data (Fig. 7a) found significantly elevated levels 
of CD25+ cells following the SP isolation relative to RT (p=0.038) and CH (p=0.029). Further, 
the EX trial exhibited a significantly greater number of activated cells relative to the CT trial 
when using the SP isolation (p=0.04). The percent of activated CD4- cells paralleled this result 
with SP showing increased values compared to RT (p=0.032) and CH (p=0.066). The increased 
values in the EX trial did not reach a significant level compared to CT (p=0.069). 
Fig. 6. PHA stimulated T cell activation post-exercise is minimally impacted by cell isolation delays. a) 
Control trial CD4-CD25+ cell count measures. b) Exercise trial CD4-CD25+ cell count measures. c) Control trial 
CD4+CD25+ cell count measures. d) Exercise trial CD4+CD25+ cell count measures. Values are presented as 
means ± SD. SP: Standard Protocol; RT: Overnight at Room Temperature; CH: Overnight at 4˚C. * indicates 
statistically significant difference from SP. 
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CD4+CD25+ cell counts post-exercise did not exhibited significant decreases (p=0.087)  
in activation after resting overnight (Fig. 7b). There was a main effect for delay (p=0.026) with 
SP increased relative to both RT and CH isolations. Figure 8 represents cell activation responses 





Fig. 8. Exercise-induced measures of CD3+CD28 stimulated T cell activation are decreased following 
overnight delays in T cell isolation. a) Control trial CD4-CD25+ cell count measures. b) Exercise trial CD4-
CD25+ cell count measures. c) Control trial CD4+CD25+ cell count measures. d) Exercise trial CD4+CD25+ cell 
count measures. Values are presented as means ± SD. SP: Standard Protocol; RT: Overnight at Room 
Temperature; CH: Overnight at 4˚C.  
Fig. 7. Post-exercise T cell activation following CD3+CD28 stimulation exhibits a greater increase CD4- 
cell populations. a) CD4-CD25+ cell counts. b) CD4+CD25+ cell counts. Values are presented as means ± SD. † 
indicated a significant difference between trials. * indicates a significant difference from SP. 
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4.2 Study 2: Do Military and Tactical Experiences Model the Characteristic Exercise 
Response 
 
4.2.1 Heart rate and approximate core temperature differed significantly by group 
 
 Average HR during the training session was significantly elevated in HI compared to 
MOD groups (158 ± 6 bpm vs. 130 ± 9 bpm; p<0.001) with a significant group x time interaction 
effect (p<0.001) for time in heart rate zones (Fig. 1). Time spent in each respective heart rate 
zone significantly differed between groups. Significant differences between approximate 
measures of mean (p<0.001) and peak (p=0.002) core body temperature were also observed 
between HI and MOD groups during the training sessions (mean: 38.6 ± 0.3 vs. 37.9 ± 0.2; peak: 
39.3 ± 0.5 vs. 38.4 ± 0.4 respectively) although these are not likely to be biologically relevant in 
this context. Further, a significant group x time interaction was identified for percent of time 
spent in the individual ROG states (p<0.001). Together these data suggest the HI group testing 





4.2.2 Endocrine responses marginally elevated in high intensity session 
 
 Analyses of catecholamine measures did not uncover any significant group x time 
interaction effects (Fig. 2). Both EPI (p<0.001) and NE (p=0.003) did, however, exhibit main 
effects for time. There was a significant group x time interaction for CORT (p=0.028) with a 
significantly higher concentration observed in the HI compared to MOD group at the Post 
measure (p=0.011). There were no significant differences in baseline endocrine concentrations 
between groups.  
Fig. 1. Measures of training intensity significantly differed by group. a) Time spent in heart rate zones 
during training session, b) Approximate measures of core body temperature during training, and c) Time in 
Bioharness Alert Algorithm Status (ROG states). Green: OK – vital signs within expected normal values. 
Orange: Alert – vital signs outside of “normal,” observation recommended. Red: Alert – vital signs significantly 
outside of normal range, action may be needed. Values are presented as means ± SD. * Indicates significantly 







4.2.3 T cell proliferation significantly increased in the high intensity group 
 
 Phytohaemagglutinin stimulated T cell proliferation cell counts (p=0.025) and percent 
(p<0.01) were significantly increased in the HI group at all time points, including the baseline 
measures, relative to the MOD. Due to the significant difference in baseline measures, we 
examined the curve profiles of proliferation responses following each session. Figure 3 shows 
proliferation response curves normalized to baseline for cell count data. While the MOD groups 
say no significant changes over time, the HI group saw an immediate, and significant (p=0.021), 
increase in cell proliferation at the Post measure. 
Fig. 2. Endocrine concentrations relative to Pre measures increased following training sessions. a) 
Epinephrine, b) Norepinephrine, and c) Cortisol. All values have been normalized to Pre. * Indicates 





 A similar group x time interaction effect was observed for counts (p<0.001) and percent 
(p<0.001) of T cells stimulated using CD3+CD28 (Fig. 4). Only the HI group was significantly 
increased at the Post measure (p<0.001) while both groups were significantly elevated at 4 h and 
6 h relative to their baseline controls. We did identify significant differences between groups 
(Fig. 5) at the Pre (p=0.02), Post (p<0.001), and 1 h (p=0.003) measures where it was evident 
that the HI group responded to the training session with enhanced proliferation whereas the 




        
Fig. 3. PHA stimulated T cell proliferation increased immediately in the HI group compared to MOD. a) 
Moderate Intensity group cell count data. b) High Intensity group cell count data. All values are normalized to 
the Pre time point. - - - Indicates mean response curve. 
Fig. 4. CD3+CD28 stimulated T cell proliferation increased immediately in the HI group compared to 
MOD. a) Moderate Intensity group cell count data. b) High Intensity group cell count data. All values are 
normalized to the Pre time point. - - - Indicates mean response curve. 
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4.2.4 Alterations in peripheral cytokine concentrations do not explain changes in cell 
proliferation 
 
 Given the variation in proliferative responses we expected to see cytokine profiles 
indicative of increased T cell activity. To the contrary, we found that cytokine measures for a 
number of immunomodulatory cytokines were below detectable limits for the majority of our 
samples. These cytokines included: IL-1, IL-2, IL-4, IL-5, and IL-6.  
 A significant group x time interaction effect (p=0.004) was observed for IL-10 with the 
HI group have significantly higher concentrations at Post (p=0.013). Peripheral concentrations 
remained elevated in this group at 1 h but did not maintain a level of statistical significance 
(p=0.055) (Fig. 6). While the MOD group saw little to no change across time measures, the HI 
group exhibited not only similarly scaled increases but also shared the same kinetic profile post-
training suggestive of a strong patterned response to the training session.   
 
Fig. 5. HI group participants showed a tendency toward increased proliferation post-session while the 










 TNF- exhibited a similar group x time interaction effect (p=0.012) (Fig. 7) with the HI 
group having elevated concentrations at both the Post (p=0.023) and 1 h (p=0.038) measures 
relative to the MOD session. The observed concentrations were not as large as those observed for 
IL-10, but represent a similar profile in terms of the response curve over the recovery period. 
Expecting that the TNF- concentrations may have been muscle-derived, CK was also 
investigated but no significant differences were observed between groups (Fig. 8).     
Fig. 6. IL-10 responses significantly elevated in HI group post training. a) IL-10 responses between groups 
following the two training sessions differed at the Post measure (Mean ± SD), b) Individual response curves for 
MOD participants normalized to Pre concentrations, and c) Individual response curves for HI participants 









    
 
 
4.2.5 CTLA-4 and HMGB1 concentrations not responsible for changes in functional 
immune responses 
 
Fig. 7. TNF- responses significantly elevated in HI group post training and out to 1 hr. a) TNF- 
responses between groups following the two training sessions differed at the Post and 1 hr measures (Mean ± 
SD), b) Individual response curves for MOD participants normalized to Pre concentrations, and c) Individual 
response curves for HI participants normalized to Pre concentrations. * Indicates significantly different between 
groups. - - - Indicates mean response curve. 
 
  
Fig. 8. Creatine kinase concentrations tended to increase over the recovery 
period with no significant interaction effects identified. Values are 




 There was a significant group x time interaction effect (p=0.017) for mean fluorescence 
intensities (MFI) of CTLA-4 in cells stimulated with CD3+CD28. The HI group had 
significantly elevated values at the Post measure (p=0.031) with no other time points being 
significantly different (Fig. 9). The MOD group, however, saw an increase at the 4 h time point 
relative to the HI group, but it was not statistically significant (p=0.096). There were no 





 High mobility group box-1 protein (HMGB1), a marker of oxidative stress, was also 
investigated as a potential mechanism for increased T cell proliferation. There were no 
significant interaction effects observed over the time points measured. There was, however, 
some variability in individual response curves between groups suggestive of possible training 
derived alterations but no statistically significant changes were observed (Fig. 10).  
Fig. 9. Mean fluorescence intensity of CTLA-4 following CD3+28 stimulation elevated in HI group post-
training. a) CTLA-4 MFI between groups following the two training sessions differed at the Post measure 
(Mean ± SD), b) Individual response curves for MOD participants normalized to Pre measures, and c) Individual 
response curves for HI participants normalized to Pre measures. * Indicates significantly different between 







4.2.6 Leukocyte responses to training did not significantly differ by group 
 
 All immune parameters exhibited significant main effects for time but only neutrophil 
cell counts displayed a significant group x time interaction effect (p=0.004) (Fig. 11). The HI 
group had significantly elevated neutrophil counts at the Post (p=0.045) and 1 hr (p=0.027) time 
points. All other leukocyte measures demonstrated characteristic cell trafficking alterations with 
both cell counts and percentages decreased immediately post training and rising to, or above, 
baseline values during the recovery period. 
    
 
 
4.3 Study 3: Immunoendocrine responses to the Marine Corps Martial Arts Program 
 
Fig. 10. Individual response curves for peripheral HMGB1 concentrations. a) MOD, b) HI. Values have 
been normalized to Pre. - - - Indicates mean response curve. 
  
Fig. 11. Neutrophils significantly elevated in the HI group. Values are presented as means ± SD. * Indicates 




4.3.1 Heart rate response to training 
 
 The MCMAP is an effective exercise stimulus as demonstrated by the summative time in 
heart rate zone data (Fig. 1), with approximately 27 min of each visit spent working at a HR ≥ 
70% of HRmax. Mean predicted HRmax for the study participants was 194 ± 1 bpm. Average HR 
during training was: Visit 1 – 140 ± 10 bpm; Visit 2 – 135 ± 18 bpm; and Visit 3 – 138 ± 17 
bpm. There were no significant differences in heart rate responses across visits suggesting that 
the physiological stimulus of MCMAP sessions are fairly standard across time with the Martial 
Arts Instructors (MAI) manipulating the training to maintain the physical intensity over time. 
 
    
 
4.3.2 Responses to training analyzed using serial measurements 
 
 Analysis of all blood parameters using serial measurement parallels the HR response with 
no measures showing any statistical difference across visits. This supports the notion that 
physical intensity and other stress components are managed within each visit to maintain a given 
intensity of training no matter the Marine’s skill level or combative lesson for that day. Summary 
results for all measures are presented in Appendix C. 
4.3.3 Endocrine responses to training 
 





 Characteristic endocrine responses to a military training protocol were observed and 
included substantial increases in peripheral catecholamines immediately post training. To 
quantify endocrine responses, both within and between visits, blood parameters were mapped 
and trend lines visualized. Epinephrine and norepinephrine increased significantly post training 
with an average increase relative to baseline of 2.8 and 2.4 respectively (Fig. 2). These 
concentrations decreased rapidly over the recovery period with values at, or near baseline levels 
by the end of the one-hour recovery period. Cortisol remained relatively stable from pre-to-post 
training with only a moderate increase observed relative to baseline (1.15). Examination of the 
random effects values suggests that, as would be expected, higher endocrine concentrations at 
the Post measure are correlated with a smaller slopes over the recovery period. These data 
generally indicate standard MCMAP training generates a strong sympathetic adrenal-medullary 
response with lesser engagement of the hypothalamic-pituitary-adrenal axis. Figures showing 
endocrine responses over the recovery period along with tables showing the multilevel regression 
model results can be found in Appendix C. 
 
 
Fig. 2. Fold changes in endocrine concentrations following training sessions. a) Epinephrine, b) 




4.3.4 Immune responses to training. 
 
 Regarding all the immune variables, every measure examined showed significant change 
over time during the recovery period. Stereotypical alterations in circulating lymphocytes and 
leukocytes were observed following MCMAP training sessions with peak peripheral cell counts 
typically reached immediately post training and then falling below baseline values during the 
one-hour recovery (Fig. 3).  
 
 
 Changes in the percent of circulating lymphocytes followed characteristic patterns (Fig. 
4) with percentages of CD3+, CD4+, and CD19+ cells all increasing over the recovery period. 
These increases result from the interplay between NK cells, and to a lesser extent CD8+ cells, 
which peak at the Post measure and subsequently decrease over the one-hour period. The 
changes in percent of lymphocytes in circulation during the recovery period are, therefore, highly 
impacted by the initial influence of NK and CD8+ cells. 
Fig. 3. Representative changes in lymphocyte and leukocyte populations following MCMAP training. a) 







 Leukocyte counts followed a similar trend with peak values reached at the Post measure 
with the exception of neutrophils, which continued to increase over the recovery period (Fig. 5). 
These changes are also reflected in the percent data with circulating neutrophils representing a 




Fig. 4. Percent changes in lymphocyte subsets are driven by increases in circulating Natural Killer and 
CD8+ cells. a) Natural killer cells, b) CD19+ cells, c) CD8+ cells, and d) CD4+ cells.  




 Both immunoglobulins-G and –M showed similar curvilinear trends over the recovery 
period with peak concentrations observed at the Post measure. Neutrophil oxidative burst 
capacity showed a very slight increasing trend over the recovery without any real substantial 
deviation over time. Summary multilevel regression results and figures for all immune 
















































 The projects undertaken as part of this research effort were selected to provide a 
foundation for future work investigating changes in immunocompetence following layered stress 
challenges. It is evident that impaired immune function can negatively impact an individual, but 
what is not clear is whether the paradigms used to model high-intensity, layered stress scenarios 
are appropriate. Additionally, the best methods to assess these changes outside the laboratory 
have not been determined. The results identified in this project were largely in agreement with 
our hypotheses regarding stability of T cell surface markers, T cell proliferative responses, and 
alteration in immune cell circulation following standard U.S. Marine Corps Martial Arts 
Training. The one exception to these predicted results was the enhanced proliferative response 
generated by exposure to a high-intensity, layered stress environment.  
 Functional immune responses to exercise have traditionally been investigated within a 
highly-controllable laboratory environment and have used immunoendocrine responses induced 
by various exercise regimens as platforms to generalize results to the stress environments of 
competitive events or even military wartime operations. Recently, scientists have begun 
examining paired physical and psychological stressors (dual stress challenges) in laboratory 
settings with the goal of increasing the veracity of collected data and allowing more accurate 
generalization of the findings to military and first responder populations operating in tactical 
situations. While these are excellent models for teasing out the impact of a psychological stressor 
above that of exercise alone, it is possible that they do not generalize outside of a laboratory 
setting.   




 In light of these considerations we aimed to determine the feasibility of offsite blood 
collection for the purposes of assessing T cell proliferative capacity in a field environment. The 
changes we observed comparing both delayed protocols for T cell isolation and different cell 
stimulating methods suggest that PHA stimulation is more robust to overnight delays in blood 
processing. This is likely a result of how PHA signals into the cell to initiate T cell proliferation. 
PHA binds to and subsequently cross-links glycoproteins on the T cell surface; specifically, PHA 
can cross-link TCR-CD3 complexes allowing for sufficient activation of intracellular signaling 
(172). This blunt force method of cell activation bypasses the two-signal process required for 
physiological activation of T cells that is approximated using co-stimulation by CD3+CD28 
antibodies. In our study, T cells were isolated from whole blood after an overnight rest in either a 
room temperature or chilled condition. T cells that were isolated following the overnight delay 
did not respond as well to co-stimulation by CD3+CD28, suggesting there exists a subtler 
mechanism for in vitro T cell activation and proliferation. More importantly, these findings 
indicate that the intracellular pathways which exercise may stimulate are sufficiently diminished 
after an overnight delay that co-stimulation through CD3+CD28 is not the ideal method for 
analyses of T cell proliferation in this setting. To our knowledge, this is the first study examining 
the effect of delayed isolation protocols on measures of proliferation and cell activation using 
different stimulating agents.  
5.3 Functional immune responses to layered stressors 
 
 The increases in proliferation following a high intensity, layered stress training session 
were unexpected. We anticipated the intensity and duration of the physical activity would 
produce a moderate-to-large suppression of proliferative capacity over the recovery period. 
However, the high-intensity group’s increase in proliferative ability is similar to other reports 
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(139, 141) identified as part of our lab’s recent meta-analytic findings (Siedlik, Unpublished), 
suggesting increased proliferation in high-intensity, competitive environments. These findings 
indicate there is likely a psychological component involved in this response that is not being 
detected through our current analytic strategies. In an effort to identify potential mechanisms for 
the observed proliferative response we investigated a number of relevant immunomodulatory 
pathways including endocrine measures, cytokine concentrations, and HMGB1.  
 Differences observed in the endocrine and immunomodulatory responses across high and 
moderate intensity exercise groups failed to provide a mechanistic target for the observed 
functional T cell responses. Several studies have observed exacerbated catecholamine responses 
in veteran firefighters given a work-relevant mental task while cycling at a moderate intensity 
(60% VO2max) compared to an exercise alone condition (13-15). Similarly increased 
concentrations of cortisol have been observed in firefighter and civilian populations undergoing 
analogous dual stress challenges (15, 16, 158). Most relevant to the present work, applications of 
dual stress challenges compared to exercise alone, have observed increased immune cell 
trafficking, markers of oxidative stress, and alterations immunomodulatory cytokines (13, 14, 
159).   
 The significant difference in peripheral TNF- concentrations across the groups is 
probably derived from increased secretions by skeletal muscle. Muscle has been widely accepted 
as a potent endocrine organ during high intensity exercise (173) and not only explains group 
difference based on physical intensity level but also addresses the relatively low increases (~1.5 
fold change) in the circulation. This finding is mirrored by the peripheral IL-6 response (~1.6 
fold change) and suggests these measures are representative of changes in skeletal muscle 
inflammatory processes and not necessarily derived from immune cell activity. 
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 The IL-10 response observed in the high intensity group (~22.6 fold change) is strongly 
indicative of a negative feedback mechanism aimed at inhibiting T cell proliferation in these 
subjects. IL-10 is known to indirectly regulate T cell functional responses via a direct effect on 
monocytes and macrophages (174). IL-10 inhibits costimulatory molecules B7-1 and B7-2 and 
MHC Class II expression on monocytes and macrophages thereby subverting the second-signal 
mechanism required for cell proliferation (175). Further, IL-10 can directly inhibit the tyrosine 
phosphorylation of CD28 and subsequent PI3K binding in T cells, inhibiting production of a 
number of immunomodulatory cytokines including IFN-, IL-2, IL-4, IL-5, and TNF-
. To this end, the large scale increases observed in all high intensity group participants may 
be a physiological response to prevent an overshoot in the proliferative immune response.  
 During the recovery portion, the observed IL-10 response is probably in rebuttal to a 
significant inflammatory and/or proliferative response during the training session that we were 
unable to quantify without an in-session blood measure. An in-session measure would potentially 
clarify the cytokine data as well. Due to the variations in the half-life of these signaling proteins 
and the interplay between them, the data presented here may not be representative of the initial 
insult to the physiological system but instead approximate the body’s attempt to mitigate the 
stress response and return to homeostasis following the primary stress exposure. Unfortunately 
we were unable to identify a potential mechanism for enhanced proliferation. Differences in 
measured endocrine parameters are trivial enough to preclude those as being likely mediators for 
increased proliferation. Similarly, the observed cytokine profiles limit any hypotheses toward 
cytokine-mediated cell signaling.  
Our hypothesis that increased oxidative stress may cause greater expression of damage 
associated molecular pattern (DAMP) molecules that subsequently stimulates lymphocyte 
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proliferation was also not borne out in our observed data. The oxidative stress response to 
exercise is similar to lymphocyte trafficking in that it is heavily influenced by exercise intensity 
and duration. The majority of endogenous reactive oxygen species (ROS) are produced in the 
mitochondrial electron transport chain (177). Studies have shown diminished markers of 
oxidative stress at moderate intensity with both high intensity aerobic and anaerobic exercise 
showing elevated markers of oxidative stress in comparison (178). Regardless of the stimulant, 
increased concentration of ROS can lead to macromolecular damage and impairments of cellular 
function (179).   
 HMGB1 is secreted by macrophages and dendritic cells in response to increased 
oxidative stress. Moreover, mitochondrial HMGB1 expression is increased in response to 
oxidative stress (179). HMGB1 is one of the prototypical DAMPs and has been shown to 
increase proliferation of activated CD4+ and CD8+ cells in culture (180). In this study we did not 
observe any substantial HMGB1 concentration differences between groups suggesting it is likely 
not initiating the increases in proliferation. Although it has been presented here in a very 
simplistic model, HMGB1 is a redundant molecule and other DAMPs released in response to 
oxidative stress such as S100 proteins and heat shock proteins may serve in the same mechanistic 
roles (181). Again, we anticipate future work will examine other DAMPs and variations in not 
only the level of stress but also differences in fitness levels as way to illuminate possible 
mechanisms for enhanced signaling.     
   On a macro level, the main findings from the first two studies suggest that the exercise 
models currently utilized to approximate stressful environments are probably insufficient for 
modeling the physiologic response. This, therefore, defines the primary impetus for Project 
Three, which provides a specific accounting of the physiologic immunoendocrine response to 
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standardized U.S. Marine Corps training. As identified by the heart rate data recorded, MCMAP 
is not a tremendously stressful training environment but does provide an accurate assessment of 
the physiological response to real-life training, which we believe is the next evolution of dual-
challenge stress research in a field environment. It is important to note that the heart rate 
responses observed within MCMAP sessions are similar to those measured in laboratory based 
dual stress challenge testing (13-16, 158, 159, 164). Similarly, observed endocrine measures 
from MCMAP training closely resemble both the catecholamine (13-15) and cortisol responses 
(15, 16, 158) identified in subjects undergoing dual stress challenges. 
 Lymphocyte redistribution following MCMAP is similar to that shown in research 
examining lymphocyte subset trafficking in firefighters participating in paired exercise and 
computer-based simulations (13). Together these would suggest that the general framework of 
current MCMAP training is a real-world analogue of laboratory based dual stress research 
protocols. To date, no research has yet examined leukocyte redistribution trends following dual 
stress challenges and we anticipate our data will provide a more complete profile of the 
immunoendocrine response following training and exposure to combined stress environments.  
 In two studies by Huang, et al. (14, 159), IL-2 responses have been examined as part of 
the immune response to laboratory based dual stress challenges with conflicting results. Our full 
analyses of immunoendocrine responses to MCMAP training did not account for changes in 
cytokine concentrations following training. However, earlier work from our lab investigating a 
single bout of MCMAP training did not find a significant IL-2 response (165). Taken together, 
we propose that the library of response curves we have developed for immunoendocrine 
parameter changes following standard U.S. Marine Corps training adequately quantify the effects 
of dual stress challenges in a field environment. 
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 In our analyses, we benefited from the uniformity of the subjects training status. They 
had roughly the same age and anthropomorphic characteristics, they were at the same point in 
their training pipeline (i.e. beginning formal military occupational specialty [MOS] training) and 
they adhered to a fairly standard training protocol for the roughly 17 weeks prior to enrolling in 
this study. This allows for interpreting the data within the context of newly enlisted, male 
Marines entering formal MOS training. The regression equations derived from these data will 
serve as a foundation for modeling stress responses and provide for identification of novel 
training environments, both in laboratory and field settings that generate significantly different 
immunoendocrine recovery profiles. Moreover, this data set will provide a base from which 
future research can assess deviations in stress responses that may results from advanced training 
or experience on operational deployments.  
5.4 Conclusions 
 
 In summation, the evidence presented here suggests a methodological outline for best 
practices regarding field assessments of immune function where isolation of T cells from whole 
blood may be delayed due to logistical constraints. Further, we submit that variations in exercise 
intensity and duration do not necessarily approximate military operational or tactical stress 
responses. The time course for immunoendocrine responses to stressors of this nature will need 
to be further assessed to ascertain the functional changes occurring at the time of stress onset.  
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Table 1. Measures of T cell proliferation. Values are presented as Mean ± SD. 
Proliferation Cell Count Percent 
    Pre Post Pre Post 
No Stim 
SP 
CT 1224 ± 617 1303 ± 909 2.4 ± 1.6 1.6 ± 0.9 
EX 941 ± 1000 941 ± 774 0.8 ± 0.5 1.0 ± 0.7 
              
RT 
CT 1644 ± 1754 1182 ± 856 2.1 ± 2.4 1.7 ± 0.8 
EX 455 ± 300 779 ± 647 0.7 ± 0.8 0.8 ± 0.6 
              
CH 
CT 2537 ± 2504 1360 ± 714 2.1 ± 1.7 1.6 ± 0.9 
EX 518 ± 317 593 ± 331 0.7 ± 0.4 0.8 ± 0.5 
 
               
Proliferation Cell Count Percent 
    Pre Post Pre Post 
CD3+CD28 
SP 
CT 49727 ± 60006 47906 ± 54041 32.4 ± 23.8 31.2 ± 19.2 
EX 89050 ± 39987 115394 ± 57251 44.5 ± 20.9 60.1 ± 15.6 
              
RT 
CT 44400 ± 23299 48547 ± 55691 33.0 ± 16.1 32.4 ± 21.3 
EX 50097 ± 62762 37365 ± 25624 26.0 ± 20.1 34.0 ± 17.5 
              
CH 
CT 68331 ± 61640 70565 ± 55141 34.0 ± 20.4 40.9 ± 23.8 
EX 50958 ± 44451 48314 ± 34881 32.5 ± 14.7 36.3 ± 18.8 
 
               
Proliferation Cell Count Percent 
    Pre Post Pre Post 
PHA 
SP 
CT 9689 ± 16355 7342 ± 11557 16.0 ± 27.3 12.6 ± 22.5 
EX 14835 ± 18713 31165 ± 25473 31.2 ± 29.2 43.0 ± 34.2 
              
RT 
CT 19095 ± 34844 4475 ± 3607 17.4 ± 29.2 9.3 ± 12.5 
EX 7952 ± 8453 29095 ± 30501 21.0 ± 17.5 38.7 ± 36.5 
              
CH 
CT 15685 ± 25787 22160 ± 39668 21.3 ± 25.2 17.0 ± 26.9 









Table 2. Measures of T cell activation (CD4-CD25+). 
Activation Cell Count Percent 
    Pre Post Pre Post 
No Stim 
SP 
CT 1950 ± 2707 1643 ± 1280 2.3 ± 2.6 2.1 ± 1.6 
EX 4261 ± 5358 6603 ± 8035 3.2 ± 3.2 5.9 ± 7.2 
              
RT 
CT 1833 ± 1552 1267 ± 803 2.2 ± 1.8 1.7 ± 0.8 
EX 1180 ± 756 2063 ± 2871 1.3 ± 0.8 2.6 ± 3.3 
              
CH 
CT 1689 ± 1203 1830 ± 2018 1.6 ± 1.1 1.6 ± 1.4 
EX 830 ± 529 2591 ± 3498 1.0 ± 0.6 2.3 ± 2.2 
 
 
              
Activation Cell Count Percent 
    Pre Post Pre Post 
CD3+CD28 
SP 
CT 46782 ± 48541 48928 ± 40535 33.3 ± 17.9 35.9 ± 12.6 
EX 85968 ± 35436 105742 ± 54577 43.8 ± 20.2 54.2 ± 19.5 
              
RT 
CT 40173 ± 17970 44122 ± 44198 30.0 ± 11.4 31.6 ± 16.4 
EX 42169 ± 46624 34334 ± 24292 25.1 ± 14.3 29.8 ± 20.0 
              
CH 
CT 63811 ± 56640 49396 ± 37010 32.5 ± 16.7 34.2 ± 17.1 
EX 32841 ± 26183 47240 ± 31737 32.1 ± 13.6 36.4 ± 18.1 
 
 
              
Activation Cell Count Percent 
    Pre Post Pre Post 
PHA 
SP 
CT 6041 ± 4865 6645 ± 3721 8.1 ± 6.0 9.7 ± 6.6 
EX 7178 ± 6955 13829 ± 9762 14.7 ± 10.0 18.3 ± 13.3 
              
RT 
CT 8893 ± 10183 4625 ± 3872 8.9 ± 8.2 7.1 ± 3.7 
EX 3360 ± 2963 10510 ± 11214 9.4 ± 5.1 13.5 ± 13.1 
              
CH 
CT 6993 ± 6499 10502 ± 8010 10.7 ± 6.0 8.8 ± 4.9 








Table 3. Measures of T cell activation (CD4+CD25+). 
Activation Cell Count Percent 
    Pre Post Pre Post 
No Stim 
SP 
CT 14992 ± 13065 15676 ± 6942 20.0 ± 9.8 20.1 ± 7.6 
EX 26711 ± 25483 25408 ± 24008 21.2 ± 12.9 23.3 ± 18.1 
              
RT 
CT 14550 ± 7637 11727 ± 7159 17.3 ± 8.5 15.2 ± 3.3 
EX 11356 ± 6974 12100 ± 13649 11.9 ± 3.9 16.0 ± 15.6 
              
CH 
CT 17524 ± 9296 16560 ± 12537 15.2 ± 6.5 15.7 ± 7.5 
EX 18324 ± 19666 13502 ± 11906 11.6 ± 3.1 14.1 ± 8.6 
 
 
              
Activation Cell Count Percent 
    Pre Post Pre Post 
CD3+CD28 
SP 
CT 31358 ± 33131 31150 ± 22404 22.8 ± 6.9 22.5 ± 5.6 
EX 42626 ± 19611 40973 ± 22563 21.0 ± 5.1 21.1 ± 6.7 
              
RT 
CT 28102 ± 13312 27605 ± 23307 21.8 ± 8.4 21.7 ± 5.1 
EX 27324 ± 30382 16089 ± 12597 17.5 ± 6.9 17.6 ± 8.6 
              
CH 
CT 41882 ± 29456 43889 ± 30807 21.8 ± 8.9 25.8 ± 11.3 
EX 28237 ± 19728 24201 ± 14622 20.1 ± 4.0 19.8 ± 4.2 
 
 
              
Activation Cell Count Percent 
    Pre Post Pre Post 
PHA 
SP 
CT 20756 ± 10886 22656 ± 6323 31.5 ± 15.3 29.8 ± 17.2 
EX 19854 ± 11722 33412 ± 17139 42.9 ± 17.4 43.7 ± 23.3 
              
RT 
CT 26410 ± 23865 15871 ± 8820 27.8 ± 18.0 27.3 ± 14.8 
EX 12734 ± 6763 28593 ± 20596 38.4 ± 14.0 38.3 ± 25.1 
              
CH 
CT 22904 ± 19407 33301 ± 34891 35.5 ± 19.5 31.2 ± 20.0 








Table 4. Cell Viability (%).           
    Pre Post 
No Stim 
SP 
CT 41.5 ± 20.8 49.4 ± 17.4 
EX 54.5 ± 10.3 48.3 ± 11.0 
        
RT 
CT 47.1 ± 12.3 45.2 ± 15.6 
EX 42.7 ± 11.8 39.6 ± 8.0 
        
CH 
CT 51.0 ± 11.4 50.7 ± 12.9 
EX 41.4 ± 11.7 38.9 ± 12.0 
 
 
        
    Pre Post 
CD3+CD28 
SP 
CT 37.8 ± 10.5 38.6 ± 10.9 
EX 38.8 ± 8.7 32.7 ± 8.2 
        
RT 
CT 44.4 ± 6.8 41.4 ± 9.0 
EX 35.0 ± 10.6 29.8 ± 12.2 
        
CH 
CT 37.3 ± 8.7 36.7 ± 13.2 
EX 33.4 ± 9.5 29.2 ± 11.2 
 
         
    Pre Post 
PHA 
SP 
CT 38.4 ± 16.2 41.2 ± 12.1 
EX 29.6 ± 15.7 28.3 ± 9.4 
        
RT 
CT 45.8 ± 10.6 39.6 ± 17.3 
EX 19.5 ± 8.6 24.0 ± 9.9 
        
CH 
CT 42.8 ± 15.0 45.4 ± 10.8 









































































































































































































































































































































































































































































































































































































































































































































































































































 Control Proliferation Count (non stim) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 1076 2055 703 603 1030 847 
S2 1579 437 5061 474 3130 2111 
S3 744 1407 1342 2564 7336 1935 
S4 1921 2383 1789 1394 1554 907 
S5 1700 1495 416 1669 1587 1926 





 Control Proliferation Count (3+28) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 9161 17509 53259 4520 10486 22704 
S2 23213 7854 62987 15768 159651 88537 
S3 3216 23290 3951 7957 9954 5403 
S4 147258 61953 39064 92754 72522 144422 
S5 13880 25211 38445 29396 35836 44669 





 Control Proliferation Count (PHA) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 1181 1555 1365 1522 4184 2811 
S2 6353 3018 9936 447 5206 1460 
S3 4022 3779 3548 2694 6472 1953 
S4 1451 2406 3400 7711 4060 22120 
S5 2285 2407 6361 4873 5903 3118 





 Control Proliferation % (non stim) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 4.2 2.3 1.5 2 1.9 1.7 
S2 4.4 2.2 6.9 1.6 2.4 3 
S3 2.4 1.3 1.3 3 5.3 1.8 
S4 1.2 2.4 1.8 1.6 1.5 0.8 
S5 1.9 1.4 0.4 1.2 1.1 1.7 




 Control Proliferation % (3+28) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 20.8 15.7 44.4 9.4 14.9 27.5 
S2 32.8 27.1 40.5 31.2 52.8 57 
S3 4.2 19.7 5.7 10 9.2 3.7 
S4 53.8 39.1 30.2 46.3 39.2 56.5 
S5 15.9 19.2 26.2 32.7 28 33.4 




 Control Proliferation % (PHA) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 10 3.8 2.9 4.1 8.7 6.1 
S2 5.6 4.3 7 1.9 28.7 2.7 
S3 3.2 2.9 7.4 2.7 5.4 2 
S4 1.8 3.3 3.9 8.5 7.7 16.7 
S5 3.9 3 6.4 4.2 7.5 3.6 





 Exercise Proliferation Count (non stim) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 247 178 144 1082 1018 174 
S2 1006 484 865 1103 500 484 
S3 547 778 798 1775 523 652 
S4 518 629 345 146 145 359 
S5 412 2355 275 220 694 777 




 Exercise Proliferation Count (3+28) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 107800 100855 121018 34582 127207 74223 
S2 106867 167783 10922 36000 18671 25922 
S3 8657 20289 1214 2476 3393 1317 
S4 102327 178203 139648 47349 71200 43990 
S5 93844 98000 6825 24194 52944 44462 




 Exercise Proliferation Count (PHA) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 409 1659 482 955 2536 9282 
S2 6205 33584 1629 2897 3910 20009 
S3 1051 2693 1445 1468 630 1147 
S4 4830 31027 11912 47223 6641 3240 
S5 31889 60771 22037 56330 26802 87691 





 Exercise Proliferation % (non stim) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 0.3 0.2 0.1 1.1 0.7 0.2 
S2 1.2 0.9 1.3 1.1 1.1 0.6 
S3 0.7 1.2 2.1 1.8 1 1.4 
S4 0.5 0.6 0.2 0.3 0.2 0.6 
S5 0.4 2.2 0.2 0.3 0.6 0.5 




 Exercise Proliferation % (3+28) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 38.6 58.6 50.7 26.2 46.1 33.8 
S2 62.5 75.5 13.8 40.3 30.4 36.4 
S3 7.1 30.4 2.4 4.1 5 3.5 
S4 46.5 66.3 49.9 44 43.7 36.7 
S5 64.7 67.5 14.6 34.1 36.5 47.1 




 Exercise Proliferation % (PHA) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 0.5 1.4 2.9 2.1 6.3 11.6 
S2 18.2 39 12.4 12.5 36.7 44 
S3 1.9 3.8 2.4 2.2 1.1 1.8 
S4 36.9 61.9 28.1 69.1 22.8 16.5 
S5 63.3 81.4 41.6 73.3 66.9 78.6 





 Control CD4-CD25+ (non stim) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 248 2523 1268 733 1394 625 
S2 461 287 401 250 897 469 
S3 273 379 981 1009 1055 449 
S4 1253 1186 1128 1201 1036 1518 
S5 2209 1917 2574 2018 1678 2229 




 Control CD4-CD25+  (3+28) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 8705 23574 47046 5585 13375 20746 
S2 29595 12631 56625 17375 159651 36953 
S3 5152 26972 5652 9490 8550 5403 
S4 127714 62444 38342 97427 62871 104045 
S5 26256 44385 43790 32504 44727 48990 




 Control CD4-CD25+  (PHA) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 459 2165 2872 2188 5883 4114 
S2 12821 11925 4572 1003 2394 11949 
S3 4756 5577 1093 2166 2736 1787 
S4 2769 3937 4809 9081 3847 15879 
S5 4316 6086 11666 9954 7429 6309 







 Control CD4+CD25+ (%) (non stim) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 14.3 15.3 18.7 15.9 14.8 14.2 
S2 17.4 22 10.6 11.4 10.1 11.5 
S3 16.5 12.5 11.8 12.2 11.8 8.9 
S4 12.2 17.6 12.1 14.6 12.1 13.7 
S5 20.4 19.1 17.3 16.6 14.2 15.5 




   Control CD4+CD25+ (%) (3+28) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 18 17.2 25.1 15.4 17.8 19.6 
S2 17.6 20.7 17.9 19.6 27.1 23.8 
S3 16.8 16 13.9 17.8 15.2 10.9 
S4 34.8 27.6 16.1 24.5 12.1 35 
S5 24 23 20.5 23.7 22 23 




  Control CD4+CD25+ (%) (PHA) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 36.3 32.6 27.9 22.4 28.2 28.1 
S2 19 27.2 15.3 20.3 57.1 21.8 
S3 22.6 4.2 14.3 14.9 16.1 13.3 
S4 23.1 29.8 21.8 25.4 23 31.7 
S5 27.6 27.1 24.4 24.3 25.4 22.4 






Exercise CD4-CD25+ (non stim) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 349 982 775 282 1405 275 
S2 788 356 730 79 300 335 
S3 537 18 154 799 185 423 
S4 3083 6333 2063 1013 701 1310 
S5 6834 20056 1394 2559 981 9074 




   Exercise CD4-CD25+ (3+28) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 92336 87048 109291 26882 11513 70768 
S2 104879 157898 16765 23390 17774 24240 
S3 14428 11748 1347 3600 4540 2312 
S4 97654 158425 93435 43045 66254 42796 
S5 99513 100110 10467 32888 61504 52657 




  Exercise CD4-CD25+ (PHA) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 3118 7573 800 734 3364 23009 
S2 3881 15916 1194 642 1288 6336 
S3 2883 956 1322 1851 1137 2871 
S4 2089 10726 5294 12842 2827 1511 
S5 11674 29135 8333 20477 7528 37485 





 Exercise CD4+CD25+ (non stim) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 9091 8914 10045 1364 16603 5027 
S2 9521 5319 4840 1224 57554 4168 
S3 10311 417 3328 8722 3619 5380 
S4 28342 37083 22136 9730 9506 9768 
S5 27623 40345 15550 13394 11222 32203 




  Exercise CD4+CD25+ (3+28) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 51818 33373 43182 19736 64333 39178 
S2 33385 43891 9175 9872 14835 13617 
S3 20561 6716 5142 8680 8630 5530 
S4 56636 69370 82416 2541 32536 21259 
S5 23908 31348 7633 17212 28614 22157 




  Exercise CD4+CD25+ (PHA) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 16881 26310 5300 12431 15127 21572 
S2 17238 48542 4927 5818 5798 23899 
S3 14142 6137 11227 13741 10104 15271 
S4 7518 31251 21107 47394 16175 12224 
S5 21490 33828 18509 37284 15573 40242 





   Exercise CD4-CD25+ (non stim) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 0.4 1.3 0.8 0.1 1 0.3 
S2 1 0.6 1.1 0.1 0.6 0.4 
S3 0.7 0 0.4 0.8 0.3 0.9 
S4 2.7 6.1 1.4 2 0.9 2.1 
S5 6.1 18.7 1.2 3.7 0.9 5.3 




   Exercise CD4-CD25+ (3+28) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 33 50.5 45.8 7.3 41.7 32.2 
S2 61.3 71 21.2 26.2 28.9 34 
S3 11.8 17.6 2.7 6 6.7 6.1 
S4 44.4 58.9 33.4 40 40.7 35.8 
S5 68 69 22.3 46.4 42.4 55.8 




   Exercise CD4-CD25+ (PHA) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 3.5 6.5 4.7 0.3 8.4 8 
S2 11.4 18.5 9.1 2.8 12.1 13.9 
S3 5.2 1.4 2.2 2.7 1.9 4.6 
S4 15.9 21.4 12.5 18.8 9.7 7.7 
S5 23.2 39 15.7 26.6 18.8 33.6 






  Exercise CD4+CD25+ (%) (non stim) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 9.2 11.6 10.4 0.5 12.1 5.4 
S2 11.5 9.5 7.1 1.2 12.2 5.4 
S3 13.1 0.7 8.8 13 6.6 11.5 
S4 25.2 35.5 14.8 19.2 12.1 15.3 
S5 24.6 37.6 13 19.1 10.3 18.9 




  Exercise CD4+CD25+ (%) (3+28) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 18.5 19.4 18.1 5.4 23.3 17.8 
S2 19.5 19.7 11.6 11.1 24.1 19.1 
S3 16.8 10.1 10.2 14.5 12.7 14.6 
S4 25.8 25.8 29.5 23.7 20 17.8 
S5 16.5 21.6 16.3 24.3 19.7 23.5 




   Exercise CD4+CD25+ (%) (PHA) 
  Pre Post Pre.RT Post.RT Pre.CH Post.CH 
S1 18.8 22.5 31.5 5.5 37.7 27.1 
S2 50.5 56.4 37.5 25.2 54.4 52.5 
S3 25.6 8.7 18.3 20.3 17.2 24.5 
S4 57.4 62.3 49.8 69.3 55.5 62.2 
S5 42.7 45.3 34.9 48.5 38.9 36.1 















Time (min) in Heart Rate Zones 











S1 187 132 5.5 6.0 14.6 3.7 1.9 
S2 194 159 2.1 4.3 6.5 3.8 15.2 
S3 237 157 5.4 3.2 5.7 3.4 15.0 
S4 203 167 2.1 0.4 7.0 7.8 15.3 
S5 192 129 12.7 4.7 2.9 6.8 1.9 
S6 183 154 0.2 2.5 10.2 12.7 5.7 
 
 
 Heart Rate (CT) 
Subject Peak Average 
S1 108 75 
S2 80 74 
S3 95 86 
S4 104 79 
S5 101 72 



















































Table 4. Leukocyte and lymphocyte cell counts (Mean ± SD). 
  Pre Post 1hr 4hr 6hr 
Neutrophils (cells/ul)             
HI 2896 ± 834 8941 ± 3926 11037 ± 4046 8945 ± 2381 6913 ± 1748 
MOD 3321 ± 549 5609 ± 1705 6839 ± 2627 7034 ± 2503 5738 ± 1806 
                
Monocytes (cells/ul)             
HI 435 ± 108 544 ± 184 643 ± 172 578 ± 166 784 ± 302 
MOD 467 ± 195 415 ± 250 465 ± 202 497 ± 153 660 ± 225 
                
Eosinophils (cells/ul)             
HI 190 ± 89 112 ± 78 42 ± 44 56 ± 51 97 ± 70 
MOD 210 ± 206 121 ± 133 82 ± 96 100 ± 121 118 ± 138 
                
Basophils 
(cells/ul)              
HI 32 ± 10 33 ± 27 24 ± 12 26 ± 15 34 ± 16 
MOD 31 ± 17 26 ± 8 21 ± 13 17 ± 9 36 ± 11 
                
Lymphocytes (cells/ul)             
HI 2159 ± 453 1532 ± 357 1130 ± 296 1670 ± 325 1910 ± 454 






Table 5. Leukocyte and lymphocyte (%) (Mean ± SD). 
  Pre Post 1hr 4hr 6hr 
Neutrophils (%)             
HI 50.2 ± 5.5 78.1 ± 8.7 84.5 ± 5.9 78.6 ± 5.4 70.5 ± 7.0 
MOD 49.8 ± 7.7 71.0 ± 7.5 75.5 ± 8.0 72.2 ± 8.4 65.3 ± 6.7 
                
Monocytes (%)            
HI 7.9 ± 2.1 5.4 ± 2.3 5.4 ± 2.0 5.2 ± 1.5 8.1 ± 2.5 
MOD 6.9 ± 2.3 5.1 ± 1.7 5.2 ± 1.3 5.3 ± 1.3 7.5 ± 1.6 
                
Eosinophils (%)             
HI 3.3 ± 1.0 1.1 ± 0.9 0.4 ± 0.5 0.6 ± 0.5 1.0 ± 0.7 
MOD 3.0 ± 2.7 1.6 ± 1.8 1.1 ± 1.3 1.2 ± 1.4 1.5 ± 1.6 
                
Basophils (%)            
HI 0.6 ± 0.2 0.3 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 0.4 ± 0.2 
MOD 0.5 ± 0.3 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.4 ± 0.1 
                
Lymphocytes (%)            
HI 38.1 ± 4.4 15.1 ± 6.1 9.6 ± 4.1 15.4 ± 4.3 20.1 ± 5.4 
MOD 39.9 ± 6.2 21.9 ± 6.8 18.0 ± 7.3 21.2 ± 7.0 25.3 ± 5.8 
 
Table 6. Time in HR Zone (min) (Mean ± SD). 
  HI MOD 
<60% 5.1 ± 2.8 34.8 ± 17.1 
60% -70% 14.3 ± 7.4 33.6 ± 5.5 
70%-80% 17.9 ± 4.2 26.5 ± 6 
80%-90% 25.1 ± 7.1 14.8 ± 5.7 
>90% 35.9 ± 14.9 6.4 ± 5.1 
       
Table 7. Time in ROG states (min) (Mean ± SD). 
  HI MOD 
Green 25.0 ± 9.8 59.9 ± 12.5 
Orange 12.7 ± 5.7 12.8 ± 3.4 




Creatine kinase concentrations (AU).     
Subject Pre Post 1hr 4hr 6hr 
TB02 1239.23 1380.95 1428.74 1611.66 1720.42 
TC03 149.96 410.33 388.91 448.23 647.63 
TD04 423.51 555.35 845.38 1430.39 1112.34 
TE05 182.92 543.81 667.40 978.86 916.24 
TH06 710.25 474.60 1644.61 571.82 528.98 
TI07 177.97 863.50 517.44 395.50 677.29 
TM09 265.31 334.53 405.39 304.86 423.51 
TS10 123.59 191.16 268.61 331.23 435.05 
CA01 2025.28 1667.68 1555.63 1413.91 1666.04 
CB02 163.14 219.17 385.61 660.81 858.56 
CC03 937.66 1290.31 1242.52 532.27 1743.49 
CD04 388.91 411.98 517.44 1545.74 617.97 
CE05 242.24 388.91 481.19 878.34 957.44 
CH06 1181.55 477.89 703.66 2162.06 2165.35 
CK07 461.41 453.18 716.84 553.70 380.67 
CM08 140.07 303.22 484.49 392.20 318.05 
 
HMGB1 Concentrations (ng/ml)    
  Pre Post 1hr 4hr 6hr 
TB02 26.47 31.10 30.32 26.77 25.71 
TC03 28.30 26.72 24.82 27.50 25.65 
TD04 17.55 23.61 17.60 15.97 19.69 
TE05 17.83 16.82 17.19 18.43 17.46 
TH06 13.14 22.16 20.89 21.29 18.93 
TI07 12.39 13.84 16.36 15.01 15.37 
TM09 19.97 6.79 8.75 8.32 11.04 
TS10 16.84 20.05 19.79 16.33 14.76 
CA01 25.07 26.08 25.07 26.38 27.85 
CB02 19.87 20.37 23.56 23.06 23.61 
CC03 31.88 29.61 27.36 29.93 27.25 
CD04 30.14 28.10 27.85 25.03 26.81 
CE05 23.68 22.89 22.36 24.47 23.58 
CH06 11.01 10.86 11.06 11.32 10.99 
CK07 14.01 12.50 12.67 13.05 11.42 




IL-1 (pg/ml)       IL-2 (pg/ml)      
Subject Pre Post 1hr 4hr 6hr  Subject Pre Post 1hr 4hr 6hr 
TB02 10.0 9.1 9.1 8.4 8.5  TB02 20.0 25.1 21.2 19.0 21.9 
TC03 0.0 0.0 0.0 0.0 0.0  TC03 0.0 0.0 0.0 0.0 0.0 
TD04 0.0 0.0 0.0 0.0 0.0  TD04 0.0 0.0 0.0 0.0 0.0 
TE05 0.0 0.0 0.0 0.0 0.0  TE05 0.0 0.0 0.0 0.0 0.0 
TH06 0.0 0.0 0.0 0.0 0.0  TH06 0.0 0.0 0.0 0.0 0.0 
TI07 0.0 0.0 0.0 0.0 0.0  TI07 0.0 0.0 0.0 0.0 0.0 
TM09 0.0 0.0 0.0 0.0 0.0  TM09 0.0 0.0 0.0 0.0 0.0 
TS10 5.9 6.8 5.2 6.1 6.1  TS10 7.1 11.8 6.8 7.6 7.2 
CA01 0.0 0.0 0.0 0.0 0.0  CA01 0.0 0.0 0.0 0.0 0.0 
CB02 0.0 0.0 0.0 0.0 0.0  CB02 0.0 0.0 0.0 0.0 0.0 
CC03 16.5 20.2 18.1 5.3 16.5  CC03 19.5 24.4 20.9 5.5 19.7 
CD04 0.0 0.0 0.0 15.5 0.0  CD04 0.0 0.0 0.0 19.3 0.0 
CE05 6.6 7.9 7.8 8.1 9.5  CE05 9.1 9.7 9.2 9.8 10.2 
CH06 0.0 0.0 0.0 0.0 0.0  CH06 0.0 0.0 0.0 0.0 0.0 
CK07 0.0 0.0 0.0 0.0 0.0  CK07 0.0 0.0 0.0 0.0 0.0 
CM08 0.0 0.0 0.0 0.0 0.0  CM08 0.0 0.0 0.0 0.0 0.0 
             
IL-4 (pg/ml)       IL-6 (pg/ml)      
Subject Pre Post 1hr 4hr 6hr  Subject Pre Post 1hr 4hr 6hr 
TB02 53.5 64.8 71.8 55.9 58.1  TB02 43.3 57.9 49.3 40.5 50.1 
TC03 0.0 0.0 0.0 0.0 0.0  TC03 0.0 0.0 0.0 0.0 0.0 
TD04 0.0 0.0 0.0 0.0 0.0  TD04 0.0 0.0 0.0 0.0 0.0 
TE05 0.0 5.8 8.5 0.0 0.0  TE05 0.0 10.8 7.4 0.0 0.0 
TH06 0.0 0.0 0.0 0.0 0.0  TH06 0.0 0.0 0.0 0.0 0.0 
TI07 0.0 0.0 0.0 0.0 0.0  TI07 0.0 0.0 0.0 0.0 0.0 
TM09 0.0 0.0 0.0 0.0 0.0  TM09 0.0 19.7 11.4 0.0 0.0 
TS10 15.7 24.6 15.7 19.3 23.7  TS10 0.0 13.2 0.0 0.0 0.0 
CA01 0.0 0.0 0.0 0.0 0.0  CA01 0.0 0.0 0.0 0.0 0.0 
CB02 0.0 0.0 0.0 0.0 0.0  CB02 0.0 11.4 0.0 0.0 0.0 
CC03 93.4 115.1 101.2 4.7 91.5  CC03 6.6 8.6 7.6 0.0 8.2 
CD04 0.0 0.0 0.0 77.2 0.0  CD04 0.0 0.0 0.0 6.3 0.0 
CE05 36.1 37.5 43.3 60.7 38.2  CE05 0.0 0.0 6.4 8.1 0.0 
CH06 0.0 0.0 0.0 0.0 0.0  CH06 0.0 0.0 0.0 0.0 0.0 
CK07 4.5 0.0 0.0 6.0 0.0  CK07 10.4 6.7 25.0 34.6 20.0 






IL-10 (pg/ml)       IL-17a (pg/ml)      
Subject Pre Post 1hr 4hr 6hr  Subject Pre Post 1hr 4hr 6hr 
TB02 37.9 278.5 191.8 39.5 38.6  TB02 63.3 83.3 89.5 71.2 79.3 
TC03 0.0 65.1 20.0 0.0 0.0  TC03 0.0 0.0 0.0 0.0 0.0 
TD04 0.0 85.7 26.1 0.0 0.0  TD04 0.0 0.0 0.0 0.0 0.0 
TE05 12.3 189.0 90.9 15.5 14.9  TE05 27.5 32.7 24.1 19.2 23.7 
TH06 0.0 51.7 18.8 0.0 0.0  TH06 35.8 0.0 0.0 0.0 0.0 
TI07 0.0 39.3 21.5 0.0 0.0  TI07 0.0 23.6 20.6 16.6 19.6 
TM09 0.0 54.6 43.2 0.0 0.0  TM09 0.0 24.8 28.0 31.4 25.7 
TS10 20.6 128.8 59.6 22.5 21.8  TS10 10.9 72.2 15.7 12.6 12.4 
CA01 0.0 3.8 0.0 0.0 0.0  CA01 0.0 0.0 0.0 0.0 0.0 
CB02 0.0 15.2 13.1 0.0 0.0  CB02 0.0 0.0 0.0 0.0 0.0 
CC03 48.2 64.9 60.0 0.0 51.5  CC03 0.0 4.3 0.0 0.0 0.0 
CD04 0.0 0.0 0.0 45.6 2.0  CD04 3.3 0.0 0.0 4.3 0.0 
CE05 19.1 20.1 20.9 14.2 20.2  CE05 0.0 0.0 0.0 0.0 0.0 
CH06 0.0 0.0 0.0 0.0 0.0  CH06 16.6 15.6 3.0 0.0 0.0 
CK07 5.7 6.7 6.3 12.0 3.6  CK07 83.6 39.4 147.9 126.3 89.2 
CM08 75.7 0.0 0.0 225.6 186.5  CM08 6.0 0.0 0.0 3.2 0.0 
             
INF- (pg/ml)       TNF- (pg/ml)      
Subject Pre Post 1hr 4hr 6hr  Subject Pre Post 1hr 4hr 6hr 
TB02 192.9 262.5 295.9 219.6 288.2  TB02 34.3 56.3 37.4 32.8 29.0 
TC03 0.0 0.0 0.0 0.0 0.0  TC03 18.1 29.0 23.5 17.4 16.5 
TD04 12.0 12.5 10.7 7.9 11.7  TD04 16.8 19.8 16.5 16.9 18.3 
TE05 26.5 35.8 32.0 24.1 28.0  TE05 11.9 23.6 22.2 13.6 12.2 
TH06 21.4 7.9 7.9 0.0 0.0  TH06 10.3 20.3 21.9 10.9 11.6 
TI07 0.0 9.9 10.7 9.6 10.9  TI07 6.0 8.5 8.7 6.8 6.6 
TM09 6.0 13.6 12.5 17.3 9.9  TM09 9.5 13.8 11.6 8.4 7.6 
TS10 50.3 226.1 50.0 37.4 35.3  TS10 9.7 18.7 9.3 10.5 7.8 
CA01 0.0 0.0 0.0 0.0 0.0  CA01 12.3 12.1 10.8 10.0 8.9 
CB02 0.0 0.0 0.0 0.0 0.0  CB02 14.7 23.9 21.9 16.5 17.7 
CC03 8.4 8.4 7.6 0.0 0.0  CC03 6.8 6.4 6.9 11.1 6.5 
CD04 0.0 0.0 0.0 11.6 0.0  CD04 15.1 11.8 12.7 6.4 15.9 
CE05 13.0 13.0 10.2 20.3 15.8  CE05 6.9 6.2 7.6 7.5 6.1 
CH06 30.2 21.1 0.0 0.0 0.0  CH06 8.2 7.8 6.8 6.3 6.5 
CK07 188.9 90.0 359.0 388.6 204.0  CK07 9.8 9.9 10.5 16.6 13.1 




Non Stimulated Proliferation 
  Pre Post 1hr 4hr 6hr 
TB02 233 1091 685 2782 1109 
TC03 352 2291 2655 5491 3109 
TD04 11245 1981 3309 15836 16019 
TE05 155 1537 1800 1259 868 
TH06 773 9309 704 2500 3036 
TI07 283 1333 764 1055 907 
TM09 1042 4759 1145 2278 3426 
TS10 348 5944 3800 5509 2509 
CA01 364 302 222 1000 4963 
CB02 717 796 547 887 2585 
CC03 500 1333 426 527 6236 
CD04 528 436 113 472 9222 
CE05 127 1036 1073 1333 3058 
CH06 389 891 18 778 1600 
CK07 73 491 327 741 2127 
CM08 518 283 945 803 3415 
 
Non Stimulated Proliferation (%) 
  Pre Post 1hr 4hr 6hr 
TB02 0.2 0.8 0.5 1.7 0.7 
TC03 0.6 2.1 2.6 2.8 2.3 
TD04 4.8 2 2.3 8.3 8.3 
TE05 0.1 1.5 1.5 1.3 0.7 
TH06 0.3 6.4 1.5 1.1 1.6 
TI07 0.4 0.8 0.7 0.8 0.8 
TM09 0.8 3.4 0.8 1.1 2.1 
TS10 0.5 7.9 3.7 2.3 2.1 
CA01 0.2 0.4 0.1 0.6 3.6 
CB02 0.4 1 0.4 1 2 
CC03 0.6 2.1 0.6 0.3 5.3 
CD04 0.3 0.4 0.1 0.2 5.6 
CE05 0.1 0.7 0.4 0.8 1.2 
CH06 0.3 1 0.1 0.5 1.1 
CK07 0.1 0.5 0.3 0.5 1.3 






3+28 Stimulated Proliferation 
  Pre Post 1hr 4hr 6hr 
TB02 68421 149661 188571 171273 144855 
TC03 60730 165200 238964 227554 189018 
TD04 108870 221382 123315 120357 117667 
TE05 58236 203527 91056 86981 136418 
TH06 145509 235696 168259 265982 215182 
TI07 56902 250545 37073 192327 179673 
TM09 112890 215000 163254 234291 160214 
TS10 109939 258719 215182 226745 314052 
CA01 85268 13717 112482 239393 293407 
CB02 89245 18491 43315 68709 142418 
CC03 12566 6075 5635 134500 261019 
CD04 26212 2727 17925 127296 91811 
CE05 23891 9564 96722 116182 241509 
CH06 45418 5667 252 94352 168945 
CK07 7455 6245 13611 121148 293268 
CM08 79851 1423 84596 280160 270160 
 
3+28 Stimulated Proliferation (%) 
  Pre Post 1hr 4hr 6hr 
TB02 31.4 60.2 67.3 57.4 58.2 
TC03 51 77.6 79.6 65.4 73.1 
TD04 48.9 80.8 55.9 58.9 56.9 
TE05 45.8 77.3 49 50.8 57.8 
TH06 49.4 73.7 80.2 62 62 
TI07 41.9 69.4 40.6 60.2 63.8 
TM09 58.8 67.9 55.2 59.8 59.6 
TS10 57.8 84 76.8 59.5 76.8 
CA01 37.7 12.2 40.6 68.9 72.7 
CB02 34 13.8 23.4 47.7 58.1 
CC03 11.8 5.6 6.1 46.8 74.3 
CD04 14.3 3 11.9 50 47.4 
CE05 10.8 6.3 30 44.6 60.2 
CH06 26 8.3 2.3 50.2 64.1 
CK07 9.1 5.3 10.7 54.4 73.2 




PHA Stimulated Proliferation 
  Pre Post 1hr 4hr 6hr 
TB02 8463 84759 75815 93036 52241 
TC03 51532 127519 185038 152870 181345 
TD04 65618 138148 115370 99778 85418 
TE05 6600 32241 94925 45741 40873 
TH06 61027 169982 38407 59527 84302 
TI07 19232 61630 44385 116982 223691 
TM09 54036 82090 86462 25759 78444 
TS10 17165 173418 279327 146500 131905 
CA01 8018 2278 9500 6481 7660 
CB02 10148 8407 20255 5527 5151 
CC03 1472 3315 1036 4982 7722 
CD04 8782 15321 18648 66741 18904 
CE05 2148 4000 38093 13660 14604 
CH06 2717 1815 155 6429 21774 
CK07 6407 3558 25788 57547 21423 
CM08 5890 1425 46963 35250 13735 
 
PHA Stimulated Proliferation (%) 
  Pre Post 1hr 4hr 6hr 
TB02 15 49.5 40.4 44.5 33.2 
TC03 58.9 77.1 74.9 53.1 70.6 
TD04 33.5 66 55 46.4 46.3 
TE05 9.7 47.5 53.4 38.9 38.1 
TH06 36.1 78.6 58.6 36.2 47.9 
TI07 25.3 33.4 29.4 53 69.8 
TM09 40.4 44.8 42.3 14.4 41.2 
TS10 25.3 78.9 78.4 47.4 56.6 
CA01 5.4 3.5 6.2 5.9 8 
CB02 7.6 12.1 17 10.3 6.1 
CC03 1.8 5.1 1.9 3.9 10.6 
CD04 5.9 12.7 14.5 27.3 12.4 
CE05 1.2 3.1 15.1 10.3 9.1 
CH06 2.1 4.7 2.7 8.9 22.8 
CK07 9.2 3.6 19.1 34.5 19.7 





CTLA4 MFI (non stim) 
  Pre Post 1hr 4hr 6hr 
TB02 274 496 470 358 370 
TC03 1520 664 839 763 665 
TD04 768 343 380 1091 485 
TE05 143 343 377 374 524 
TH06 470 500 585 1845 458 
TI07 338 366 251 459 1054 
TM09 1050 281 359 419 562 
TS10 1896 681 2058 612 400 
CA01 262 313 884 281 1446 
CB02 327 341 297 323 236 
CC03 258 578 268 379 232 
CD04 268 374 658 386 260 
CE05 673 336 458 337 271 
CH06 268 2946 636 415 297 
CK07 338 289 289 372 332 
CM08 537 459 348 323 302 
 
CTLA4 MFI (3+28) 
  Pre Post 1hr 4hr 6hr 
TB02 277 418 441 375 271 
TC03 723 971 314 545 451 
TD04 347 360 343 334 566 
TE05 321 541 353 354 568 
TH06 541 427 392 428 553 
TI07 404 442 282 365 405 
TM09 470 373 334 321 387 
TS10 462 332 461 501 358 
CA01 470 519 516 347 429 
CB02 465 212 283 335 266 
CC03 426 257 298 394 343 
CD04 304 251 283 379 787 
CE05 370 230 458 723 264 
CH06 234 325 189 542 260 
CK07 300 277 333 883 667 




CTLA4 MFI (PHA) 
  Pre Post 1hr 4hr 6hr 
TB02 337 480 415 397 412 
TC03 1005 1226 339 504 663 
TD04 378 619 351 1142 508 
TE05 275 410 702 396 483 
TH06 437 607 770 437 352 
TI07 485 332 383 432 384 
TM09 746 374 305 329 496 
TS10 467 549 329 379 564 
CA01 379 400 366 354 1236 
CB02 317 401 592 344 324 
CC03 343 280 353 376 293 
CD04 270 374 305 300 354 
CE05 402 587 402 295 248 
CH06 284 504 308 417 225 
CK07 368 342 917 374 332 
CM08 264 251 371 474 300 
 
Neutrophils (cells/ul) 
  Pre Post 1hr 4hr 6hr 
TB02 3009 16800 18655 13594 9862 
TC03 2734 7807 10811 8894 7003 
TD04 2801 7722 10816 9013 7347 
TE05 2295 8195 8615 8080 5285 
TH06 3231 9587 12859 10020 7646 
TI07 4610 11633 13498 9607 8173 
TM09 2776 5971 6973 6634 5418 
TS10 1714 3813 6068 5721 4572 
CA01 3008 4602 5752 6240 5283 
CB02 2759 5677 11779 11578 9074 
CC03 3657 6871 7185 6565 5290 
CD04 3049 2911 3355 4004 3380 
CE05 3558 5964 6771 6354 5168 
CH06 2618 4820 5290 6184 5600 
CK07 4230 5313 5332 5306 4444 





  Pre Post 1hr 4hr 6hr 
TB02 424 582 800 543 835 
TC03 423 628 743 523 670 
TD04 626 804 793 812 1434 
TE05 377 562 717 636 635 
TH06 511 479 562 787 864 
TI07 273 223 289 339 429 
TM09 490 699 694 576 828 
TS10 357 376 547 408 576 
CA01 443 304 357 499 558 
CB02 397 281 603 375 743 
CC03 540 300 368 599 722 
CD04 332 206 264 312 308 
CE05 402 470 460 442 655 
CH06 363 340 306 448 538 
CK07 339 421 469 488 656 
CM08 920 998 889 812 1100 
 
Eosinophils (cells/ul) 
  Pre Post 1hr 4hr 6hr 
TB02 132 116 0 0 12 
TC03 163 144 50 44 65 
TD04 87 29 13 23 45 
TE05 170 83 20 40 73 
TH06 291 57 29 38 97 
TI07 359 79 46 97 198 
TM09 165 285 143 163 207 
TS10 156 103 31 46 79 
CA01 698 437 291 355 432 
CB02 155 53 27 0 12 
CC03 135 73 37 67 87 
CD04 241 147 154 176 171 
CE05 174 101 74 141 128 
CH06 61 25 20 8 16 
CK07 58 41 21 44 41 





  Pre Post 1hr 4hr 6hr 
TB02 44 78 41 0 12 
TC03 31 41 13 11 28 
TD04 17 39 39 35 45 
TE05 41 52 20 40 22 
TH06 36 0 14 38 32 
TI07 39 0 30 36 44 
TM09 29 37 29 29 63 
TS10 21 17 8 15 22 
CA01 30 31 17 19 45 
CB02 56 23 40 0 47 
CC03 21 18 18 29 44 
CD04 20 10 11 13 17 
CE05 13 34 28 19 34 
CH06 28 25 20 25 31 
CK07 58 28 36 15 28 
CM08 23 35 0 12 44 
 
Lymphocytes (cells/ul) 
  Pre Post 1hr 4hr 6hr 
TB02 1892 1824 1005 1364 1379 
TC03 1749 1679 983 1428 1535 
TD04 2268 1205 1339 1717 2330 
TE05 1716 1508 727 1303 1285 
TH06 3032 1277 936 1816 2160 
TI07 2519 1166 1338 2021 2156 
TM09 2240 2208 1663 2198 2484 
TS10 1853 1391 1047 1509 1951 
CA01 3323 2426 1884 2486 2682 
CB02 2833 1566 951 1447 1923 
CC03 2748 1838 1592 2242 2558 
CD04 2860 1627 1716 1996 1824 
CE05 2553 1831 1868 2444 2516 
CH06 2431 1090 1163 1635 1615 
CK07 1715 1097 1243 1547 1732 







  Pre Post 1hr 4hr 6hr 
TB02 54.7 86.6 91.0 87.7 81.5 
TC03 53.6 75.8 85.8 81.6 75.3 
TD04 48.3 78.8 83.2 77.7 65.6 
TE05 49.9 78.8 85.3 80.0 72.4 
TH06 45.5 84.1 89.3 78.9 70.8 
TI07 59.1 88.8 88.8 79.4 74.3 
TM09 48.7 64.9 73.4 69.1 60.2 
TS10 41.8 66.9 78.8 74.3 63.5 
CA01 40.1 59.0 69.3 65.0 58.7 
CB02 44.5 74.7 87.9 86.4 76.9 
CC03 51.5 75.5 78.1 69.1 60.8 
CD04 46.9 59.4 61.0 61.6 59.3 
CE05 53.1 71.0 73.6 67.6 60.8 
CH06 47.6 76.5 77.8 74.5 71.8 
CK07 66.1 77.0 75.1 71.7 64.4 
CM08 48.5 75.1 81.1 81.6 69.7 
 
Monocytes (%) 
  Pre Post 1hr 4hr 6hr 
TB02 7.7 3.0 3.9 3.5 6.9 
TC03 8.3 6.1 5.9 4.8 7.2 
TD04 10.8 8.2 6.1 7.0 12.8 
TE05 8.2 5.4 7.1 6.3 8.7 
TH06 7.2 4.2 3.9 6.2 8.0 
TI07 3.5 1.7 1.9 2.8 3.9 
TM09 8.6 7.6 7.3 6.0 9.2 
TS10 8.7 6.6 7.1 5.3 8.0 
CA01 5.9 3.9 4.3 5.2 6.2 
CB02 6.4 3.7 4.5 2.8 6.3 
CC03 7.6 3.3 4.0 6.3 8.3 
CD04 5.1 4.2 4.8 4.8 5.4 
CE05 6.0 5.6 5.0 4.7 7.7 
CH06 6.6 5.4 4.5 5.4 6.9 
CK07 5.3 6.1 6.6 6.6 9.5 






  Pre Post 1hr 4hr 6hr 
TB02 2.4 .6 .0 .0 .1 
TC03 3.2 1.4 .4 .4 .7 
TD04 1.5 .3 .1 .2 .4 
TE05 3.7 .8 .2 .4 1.0 
TH06 4.1 .5 .2 .3 .9 
TI07 4.6 .6 .3 .8 1.8 
TM09 2.9 3.1 1.5 1.7 2.3 
TS10 3.8 1.8 .4 .6 1.1 
CA01 9.3 5.6 3.5 3.7 4.8 
CB02 2.5 .7 .2 .0 .1 
CC03 1.9 .8 .4 .7 1.0 
CD04 3.7 3.0 2.8 2.7 3.0 
CE05 2.6 1.2 .8 1.5 1.5 
CH06 1.1 .4 .3 .1 .2 
CK07 .9 .6 .3 .6 .6 
CM08 2.1 .8 .3 .1 .5 
 
Basophils (%) 
  Pre Post 1hr 4hr 6hr 
TB02 .8 .4 .2 .0 .1 
TC03 .6 .4 .1 .1 .3 
TD04 .3 .4 .3 .3 .4 
TE05 .9 .5 .2 .4 .3 
TH06 .5 .0 .1 .3 .3 
TI07 .5 .0 .2 .3 .4 
TM09 .5 .4 .3 .3 .7 
TS10 .5 .3 .1 .2 .3 
CA01 .4 .4 .2 .2 .5 
CB02 .9 .3 .3 .0 .4 
CC03 .3 .2 .2 .3 .5 
CD04 .3 .2 .2 .2 .3 
CE05 .2 .4 .3 .2 .4 
CH06 .5 .4 .3 .3 .4 
CK07 .9 .4 .5 .2 .4 





  Pre Post 1hr 4hr 6hr 
TB02 34.4 9.4 4.9 8.8 11.4 
TC03 34.3 16.3 7.8 13.1 16.5 
TD04 39.1 12.3 10.3 14.8 20.8 
TE05 37.3 14.5 7.2 12.9 17.6 
TH06 42.7 11.2 6.5 14.3 20.0 
TI07 32.3 8.9 8.8 16.7 19.6 
TM09 39.3 24.0 17.5 22.9 27.6 
TS10 45.2 24.4 13.6 19.6 27.1 
CA01 44.3 31.1 22.7 25.9 29.8 
CB02 45.7 20.6 7.1 10.8 16.3 
CC03 38.7 20.2 17.3 23.6 29.4 
CD04 44.0 33.2 31.2 30.7 32.0 
CE05 38.1 21.8 20.3 26.0 29.6 
CH06 44.2 17.3 17.1 19.7 20.7 
CK07 26.8 15.9 17.5 20.9 25.1 
CM08 37.0 15.2 10.8 11.6 19.4 
 












TB02 164 2.9 6.9 26.9 18.5 43.7 
TC03 154 7.8 11.3 19.2 25.9 34.8 
TD04 170 4.9 1.3 13.9 21.5 58.9 
TE05 160 4.1 13.3 18.4 20.9 41.3 
TH06 149 7.8 24.9 13.1 38.4 9.0 
TI07 151 9.5 23.3 14.7 29.5 19.9 
TM09 162 2.4 15.5 16.6 15.3 48.1 
TS10 156 1.2 17.7 20.2 30.6 31.4 
CA01 143 14.7 37.1 34.8 14.9 14.1 
CB02 132 30.9 40.6 32.6 7.7 5.4 
CC03 142 19.1 32.2 25.8 25.2 13.7 
CD04 119 58.3 27.2 22.7 8.7 0.5 
CE05 137 19.5 42.2 27.5 16.8 9.1 
CH06 131 34.9 33.6 25.6 20.1 2.6 
CK07 115 64.5 28.5 14.0 9.2 0.1 
CM08 123 36.2 27.6 29.4 16.0 5.6 
 
       
       




  Avg Peak 
TB02 38.8 39.5 
TC03 38.2 38.8 
TD04 39.2 40.0 
TE05 38.6 39.4 
TH06 38.2 38.7 
TI07 38.3 39.1 
TM09 38.7 39.6 
TS10 38.5 38.9 
CA01 38.1 39.2 
CB02 37.9 38.1 
CC03 38.1 38.7 
CD04 37.8 38.0 
CE05 38.0 38.5 
CH06 37.9 38.4 
CK07 37.7 38.0 
CM08 37.5 38.5 
 
      
       
       
       
       
       
       
       
       
       
       
       
       
       




































Table 1. Serial measures for endocrine responses to MCMAP training across visits.    
  Visit 1 Visit 2 Visit 3 
Cortisol (mcg/dl)          
Baseline 16.92 ± 3.37 16.70 ± 3.25 16.48 ± 3.60 
AUC 1067.83 ± 269.47 1030.42 ± 264.80 1053.02 ± 250.77 
Peak Concentration 20.47 ± 4.70 20.09 ± 4.63 20.58 ± 4.08 
Time to Peak (min) 16.67 ± 19.57 8.33 ± 10.42 12.50 ± 11.62 
Epinephrine (pcg/ml)          
Baseline 27.22 ± 28.74 38.11 ± 72.38 21.58 ± 20.88 
AUC 2267.50 ± 1623.18 2579.17 ± 2255.13 2218.54 ± 1860.68 
Peak Concentration 81.39 ± 50.70 93.06 ± 78.36 80.67 ± 63.89 
Time to Peak (min) 7.08 ± 10.45 5.00 ± 11.34 7.50 ± 10.45 
Norepinephrine (pcg/ml)          
Baseline 412.92 ± 171.54 432.75 ± 173.96 396.67 ± 139.81 
AUC 35330.42 ± 12633.12 34236.25 ± 10293.48 37547.92 ± 14682.61 
Peak Concentration 969.44 ± 476.39 987.64 ± 367.47 1134.31 ± 636.17 
Time to Peak (min) 11.67 ± 19.01 8.75 ± 16.96 13.33 ± 19.24 
 
Table 2. Serial measures for immunoglobulin-G and -M responses to MCMAP training across visits. 
  Visit 1 Visit 2 Visit 3 
IgG (mg/dl)          
Baseline 1110.78 ± 211.69 1084.08 ± 213.98 1084.47 ± 212.28 
AUC 65958.54 ± 12437.23 64556.46 ± 13601.66 64285.42 ± 12704.73 
Peak Concentration 1172.25 ± 220.58 1176.69 ± 244.07 1168.19 ± 234.02 
Time to Peak (min) 15.00 ± 20.60 5.00 ± 8.02 11.67 ± 19.01 
IgM (mg/dl)          
Baseline 117.06 ± 49.01 113.06 ± 47.93 112.81 ± 46.24 
AUC 6836.46 ± 2843.50 6567.92 ± 2882.61 6619.79 ± 2765.66 
Peak Concentration 122.00 ± 50.53 119.36 ± 51.66 119.28 ± 47.47 
Time to Peak (min) 15.83 ± 20.27 3.75 ± 10.98 10.42 ± 17.50 
 
Table 3. Serial measures for neutrophil oxidative burst (%) following MCMAP training.   
  Visit 1 Visit 2 Visit 3 
Neutrophil Oxidative Burst (%)          
Baseline 95.53 ± 4.14 92.64 ± 6.02 92.67 ± 16.33 
AUC 5716.04 ± 399.58 5469.58 ± 594.25 5703.54 ± 311.78 
Peak Concentration 98.22 ± 2.17 96.56 ± 3.52 97.72 ± 1.85 






Table 4. Serial measures for lymphocyte responses (%) to MCMAP training across visits.   
  Visit 1 Visit 2 Visit 3 
CD3+ (%)          
Baseline 68.42 ± 13.79 71.64 ± 6.19 70.39 ± 13.73 
AUC 4223.54 ± 446.92 4254.38 ± 401.72 4261.25 ± 443.49 
Peak Concentration 74.86 ± 5.61 75.14 ± 5.61 75.22 ± 5.36 
Time to Peak (min) 36.67 ± 16.60 28.75 ± 14.06 31.25 ± 19.43 
CD4+ (%)          
Baseline 40.28 ± 8.91 42.03 ± 5.78 42.31 ± 8.91 
AUC 2509.79 ± 341.59 2528.96 ± 300.23 2533.33 ± 301.49 
Peak Concentration 46.72 ± 4.80 46.75 ± 4.82 47.19 ± 4.13 
Time to Peak (min) 40.42 ± 15.96 35.83 ± 14.90 39.17 ± 18.03 
CD8+ (%)          
Baseline 26.06 ± 7.25 27.83 ± 6.12 26.42 ± 7.50 
AUC 1612.92 ± 351.89 1631.88 ± 381.96 1635.21 ± 372.98 
Peak Concentration 29.53 ± 6.95 30.17 ± 7.15 29.83 ± 7.15 
Time to Peak (min) 15.00 ± 17.20 11.67 ± 12.98 16.67 ± 18.21 
CD19+ (%)          
Baseline 15.33 ± 5.31 15.86 ± 5.20 15.44 ± 6.03 
AUC 886.25 ± 231.26 917.50 ± 248.28 883.75 ± 236.53 
Peak Concentration 17.08 ± 4.27 17.69 ± 4.55 17.08 ± 4.66 
Time to Peak (min) 38.75 ± 20.71 32.92 ± 18.57 33.75 ± 21.02 
Natural Killer Cells (%)          
Baseline 12.22 ± 8.11 11.08 ± 6.59 10.06 ± 5.69 
AUC 721.88 ± 351.28 689.79 ± 314.21 732.29 ± 335.58 
Peak Concentration 22.72 ± 10.05 23.47 ± 9.85 23.44 ± 11.00 











































Table 7. Serial measures for leukocyte responses (%) to MCMAP training across visits.   
  Visit 1 Visit 2 Visit 3 
Neutrophils (%)          
Baseline 52.52 ± 14.10 53.30 ± 6.55 53.03 ± 12.95 
AUC 4087.83 ± 687.75 3842.71 ± 562.65 3876.23 ± 552.39 
Peak Concentration 76.06 ± 9.11 72.98 ± 8.73 72.42 ± 9.23 
Time to Peak (min) 48.33 ± 21.25 40.42 ± 24.53 42.92 ± 24.62 
Monocytes (%)          
Baseline 7.99 ± 3.09 7.86 ± 1.72 7.68 ± 2.42 
AUC 367.35 ± 106.61 409.00 ± 133.46 431.81 ± 116.28 
Peak Concentration 7.55 ± 1.80 8.23 ± 2.24 8.54 ± 2.12 
Time to Peak (min) 11.67 ± 19.01 10.42 ± 17.13 12.50 ± 17.75 
Eosinophils (%)          
Baseline 3.21 ± 2.94 3.47 ± 3.15 3.32 ± 3.41 
AUC 117.54 ± 131.17 136.04 ± 146.34 131.88 ± 148.58 
Peak Concentration 2.70 ± 2.82 3.02 ± 2.98 2.86 ± 2.90 
Time to Peak (min) 10.42 ± 13.80 6.67 ± 9.78 8.33 ± 13.63 
Basophils (%)          
Baseline 0.43 ± 0.20 0.41 ± 0.21 0.43 ± 0.28 
AUC 21.60 ± 8.31 23.83 ± 9.63 27.23 ± 10.48 
Peak Concentration 0.55 ± 0.18 0.58 ± 0.22 0.64 ± 0.20 
Time to Peak (min) 16.25 ± 18.06 20.83 ± 20.99 26.25 ± 21.02 
 
Table 8. Effect of Marine Corps Martial Arts Training on endocrine parameters. Values are Mean ± SD. 
Visit Time Cortisol (mcg/dl) Epinephrine (pcg/ml) Norepinephrine (pcg/ml) 
1 Post 19.00 ± 4.37 73.83 ± 43.18 917.50 ± 489.32 
 R15 18.68 ± 4.67 50.86 ± 46.64 519.00 ± 244.38 
 R30 17.69 ± 4.98 29.89 ± 36.43 583.75 ± 355.94 
 R45 16.79 ± 5.02 17.44 ± 24.29 517.78 ± 179.55 
 R60 15.93 ± 4.74 20.75 ± 25.20 584.69 ± 180.65 
           
2 Post 18.97 ± 5.02 85.50 ± 57.45 966.47 ± 388.49 
 R15 18.76 ± 4.78 41.06 ± 37.90 496.81 ± 167.17 
 R30 17.30 ± 4.60 27.86 ± 36.64 505.89 ± 179.37 
 R45 16.03 ± 4.44 26.39 ± 28.20 517.44 ± 163.20 
 R60 14.28 ± 3.82 31.06 ± 37.85 534.31 ± 165.51 
           
3 Post 19.62 ± 4.57 77.36 ± 63.96 1101.25 ± 674.88 
 R15 19.19 ± 4.24 45.97 ± 41.22 571.36 ± 261.51 
 R30 17.32 ± 4.12 23.83 ± 22.37 556.94 ± 247.36 
 R45 16.41 ± 4.21 22.97 ± 25.16 516.92 ± 238.38 
  R60 15.05 ± 4.28 18.53 ± 20.01 551.89 ± 236.17 
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Table 9. Effect of Marine Corps Martial Arts Training on 
immunoglobulins-G & -M. Values are presented as mg/dl (Mean ± SD). 
Visit Time IgG IgM 
1 Post 1153.92 ± 209.22 120.11 ± 49.57 
 R15 1086.78 ± 194.56 112.81 ± 46.74 
 R30 1074.50 ± 207.25 111.31 ± 47.08 
 R45 1093.83 ± 232.83 113.56 ± 48.64 
 R60 1092.92 ± 205.79 113.14 ± 46.35 
        
2 Post 1167.42 ± 235.71 118.69 ± 51.37 
 R15 1077.97 ± 215.60 109.08 ± 47.71 
 R30 1066.47 ± 223.40 107.28 ± 46.10 
 R45 1055.28 ± 214.22 107.81 ± 47.55 
 R60 1065.92 ± 216.79 109.22 ± 46.89 
        
3 Post 1158.75 ± 229.52 118.08 ± 47.30 
 R15 1080.03 ± 222.54 111.11 ± 45.51 
 R30 1058.17 ± 218.65 108.36 ± 45.51 
 R45 1056.83 ± 218.42 108.92 ± 46.15 





































Table 19. Multilevel models of immunoglobulins-G & -M.    
 IgG IgM 
   SE Lower Upper  SE Lower Upper 
Fixed effect        
Intercept 80.91 23.65 34.56 127.27 6.87 1.62 3.70 10.05 
Baseline 0.98 0.02 0.94 1.02 0.98 0.01 0.95 1.00 
Time -71.97 4.57 -80.92 -63.01 -7.52 0.48 -8.46 -6.58 
Time2 13.45 1.05 11.38 15.51 1.44 0.11 1.23 1.65 
         
 Variance SD Correlation  Variance SD Correlation  
Random effect        
Visit 2579.07 50.79   45.49 6.74   
Time 152.35 12.34 -0.73  2.26 1.50 -0.81  
Subject 46.87 6.85   1.10 1.05   
Time 6.83 2.61 0.91  0.25 0.50 1.00  
Residual 1674.36 40.92     17.47 4.18     
 
Table 20. Multilevel model of neutrophil function. 
 Neutrophil Oxidative Burst 
   SE Lower Upper 
Fixed effect    
Intercept 43.16 5.18 33.01 53.32 
Baseline 0.55 0.05 0.44 0.65 
Time 0.28 0.13 0.02 0.54 
     
 Variance SD Correlation  
Random effect    
Visit 9.22 3.04   
Time 0.24 0.49 -1.00  
Subject 0.26 0.51   
Time 0.00 0.06 -1.00  















Fig. 1. Summary cortisol responses exhibited a curvilinear decrease over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 
weighted regression lines presented for each visit. 
Fig. 2. Summary epinephrine responses exhibited a curvilinear decrease over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 










Fig. 3. Summary norepinephrine responses exhibited a curvilinear decrease over time. (l.) Locally 
weighted regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) 
Locally weighted regression lines presented for each visit. 
Fig. 4. Summary CD3+ cell responses exhibited a curvilinear decrease over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 









Fig. 5. Summary CD4+ cell responses exhibited a curvilinear decrease over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 
weighted regression lines presented for each visit. 
Fig. 6. Summary CD8+ cell responses exhibited a curvilinear decrease over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 










Fig. 7. Summary CD19+ cell responses exhibited a curvilinear decrease over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 
weighted regression lines presented for each visit. 
Fig. 8. Summary natural killer cell responses exhibited a curvilinear decrease over time. (l.) Locally 
weighted regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) 











Fig. 9. Summary CD3+ cell responses (%) exhibited a curvilinear increase over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 
weighted regression lines presented for each visit. 
Fig. 10. Summary CD4+ cell responses (%) exhibited a curvilinear increase over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 












Fig. 11. Summary CD8+ cell responses (%) exhibited a curvilinear decrease over time. (l.) Locally 
weighted regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) 
Locally weighted regression lines presented for each visit. 
Fig. 12. Summary CD19+ cell responses (%) exhibited a curvilinear increase over time. (l.) Locally 
weighted regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) 












Fig. 13. Summary Natural Killer cell responses (%) exhibited a curvilinear decrease over time. (l.) Locally 
weighted regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) 
Locally weighted regression lines presented for each visit. 
Fig. 14. Summary neutrophil responses exhibited a curvilinear increase over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 













Fig. 15. Summary monocyte responses exhibited a curvilinear decrease over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 
weighted regression lines presented for each visit. 
Fig. 16. Summary eosinophil responses exhibited a curvilinear decrease over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 











Fig. 17. Summary basophil responses exhibited a curvilinear decrease over time. (l.) Locally weighted 
regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally 
weighted regression lines presented for each visit. 
Fig. 17. Summary neutrophil responses (%) exhibited a curvilinear increase over time. (l.) Locally 
weighted regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) 












Fig. 18. Summary monocytes responses (%) exhibited a curvilinear decrease over time. (l.) Locally 
weighted regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) 
Locally weighted regression lines presented for each visit. 
Fig. 19. Summary eosinophil responses (%) exhibited a curvilinear decrease over time. (l.) Locally 
weighted regression line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) 














Fig. 20. Summary basophil responses (%) exhibited an approximately linear decrease over time. (l.) 
Locally weighted regression line using all data points in the analysis. Shaded area indicates 95% confidence 
interval. (r.) Locally weighted regression lines presented for each visit. 
Fig. 21. Summary IgG responses exhibited curvilinear decrease over time. (l.) Locally weighted regression 
line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally weighted 












Fig. 22. Summary IgM responses exhibited curvilinear decrease over time. (l.) Locally weighted regression 
line using all data points in the analysis. Shaded area indicates 95% confidence interval. (r.) Locally weighted 
regression lines presented for each visit. 
Fig. 23. Summary neutrophil oxidative burst responses (%) exhibited an approximately linear increase 
over time. (l.) Locally weighted regression line using all data points in the analysis. Shaded area indicates 95% 
confidence interval. (r.) Locally weighted regression lines presented for each visit. 
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Cortisol (mcg/dl) Baseline IP  R15 R30 R45 R60 
B01-1.1 20.6 19.5 22.3 18 17 15.5 
B01-1.2 9.9 27.2 26.3 24.7 19.9 18 
B01-1.3 13.3 14 16.9 14 12.2 9.5 
E02-1.1 22.6 26.1 24.6 20.8 18.8 19.6 
E02-1.2 16.6 18.1 20.5 19.3 17.9 15.9 
E02-1.3 16.3 17.2 18.9 17.3 15.7 14 
Z03-1.1 22.7 24.7 30 29.5 30.3 24.5 
Z03-1.2 19.6 21.2 20.9 18.8 17 16 
Z03-1.3 22.4 22.7 20.7 17.4 18.4 15.3 
G04-1.1 10.9 21.9 24.5 24.4 22.5 19.6 
G04-1.2 14 20.5 19.4 17.2 15.8 13.7 
G04-1.3 16.7 23 20.8 19.4 17.4 15.9 
P05-1.1 15.7 23.6 21.5 19.6 17.9 15.1 
P05-1.2 14.4 26.2 28.7 25.2 21.7 20.5 
P05-1.3 13 20.8 16.8 17.1 12.9 12.2 
P06-1.1 15.7 11.2 10.8 8.8 9.6 9.9 
P06-1.2 18.1 14.1 12.5 10.6 8.6 7.5 
P06-1.3 12.3 17.7 19.8 15.6 14.3 14.2 
G07-1.1 11.6 7 7.6 10.9 11 10.8 
G07-1.2 12.1 12.1 10.2 8.2 7 7.5 
G07-1.3 13.4 11.2 9.5 8.6 7.8 7 
R08-2.1 11.2 24 26.5 29.7 25.3 23.8 
R08-2.2 16.5 27.8 28.9 25.1 24.1 20.7 
R08-2.3 17.2 16.2 20.5 21.6 18.2 17.8 
R09-2.1 18.5 23 22.1 21 17.1 16.7 
R09-2.2 16.3 15.8 14.6 12.6 11.6 11.4 
R09-2.3 21.1 23.6 24.4 23.6 21.6 21.1 
W10-2.1 15.4 17.5 14.6 18.5 15.4 13.8 
W10-2.2 19.4 12.6 17.6 20.1 17.9 15.2 
W10-2.3 12.9 17.3 17 15.4 13.2 10.3 
S11-3.1 22.4 15.3 15.1 13.3 13.6 11.9 
S11-3.2 18.6 19.4 15.9 13.5 11.9  
S11-3.3 16.5 16.7 16.8 15 14.8 14.6 
T12-3.1 19.9 15 16.9 14.8 13.5 11.8 
T12-3.2 19.7 18.1 20.6 18.7 18.3 14.8 
T12-3.3 18.4 24.2 24.3 23 20.9 21 
C13-3.1 14.8 11 12.5 12 10.7 10 
C13-3.2 21 14.4 14.7 8.5 10.1 8.9 
C13-3.3 20.3 20.9 18.9 18.7 18.8 15.6 
W14-3.1 19 18.3 21.4 24.2 25.1 24 
W14-3.2 15 19.4 21.8 19 17.6 15 
W14-3.3 12.3 19.7 21.5 19.3 17.8 16.2 
X15-3.1 18.4 20.6 19.2 17.9 16.7 15.9 
X15-3.2 20.3 21.8 21.1 19.9 17.9 16.1 
X15-3.3 16.8 20.7 17.5 16.8 15.1 13.8 
Y16-3.1 14 18.5 18.5 15.7 15.2 13.2 
Y16-3.2 11.7 18.1 16.5 16.8 15.9 13.3 
Y16-3.3 14.3 16.9 16.4 17.6 13.9 14.2 
Z17-3.1 16 16 16.5 14.3 13.2 11.2 
167 
 
Cortisol (mcg/dl) Baseline IP  R15 R30 R45 R60 
Z17-3.2 21.3 19.8 20.2 16.4 15.4 13.5 
Z17-3.3 18.2 18 15 16.1 15.2 14.3 
A18.01 16.8 18.8 20.7 19.8 16.7 15.4 
A18.02 14.8 14.4 13.6 13.8 13 9.9 
A18.03 24.7 25.4 23.7 21.7 20.5 19.8 
B19.01 17.9 18.8 19.9 22.5 25.3 22.8 
B19.02 19 17.8 16.7 17.6 16 14.3 
B19.03 17.4 23.9 24.6 22.3 21 20.7 
D21.01 16.8 18.5 19 17 15.8 15.1 
D21.02 18.4 20.2 19.3 19 17.1 14.4 
D21.03 20.1 29 29.1 26.2 25.9 25.8 
E22.01 17.3 14.4 16.2 14.4 12.9 11.1 
E22.02 20.5 11 17.2 17.1 16.3 14.3 
E22.03 17.9 24.3 24.6 21.4 20.9 19.3 
J24.01 20.8 19.1 17.1 17 15.5 16.5 
J24.02 22.3 25.9 23 20.6 22 21.2 
J24.03 13.4 26.6 24.5 17.7 21 18.4 
K25.01 23.6 22.8 21.7 21 20.6 19.6 
K25.02 18.5 24.8 20.9 18.9 17.3 16.2 
K25.03 20.9 28.4 24.3 21.1 23.8 21.5 
M26.01 18.3 24.1 22.9 21.1 20.1 17.9 
M26.02 20.3 29.3 27.2 23.2 24.1 19.2 
M26.03 22.2 14.5 15.4 10.8 12.8 11.7 
P27.01 15.8 15.9 15.2 14.1 13.4 13 
P27.02 16.6 17.5 16.2 15 13.3 12.4 
P27.03 15 13.8 11.6 9.6 11.2 10.3 
R28.01 13.5 18.4 16.3 13.7 13.6 13.5 
R28.02 15.9 23.9 23.1 22 20.2 18.9 
R28.03 11.1 15.2 16.3 11.7 14.4 11.6 
Z29.01 19.7 24 24.4 23.9 21.7 21.2 
Z29.02 13.9 24.3 22.9 23.6  21 
Z29.03 20.7 24.9 25.5 24 24.5 22.6 
A30.01 17.4 18.7 14.7 11.6 10.9 13.3 
A30.02 17.7 18.3 15 14.4 12.7 12.3 
A30.03 13.9 21 18.1 15.8 13.4 13 
B31.01 13.1 20.6 20.7 16.7 16.7 14.6 
B31.02 10.5 24 23.2 20.6 18.6 16.9 
B31.03 13.3 19.3 19.8 18.1 17.2 14.6 
C32.01 13.1 20.5 16 15.4 13.4 12 
C32.02 14 17.4 14.8 13.5 12.7 12 
C32.03 18.2 20.9 19.1 16.7 15.1 12.3 
D33.01 20.1 16.4 18.4 17.2 16 21.7 
D33.02 13.7 14.4 16.8 18.3 19 16.2 
D33.03 14.1 11.9 14.4 14.9 13.5 12.4 
H34.01 15.7 21.3 17.4 16.1 14.4 13.8 
H34.02 13.2 15.5 13.7 11.8 10.8 10.3 
H34.03 10.9 18.5 16.3 13.9 11 11.1 
J35.01 12.7 14.3 12.6 11.7 10.6 9.6 
J35.02 13.6 13.4 19.1 18.7 16.3 13.4 
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Cortisol (mcg/dl) Baseline IP  R15 R30 R45 R60 
J35.03 18.2 16.7 18.2 17.6 15.6 13.9 
K36.01 13.8 18.7 15.6 14.9 11.9 11 
K36.02 15.4 9.3 9 7.7 7.6 7.5 
K36.03 10.9 12.7 13.7 11.2 10.2 8.6 
M37.01 16 18.3 15.3  16.3 16.6 
M37.02 17.7 17 16.9 15.5 13 12.5 
M37.03 16.1  18.6 16 14.2 12.7 
O38.01 17.2 27.1 23.9 22.8 25.9 27.5 
O38.02 20.6 17.9 16.4 16.8 14.3 13.9 
O38.03 18.8 21 17.5 16.3 16.5 14.5 
 
 
Epinephrine (pcg/ml) Baseline IP  R15 R30 R45 R60 
B01-1.1 53 70 29 0 0 28 
B01-1.2 56 78 49 30 42 39 
B01-1.3 0 37 23 0 21 0 
E02-1.1 52 121 83 55 27 42 
E02-1.2 39 70 42 48 46 39 
E02-1.3 28 42 37 31 29 22 
Z03-1.1 25 95 83 46 50 0 
Z03-1.2 37 47 34 25 24 24 
Z03-1.3 29 40 30 27 24 0 
G04-1.1 0 29 25 21 0 0 
G04-1.2 0 54 24 0 22 21 
G04-1.3 0 54 37 34 0 0 
P05-1.1 0 33 23 27 0 0 
P05-1.2 28 83 47 69 49 36 
P05-1.3 25 43 36 26 24 0 
P06-1.1 25 28 43 28 22 0 
P06-1.2 0 29 35 0 0 0 
P06-1.3 38 164 69 55 46 57 
G07-1.1 0 37 47 21 36 28 
G07-1.2 27 53 45 32 28 0 
G07-1.3 27 22 42 23 0 0 
R08-2.1 30 168 113 51 50 44 
R08-2.2 0 166 103 44 44 64 
R08-2.3 30 102 53 42 32 28 
R09-2.1 0 22 21 0 0 0 
R09-2.2 0 0 0 0 0 0 
R09-2.3 0 0 23 0 0 0 
W10-2.1 60 62 46 31 22 0 
W10-2.2 42 120 77 41 23 31 
W10-2.3 49 38 0 0 0 0 
S11-3.1 0 45 32 0 24 0 
S11-3.2 37 85 65 35 0  
S11-3.3 0 0 0 0 0 0 
T12-3.1 53 110 47 43 32 24 
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Epinephrine (pcg/ml) Baseline IP  R15 R30 R45 R60 
T12-3.2 91 89 75 46 82 88 
T12-3.3 36 47 0 0 0  
C13-3.1 53 49 39 31 36 0 
C13-3.2 66 160 52 0 34 99 
C13-3.3 33 40  0 0 0 
W14-3.1 0 179 58 35 69 48 
W14-3.2 27 85 59 37 57 29 
W14-3.3 0 29 31 0 0 0 
X15-3.1 48 108 47  43 39 
X15-3.2 77 115 103 50 70 60 
X15-3.3 0 64 41 38 23 31 
Y16-3.1 0 50 22 27 0 28 
Y16-3.2 47 85 0 52 61 51 
Y16-3.3 0 0 0 0 0 0 
Z17-3.1 29 79 68 52 46 43 
Z17-3.2 77 121  108 91 65 
Z17-3.3 80 76 0 26 77 36 
A18.01 0 66 0 0 0 0 
A18.02 0 0 0 0 0 0 
A18.03 24 85 49 36 0 0 
B19.01 30 115 269 38  0 
B19.02 0 65 36 0 0 0 
B19.03 39 240 91 53 48 44 
D21.01 0 57 0 0 0 0 
D21.02 47 53 0 0 33 0 
D21.03 0 302 204 48 41 53 
E22.01 0 32 22 0 0 0 
E22.02 0 29 0 0 0 44 
E22.03 0 89 52 26 37 0 
J24.01 0 78 65 23 25 37 
J24.02 423 183 160 175 59 152 
J24.03 53 116 85 80 83 39 
K25.01 0 80 46 0 0 0 
K25.02 0 63 26 0 0 0 
K25.03 0 45 55 35 0 0 
M26.01 122 127 30 38 22  
M26.02 103 137 66 31 0 119 
M26.03 32 46 41 0 29 37 
P27.01 68 64 45 0 0 22 
P27.02 49 79 42 0 0 40 
P27.03 0 52 40 22 42 43 
R28.01 0 161 130 163 102 77 
R28.02 0 240 87 58 72 36 
R28.03 27 50 33 35 0 34 
Z29.01 42 70 44 0 0 48 
Z29.02 43 198 26 45  0 
Z29.03 38 156 66 0 43 27 
A30.01 69 0 51 34 0 29 
A30.02 27 91 0 0 0 0 
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Epinephrine (pcg/ml) Baseline IP  R15 R30 R45 R60 
A30.03 39 80 31 22 20 23 
B31.01 36 108 53 35 0 28 
B31.02 29 130 92 0 30 0 
B31.03 32 77 41 0 0 0 
C32.01 37 58 70 22 0 0 
C32.02 0 149 50 0 51 29 
C32.03 0 85 34 0 22 40 
D33.01 53 83 58 22 22 0 
D33.02 0 59 36 0 0 0 
D33.03 37 174 105 60 61 42 
H34.01 41 47  0 0 0 
H34.02 0 61 47 29 0 0 
H34.03 0 125 35 43 0 0 
J35.01 25 83 20 28 0 20 
J35.02 0 0 0 0 0 0 
J35.03 0 73 47 43 61 49 
K36.01 29 55 0 0 0 0 
K36.02 0 60 0 48 0 0 
K36.03 0 43 25 0 0 0 
M37.01 0 89 42  0 71 
M37.02 0 41 0 0 0 52 
M37.03 30  154 53 64 34 
O38.01 0 0 24  0 0 
O38.02 0 0 0 0 0 0 
O38.03 51 58 23 0 0 0 
 
 
Norepinephrine (pg/ml) Baseline IP  R15 R30 R45 R60 
B01-1.1 544 411 331 382 533 523 
B01-1.2 416 824 419 410 424 414 
B01-1.3 391 598 302 313 324 325 
E02-1.1 419 922 549 789 778 1009 
E02-1.2 324 1058 500 322 331 414 
E02-1.3 364 623 427 389 326 353 
Z03-1.1 267 748 499 370 399 448 
Z03-1.2 288 1062 427 430 381 355 
Z03-1.3 281 824 442 358 272 267 
G04-1.1 255 538 434 589 682 647 
G04-1.2 270 444 419 494 566 683 
G04-1.3 358 850 507 321 421 519 
P05-1.1 208 368 336 296 276 252 
P05-1.2 348 874 431 363 300 309 
P05-1.3 255 313 283 279 245 250 
P06-1.1 149 549 366 291 399 321 
P06-1.2 256 705 542 411 414 452 
P06-1.3 347 1354 492 400 339 364 
G07-1.1 158 197 202 241 336 344 
G07-1.2 258 413 381 383 465 383 
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Norepinephrine (pg/ml) Baseline IP  R15 R30 R45 R60 
G07-1.3 217 373 215 225 183 196 
R08-2.1 739 2243 1504 940 765 834 
R08-2.2 505 1732 1018 825 689 712 
R08-2.3 315 1561 651 503 391 567 
R09-2.1 772 1928 1147 725 687 641 
R09-2.2 323 866 371 385 472 451 
R09-2.3 387 1981 1279 795 657 555 
W10-2.1 137 399 205 182 201 241 
W10-2.2 302 595 237 249 253 250 
W10-2.3 180 264 165 159 153 166 
S11-3.1 616 1088 555 750 694 773 
S11-3.2 628 893 514 520 737  
S11-3.3 398 515 434 647 479 636 
T12-3.1 299 2018 655 475 534 541 
T12-3.2 832 1369 870 1024 821 578 
T12-3.3 450 547 784 1064 1028  
C13-3.1 267 871 445 466 444 730 
C13-3.2 217 416 281 295 478 522 
C13-3.3 463 721  466 573 1083 
W14-3.1 347 748 628 552 529 547 
W14-3.2 328 1371 545 504 744 461 
W14-3.3 303 453 332 483 477 538 
X15-3.1 494 1111 555  633 700 
X15-3.2 730 1360 892 805 843 739 
X15-3.3 664 634 553 790 690 748 
Y16-3.1 201 648 433 501 479 600 
Y16-3.2 335 897 505 515 553 660 
Y16-3.3 517 460 483 744 712 790 
Z17-3.1 555 991 547 490 399 640 
Z17-3.2 567 1125  760 687 638 
Z17-3.3 677 944 761 1109 843 1129 
A18.01 535 1399 675 568 534 577 
A18.02 844 891 657 678 573 594 
A18.03 744 910 680 696 640 667 
B19.01 426 1880 527 609  614 
B19.02 653 1238 583 583 630 594 
B19.03 374 2771 826 574 782 812 
D21.01 231 972 401 349 311 520 
D21.02 574 644 417 409 528 546 
D21.03 301 1886 653 539 486 638 
E22.01 573 1228 489 565 771 827 
E22.02 781 677 528 868 580 840 
E22.03 440 1452 687 708 627 794 
J24.01 408 680 417 425 415 810 
J24.02 475 801 598 495 521 895 
J24.03 321 1134 586 549 435 425 
K25.01 446 944 409 476 515 725 
K25.02 361 982 443 454 513 723 
K25.03 353 550 427 457 509 618 
172 
 
Norepinephrine (pg/ml) Baseline IP  R15 R30 R45 R60 
M26.01 413 952 672 635 474  
M26.02 298 874 490 657 731 475 
M26.03 235 702 323 281 262 291 
P27.01 547 1016 613 595 699 662 
P27.02 362 832 566 528 550 578 
P27.03 384 883 444 456 423 558 
R28.01 467 1558 487 476 459 501 
R28.02 400 685 506 439 563 478 
R28.03 300 905 382 354 313 409 
Z29.01 460 534 450 475 578 765 
Z29.02 439 359 257 401  434 
Z29.03 421 1851 587 373 323 414 
A30.01 473 811 839 1515 942 471 
A30.02 505 1752 607 595 689 819 
A30.03 712 2000 1118 1016 1044 775 
B31.01 288 530 364 409 403 487 
B31.02 329 1357 469 483 439 529 
B31.03 441 859 557 490 529 517 
C32.01 360 731 262 353 449 500 
C32.02 379 2158 573 600 480 420 
C32.03 377 1977 571 727 569 624 
D33.01 641 788 406 603 676 660 
D33.02 474 910 377 343 334 378 
D33.03 365 1054 401 483 477 512 
H34.01 150 517  270 201 230 
H34.02 220 849 379 268 226 238 
H34.03 220 2918 619 543 341 301 
J35.01 351 734 577 467 439 604 
J35.02 346 997 499 401 451 446 
J35.03 322 1286 965 1042 879 916 
K36.01 638 876 341 369 304 484 
K36.02 309 1039 375 407 322 370 
K36.03 488 1123 607 465 496 555 
M37.01 587 539 540  833 844 
M37.02 603 1005 560 593 684 724 
M37.03 612  1229 889 1043 804 
O38.01 444 563 323  364 505 
O38.02 300 739 340 315 257 433 









CD3+ (cells/ul) Baseline IP R15 R30 R45 R60 
B01-1.1 1457 1116 971 956 862 939 
B01-1.2 1326 2492 1257 1086 1057 987 
B01-1.3 1422 1487 1083 1076 1055 1151 
E02-1.1 1393 1207 899 787 693 647 
E02-1.2 1419 2288 1246 1161 1298 1204 
E02-1.3 1530 1302 1260 1252 1148 1080 
Z03-1.1 1437 1869 1277 819 854 810 
Z03-1.2 1138 1610 883 829 634 736 
Z03-1.3  1915 1139 911 860 800 
G04-1.1 1400 1418 1179 957 888 831 
G04-1.2 978 1256 1072 991 1010 995 
G04-1.3 1357 2118 1214 985 985 813 
P05-1.1 1226 1011 1041 880 835 816 
P05-1.2 1530 2744 1637 1376 1103 1174 
P05-1.3 1497 1559 1427 1304 1270 1194 
P06-1.1 2139 1886 1598 1218 1572 1704 
P06-1.2 2121 2780 2016 1852 1812 1728 
P06-1.3 1651 2464 1326 1146 1150 1152 
G07-1.1 1507 1716 1415 1399 1367 1473 
G07-1.2 1456 1945 1544 1406 1396 1436 
G07-1.3 1799 1933 1477 1283 1432 1572 
R08-2.1 1096 1710 1089 856 746 673 
R08-2.2 1171 1549 983 729 681 614 
R08-2.3 1070 1683 1141 945 919 872 
R09-2.1 1126 1710 1028 831 789 722 
R09-2.2 1378 1541 1136 1160 1022 1110 
R09-2.3 1524 1981 1600 1182 1100 1043 
W10-2.1 686 916 570 568 565 599 
W10-2.2 700 706 501 495 507 496 
W10-2.3 846 976 655 633 642 622 
S11-3.1 1405 1612 928 1045 1092 1195 
S11-3.2 1618 1220 1094 1190 1062  
S11-3.3 1160 1064 1003 1075 1061 1077 
T12-3.1 1158 1500 957 867 842 763 
T12-3.2 1156 957 1006 976 928 895 
T12-3.3 1507 1029 1006 1001 970 876 
C13-3.1 1405 1746 1068 976 1199  
C13-3.2 1505 1208 999 1031  714 
C13-3.3 1777 1306 987 996 973 1044 
W14-3.1 1290 1337 1209 835 604  
W14-3.2 1358 2472 1386 1153 1086 1031 
W14-3.3 1390 1450 1117 984 882 838 
X15-3.1 1179 1193 687 619 377 653 
X15-3.2 1375 1327 741 662 663 655 
X15-3.3 1078 856 729 700 742 791 
Y16-3.1 1558 1988 1314 1228 807 1229 
Y16-3.2 1744 2100 1219 1108 1097 1121 
Y16-3.3 2035 1646 1393 1398 1399 1331 
Z17-3.1 1735 2393 673 1385 1226 1248 
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CD3+ (cells/ul) Baseline IP R15 R30 R45 R60 
Z17-3.2 1929 2028  1236 1127 1085 
Z17-3.3 1622 1392 1257 1309 1176 1230 
A18.01 2562 3100 2033 1704 1634 1643 
A18.02 2618 2090 1692 1772 1686 1706 
A18.03 1713 1886 1275 1093 1039 878 
B19.01 1476 2076 1559 1073 993 963 
B19.02 1803 2029 1100 1105 1087 1078 
B19.03 1602 3237 1195 785 711 690 
D21.01 1012 1066 749 738 651 672 
D21.02 1466 972 787 830 747 787 
D21.03 1290 2170 1155 738 661 547 
E22.01 1682 2743 1531 1213 1141 1166 
E22.02 1829 1403 1406 1299 1234 1216 
E22.03 1706 3165 1336 1015 917 859 
J24.01 2250 1029 857 822 686 662 
J24.02 1555 1041 798 757 683 705 
J24.03 1432 1659 1050 990 928 869 
K25.01 2220 2001 1243 1221 1222 1256 
K25.02 1742 2244 1334 1222 1206 1196 
K25.03 1869 2213 1391 1426 1296 1343 
M26.01 2034 1390 955 723 638 667 
M26.02 1478 1283 908 651 688 700 
M26.03 1793 1716 1015 998 1096 1083 
P27.01 1498 1625 1174 1182 1226 1254 
P27.02 1821 1927 1562 1565 1487 1340 
P27.03 1488 1564 1195 1296 1282 1323 
R28.01 1279 1135 662 656 588 633 
R28.02 1256 717 599 567 567 550 
R28.03 989 1244 768 752 756 737 
Z29.01 1615 1268 934 890 837 831 
Z29.02 1726 1650 1325 1172  1027 
Z29.03 1014 1534 989 825 810 741 
A30.01 1219 1253 794 805 892 829 
A30.02 1095 1682 852 792 755 839 
A30.03 1172 2059 935 811 756 679 
B31.01 1877 1667 1241 1169 1066 1019 
B31.02 1987 2452 1271 1172 1107 1051 
B31.03 1927 1930 1180 1122 1109 1035 
C32.01 1109 1199 706 735 716 683 
C32.02 1133 1376 907 733 686 783 
C32.03 1468 1622 870 778 739 732 
D33.01 1485 981 930 951 904 1285 
D33.02 1588 1805 1114 955 1031 985 
D33.03 1672 1796 1207 1222 1185 1162 
H34.01 1305 1334 1024 893 913 894 
H34.02 1341 1392 853 815 867 904 
H34.03 936 1658 926 752 788 825 
J35.01 1362 1447 1138 1019 1091 1094 
J35.02 1316 1480 1005 1046 934 917 
175 
 
CD3+ (cells/ul) Baseline IP R15 R30 R45 R60 
J35.03 1552 1411 1124 1069 977 989 
K36.01 1418 1691 1067 1059 964 1083 
K36.02 1151 1784 997 1054 1079 1141 
K36.03 1295 2150 1226 1046 1084 1042 
M37.01 0 1207 1027  979 948 
M37.02 1305 882 804 767 784 779 
M37.03 1165  703 642 663 625 
O38.01 1197 1299 829 799 853 862 
O38.02 1222 1363 730 724 751 840 
O38.03 1379 1187 760 761 764 866 
 
 
CD4+ (cells/ul) Baseline IP R15 R30 R45 R60 
B01-1.1 769 522 456 502 449 461 
B01-1.2 646 960 602 585 561 508 
B01-1.3 753 707 516 548 541 585 
E02-1.1 806 624 528 546 475 428 
E02-1.2 929 1361 697 729 825 794 
E02-1.3 933 691 803 807 790 740 
Z03-1.1 738 786 607 461 504 497 
Z03-1.2 559 634 435 436 315 430 
Z03-1.3  902 582 493 494 446 
G04-1.1 880 790 734 642 578 554 
G04-1.2 654 743 624 651 612 632 
G04-1.3 846 1191 719 616 601 532 
P05-1.1 630 477 516 415 420 446 
P05-1.2 784 1197 716 607 564 617 
P05-1.3 696 684 641 619 619 621 
P06-1.1 1306 1026 969 559 975 1038 
P06-1.2 1350 1502 1217 1106 1137 1093 
P06-1.3 1069 1275 788 666 733 698 
G07-1.1 883 937 722 788 752 800 
G07-1.2 842 986 869 751 798 871 
G07-1.3 1019 982 795 768 843 924 
R08-2.1 654 865 640 533 498 451 
R08-2.2 731 773 542 448 435 407 
R08-2.3 635 913 672 568 586 568 
R09-2.1 655 812 592 497 507 445 
R09-2.2 793 827 618 607 590 580 
R09-2.3 851 958 849 700 645 591 
W10-2.1 404 554 368 369 392 388 
W10-2.2 445 466 324 327 318 333 
W10-2.3 536 587 428 423 421 424 
S11-3.1 902 976 631 691 666 767 
S11-3.2 1024 736 682 713 671  
S11-3.3 763 667 646 721 642 693 
T12-3.1 602 809 522 472 476 425 
176 
 
CD4+ (cells/ul) Baseline IP R15 R30 R45 R60 
T12-3.2 659 519 550 552 515 502 
T12-3.3 824 572 595 572 541 468 
C13-3.1 840 931 682 634 704  
C13-3.2 931 668 608 637  440 
C13-3.3 1056 852 632 667 636 631 
W14-3.1 761 625 619 504 352  
W14-3.2 832 1131 727 680 684 605 
W14-3.3 877 847 724 628 575 503 
X15-3.1 609 648 460 375 259 445 
X15-3.2 819 787 509 469 453 426 
X15-3.3 733 537 482 474 495 551 
Y16-3.1 872 973 785 805 554 779 
Y16-3.2 1159 1046 716 716 726 730 
Y16-3.3 1322 1044 843 934 912 836 
Z17-3.1 988 1061 337 752 692 682 
Z17-3.2 1020 868  741 685 677 
Z17-3.3 874 736 708 750 686 740 
A18.01 1281 1186 920 862 867 811 
A18.02 1303 956 824 919 848 874 
A18.03 843 793 661 629 634 530 
B19.01 788 919 705 599 617 592 
B19.02 1017 926 631 693 653 637 
B19.03 902 1346 651 520 482 444 
D21.01 690 570 436 464 425 461 
D21.02 947 608 514 533 491 510 
D21.03 825 1123 656 480 464 378 
E22.01 1004 915 711 691 623 667 
E22.02 1016 658 624 617 680 685 
E22.03 943 1047 630 568 562 533 
J24.01 1437 584 563 536 462 425 
J24.02 696 594 521 501 463 458 
J24.03 879 759 608 586 559 551 
K25.01 1107 834 626 660 643 675 
K25.02 781 800 646 631 657 655 
K25.03 1000 897 624 716 637 658 
M26.01 1206 770 579 477 417 405 
M26.02 894 684 548 431 473 443 
M26.03 1078 944 621 665 685 681 
P27.01 1017 1014 833 866 906 881 
P27.02 1240 1328 1124 1125 1082 1033 
P27.03 1049 981 826 880 852 917 
R28.01 783 634 418 445 387 432 
R28.02 734 428 375 377 386 366 
R28.03 630 683 472 443 496 475 
Z29.01 953 819 629 576 565 529 
Z29.02 1035 981 795 716  658 
Z29.03 626 807 586 531 520 489 
A30.01 541 614 446 462 486 475 
A30.02 576 718 439 452 428 449 
177 
 
CD4+ (cells/ul) Baseline IP R15 R30 R45 R60 
A30.03 638 836 509 451 428 376 
B31.01 978 891 741 711 662 591 
B31.02 1184 1289 814 759 719 652 
B31.03 1039 1104 747 705 674 654 
C32.01 704 676 493 497 479 467 
C32.02 757 844 586 514 478 552 
C32.03 965 935 575 526 506 502 
D33.01 1014 669 656 644 627 801 
D33.02 1149 1113 767 690 706 682 
D33.03 1233 1117 867 858 800 840 
H34.01 910 894 745 644 698 642 
H34.02 935 982 651 579 624 659 
H34.03 670 990 610 521 575 582 
J35.01 999 1040 779 690 759 777 
J35.02 935 971 715 746 678 640 
J35.03 1091 893 750 760 685 683 
K36.01 756 742 582 617 578 638 
K36.02 716 733 562 620 655 706 
K36.03 742 874 607 605 623 640 
M37.01 0 707 609  582 550 
M37.02 764 522 519 480 491 486 
M37.03 731  417 408 448 415 
O38.01 768 703 515 522 544 550 
O38.02 767 725 446 489 513 574 
O38.03 882 689 518 517 549 585 
 
 
CD8+ (cells/ul) Baseline IP R15 R30 R45 R60 
B01-1.1 631 524 422 422 403 410 
B01-1.2 690 1430 632 531 451 442 
B01-1.3 613 776 491 492 480 514 
E02-1.1 563 520 300 258 201 233 
E02-1.2 486 1200 446 382 448 453 
E02-1.3 517 542 529 469 383 359 
Z03-1.1 676 968 623 332 311 308 
Z03-1.2 525 873 410 349 220 334 
Z03-1.3  1035 528 404 354 325 
G04-1.1 483 508 454 300 268 257 
G04-1.2 308 447 381 322 341 317 
G04-1.3 481 968 485 355 314 247 
P05-1.1 569 545 482 411 387 389 
P05-1.2 826 1737 917 724 568 575 
P05-1.3 769 840 726 645 596 552 
P06-1.1 851 715 650 345 574 652 
P06-1.2 827 1073 774 656 647 670 
P06-1.3 569 1119 515 401 446 408 
G07-1.1 552 736 574 643 499 569 
178 
 
CD8+ (cells/ul) Baseline IP R15 R30 R45 R60 
G07-1.2 592 897 662 572 531 556 
G07-1.3 729 878 605 503 493 610 
R08-2.1 404 876 469 334 258 226 
R08-2.2 458 790 413 267 241 218 
R08-2.3 428 797 483 348 318 301 
R09-2.1 479 903 468 344 328 293 
R09-2.2 638 697 486 460 450 491 
R09-2.3 664 1033 751 518 466 414 
W10-2.1 214 353 190 196 184 188 
W10-2.2 217 247 157 162 161 149 
W10-2.3 247 342 217 180 211 176 
S11-3.1 478 570 347 345 364 408 
S11-3.2 573 460 388 402 378  
S11-3.3 399 392 350 394 357 385 
T12-3.1 559 880 403 345 363 315 
T12-3.2 493 451 433 418 409 352 
T12-3.3 684 422 434 392 385 399 
C13-3.1 454 760 351 327 408  
C13-3.2 523 498 346 327  236 
C13-3.3 615 452 307 324 321 359 
W14-3.1 497 624 572 406 235  
W14-3.2 516 1241 577 449 422 380 
W14-3.3 486 541 397 349 317 306 
X15-3.1 345 506 204 172 120 196 
X15-3.2 482 573 223 185 188 198 
X15-3.3 402 318 238 204 227 266 
Y16-3.1 470 921 471 460 299 437 
Y16-3.2 647 950 452 381 359 384 
Y16-3.3 690 561 466 488 490 499 
Z17-3.1 689 1236 291 611 516 525 
Z17-3.2 837 1037  468 448 405 
Z17-3.3 654 599 510 568 494 486 
A18.01 1285 1794 1025 795 756 758 
A18.02 1311 1122 828 820 797 827 
A18.03 904 1122 632 464 437 356 
B19.01 678 1074 756 441 377 367 
B19.02 735 1002 416 397 400 404 
B19.03 643 1712 472 256 243 249 
D21.01 317 488 273 249 219 223 
D21.02 489 331 262 277 230 267 
D21.03 448 1008 460 209 192 163 
E22.01 705 1753 808 527 482 523 
E22.02 799 685 745 631 543 509 
E22.03 721 2069 671 415 349 335 
J24.01 820 448 276 268 207 228 
J24.02 857 469 285 259 219 231 
J24.03 526 880 460 381 361 304 
K25.01 916 888 479 483 504 493 
K25.02 893 1354 644 542 556 539 
179 
 
CD8+ (cells/ul) Baseline IP R15 R30 R45 R60 
K25.03 896 1269 678 703 633 618 
M26.01 823 614 389 260 213 255 
M26.02 641 566 354 212 244 289 
M26.03 656 804 351 353 385 365 
P27.01 496 594 335 316 337 355 
P27.02 605 559 451 436 408 332 
P27.03 469 568 399 382 382 412 
R28.01 425 455 209 193 186 179 
R28.02 427 281 199 202 199 183 
R28.03 322 504 269 245 261 244 
Z29.01 568 400 277 273 255 277 
Z29.02 690 597 473 439  383 
Z29.03 365 624 353 304 251 249 
A30.01 601 616 339 358 407 344 
A30.02 537 953 376 355 322 364 
A30.03 570 1247 425 344 309 291 
B31.01 837 682 492 459 407 408 
B31.02 812 1054 454 409 392 394 
B31.03 858 881 429 404 409 388 
C32.01 361 463 224 239 219 214 
C32.02 364 546 299 217 206 249 
C32.03 506 660 290 231 220 232 
D33.01 429 271 272 280 270 435 
D33.02 421 677 309 251 288 273 
D33.03 462 660 351 336 336 364 
H34.01 370 380 266 234 219 234 
H34.02 370 459 217 207 233 227 
H34.03 251 654 297 205 211 218 
J35.01 366 444 302 272 287 307 
J35.02 354 451 271 277 244 239 
J35.03 435 432 323 288 266 275 
K36.01 598 960 502 392 345 393 
K36.02 428 991 430 417 418 392 
K36.03 521 1167 589 393 428 435 
M37.01 0 458 394  407 383 
M37.02 490 340 282 278 301 284 
M37.03 423  261 224 227 212 
O38.01 373 550 258 241 320 259 
O38.02 397 555 279 191 199 225 








CD19+ (cells/ul) Baseline IP R15 R30 R45 R60 
B01-1.1 228 129 144 116 138 120 
B01-1.2 210 213 157 135 153 124 
B01-1.3 195 113 152 135 134 145 
E02-1.1 175 99 120 94 107 88 
E02-1.2 210 240 204 176 170 151 
E02-1.3 230 183 171 181 163 164 
Z03-1.1 232 202 143 130 145 132 
Z03-1.2 190 208 153 151 102 126 
Z03-1.3  286 207 161 159 145 
G04-1.1 326 259 215 187 159 184 
G04-1.2 218 281 232 236 223 238 
G04-1.3 259 321 211 201 208 168 
P05-1.1 205 119 127 121 119 124 
P05-1.2 206 259 208 218 137 146 
P05-1.3 215 213 223 189 201 204 
P06-1.1 420 318 270 291 296 334 
P06-1.2 395 441 356 393 378 369 
P06-1.3 319 466 268 245 217 233 
G07-1.1 374 352 309 279 340 319 
G07-1.2 339 365 330 322 384 349 
G07-1.3 495 374 333 306 352 353 
R08-2.1 247 396 218 191 164 159 
R08-2.2 262 301 208 158 141 141 
R08-2.3 250 413 229 234 186 203 
R09-2.1 311 380 213 198 186 164 
R09-2.2 359 368 326 317 271 317 
R09-2.3 422 382 303 249 230 243 
W10-2.1 141 219 130 147 153 180 
W10-2.2 204 174 132 129 138 143 
W10-2.3 210 203 124 149 128 148 
S11-3.1 281 290 164 198 212 248 
S11-3.2 310 213 222 279 267  
S11-3.3 218 171 207 219 222 234 
T12-3.1 147 116 113 111 120 87 
T12-3.2 142 105 129 116 100 108 
T12-3.3 177 138 128 139 135 130 
C13-3.1 170 200 140 135 160  
C13-3.2 165 146 140 133  78 
C13-3.3 178 133 120 116 111 155 
W14-3.1 541 282 396 247 218  
W14-3.2 526 694 408 389 349 345 
W14-3.3 520 391 364 319 335 319 
X15-3.1 250 241 162 150 78 145 
X15-3.2 266 277 183 163 174 146 
X15-3.3 211 174 163 152 178 213 
Y16-3.1 442 373 268 291 161 283 
Y16-3.2 357 365 300 243 231 229 
Y16-3.3 485 345 323 305 334 287 
Z17-3.1 343 329 119 260 220 258 
181 
 
CD19+ (cells/ul) Baseline IP R15 R30 R45 R60 
Z17-3.2 340 275  260 226 248 
Z17-3.3 312 268 329 331 267 282 
A18.01 465 378 271 283 274 260 
A18.02 425 253 292 328 311 300 
A18.03 170 166 168 176 156 131 
B19.01 266 337 250 139 156 139 
B19.02 272 250 187 170 183 178 
B19.03 209 421 172 116 101 95 
D21.01 464 449 351 300 280 269 
D21.02 666 339 309 315 285 288 
D21.03 553 464 323 284 252 219 
E22.01 310 344 273 237 203 200 
E22.02 279 210 208 202 176 205 
E22.03 291 299 222 181 166 169 
J24.01 494 172 173 178 150 142 
J24.02 202 155 137 144 136 159 
J24.03 252 194 151 120 132 139 
K25.01 358 230 186 172 168 198 
K25.02 237 231 166 160 162 184 
K25.03 233 222 163 175 152 172 
M26.01 463 234 175 156 148 183 
M26.02 325 191 200 183 191 177 
M26.03 393 256 195 204 246 247 
P27.01 232 238 212 207 214 202 
P27.02 321 401 343 384 312 279 
P27.03 228 234 181 180 197 198 
R28.01 493 353 246 231 237 249 
R28.02 502 195 224 211 225 216 
R28.03 377 305 240 269 265 310 
Z29.01 428 274 224 233 229 241 
Z29.02 369 273 282 308  272 
Z29.03 245 274 193 200 203 188 
A30.01 279 277 204 240 270 214 
A30.02 284 320 201 203 207 254 
A30.03 270 410 223 213 207 199 
B31.01 416 345 259 238 257 255 
B31.02 424 484 299 261 240 265 
B31.03 422 420 244 242 248 247 
C32.01 407 362 266 249 268 250 
C32.02 446 441 326 278 269 325 
C32.03 605 526 304 290 312 305 
D33.01 351 211 188 208 183 235 
D33.02 357 326 238 220 224 215 
D33.03 439 360 262 325 321 314 
H34.01 354 312 241 244 247 234 
H34.02 521 424 253 293 335 345 
H34.03 373 443 258 248 283 283 
J35.01 376 344 301 295 327 295 
J35.02 385 400 263 286 250 256 
182 
 
CD19+ (cells/ul) Baseline IP R15 R30 R45 R60 
J35.03 407 387 316 315 278 261 
K36.01 355 285 246 262 273 275 
K36.02 298 310 234 238 242 303 
K36.03 359 345 252 255 236 209 
M37.01 0 284 246  257 235 
M37.02 313 200 113 194 231 225 
M37.03 229  160 174 170 156 
O38.01 247 205 136 134 141 157 
O38.02 214 178 183 118 136 163 
O38.03 252 180 135 135 147 162 
 
 
NK Cells (cells/ul) Baseline IP R15 R30 R45 R60 
B01-1.1 125 92 60 49 33 70 
B01-1.2 120 548 107 62 78 83 
B01-1.3 67 216 106 86 60 65 
E02-1.1 316 288 120 102 64 98 
E02-1.2 177 672 158 99 142 116 
E02-1.3 167 316 185 135 81 96 
Z03-1.1 530 1126 457 126 115 120 
Z03-1.2 533 1185 312 262 224 238 
Z03-1.3  1105 380 246 213 169 
G04-1.1 150 302 128 79 72 75 
G04-1.2 88 335 178 100 124 103 
G04-1.3 149 590 177 72 69 63 
P05-1.1 238 372 257 176 197 185 
P05-1.2 351 1649 615 348 204 200 
P05-1.3 434 537 406 309 221 217 
P06-1.1 236 468 172 148 124 131 
P06-1.2 202 858 212 166 136 105 
P06-1.3 123 1250 303 141 106 103 
G07-1.1 47 91 114 50 63 80 
G07-1.2 73 145 73 38 42 52 
G07-1.3 84 163 71 39 41 69 
R08-2.1 375 1420 437 218 96 104 
R08-2.2 162 1148 400 202 129 159 
R08-2.3 291 1412 399 209 129 162 
R09-2.1 113 833 151 101 62 65 
R09-2.2 96 461 133 120 95 138 
R09-2.3 216 902 421 121 78 78 
W10-2.1 573 599 148 133 113 93 
W10-2.2 264 489 138 84 83 141 
W10-2.3 260 635 217 109 72 82 
S11-3.1 103 317 79 64 79 80 
S11-3.2 67 130 62 69 71  
S11-3.3 96 113 85 75 95 95 
T12-3.1 164 644 110 47 44 57 
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NK Cells (cells/ul) Baseline IP R15 R30 R45 R60 
T12-3.2 55 145 109 65 61 91 
T12-3.3 193 115 86 107 128 158 
C13-3.1 186 483 64 66 168  
C13-3.2 185 224 125 109  97 
C13-3.3 302 162 85 70 99 153 
W14-3.1 78 258 121 41 56  
W14-3.2 60 622 103 73 78 96 
W14-3.3 47 130 55 46 38 44 
X15-3.1 299 489 111 133 61 95 
X15-3.2 292 450 104 71 79 104 
X15-3.3 150 225 131 89 103 148 
Y16-3.1 199 973 200 130 104 238 
Y16-3.2 266 1181 282 199 236 299 
Y16-3.3 187 298 219 157 267 241 
Z17-3.1 417 1576 192 256 259 204 
Z17-3.2 476 1228  221 167 200 
Z17-3.3 473 285 224 176 179 208 
A18.01 139 510 223 103 72 87 
A18.02 217 253 95 98 109 116 
A18.03 179 347 128 70 82 57 
B19.01 276 1032 717 187 97 128 
B19.02 289 822 148 89 116 76 
B19.03 224 2194 242 82 93 186 
D21.01 134 658 158 88 95 100 
D21.02 215 361 118 118 105 113 
D21.03 173 1247 448 106 95 93 
E22.01 50 379 76 28 25 37 
E22.02 107 110 104 57 32 44 
E22.03 76 558 84 52 34 44 
J24.01 150 127 52 66 57 59 
J24.02 414 209 92 87 81 104 
J24.03 122 369 150 97 88 71 
K25.01 250 582 150 84 113 121 
K25.02 290 483 103 89 85 94 
K25.03 98 481 133 142 117 122 
M26.01 724 945 420 213 218 355 
M26.02 513 713 256 78 140 326 
M26.03 468 955 215 182 197 248 
P27.01 604 739 192 188 164 173 
P27.02 549 444 132 139 155 167 
P27.03 306 843 183 210 239 187 
R28.01 458 1089 159 102 94 117 
R28.02 283 560 185 103 114 148 
R28.03 143 1048 265 135 145 133 
Z29.01 573 554 194 194 168 319 
Z29.02 694 798 149 90  385 
Z29.03 407 2051 582 174 151 130 
A30.01 293 236 61 67 104 66 
A30.02 136 694 79 50 41 50 
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NK Cells (cells/ul) Baseline IP R15 R30 R45 R60 
A30.03 196 1018 100 56 62 95 
B31.01 297 278 110 80 90 116 
B31.02 170 1042 90 60 65 93 
B31.03 372 500 88 77 82 90 
C32.01 278 702 109 127 144 146 
C32.02 176 1068 241 112 80 137 
C32.03 193 1356 171 73 73 132 
D33.01 228 85 91 76 86 263 
D33.02 84 598 127 50 54 63 
D33.03 96 467 123 66 94 60 
H34.01 97 155 65 47 54 60 
H34.02 92 234 72 65 60 77 
H34.03 64 775 161 76 71 62 
J35.01 213 656 136 104 125 251 
J35.02 156 988 148 132 133 145 
J35.03 162 974 380 233 250 272 
K36.01 268 461 106 116 90 100 
K36.02 92 546 66 100 114 96 
K36.03 106 734 109 97 110 86 
M37.01 0 523 435  331 243 
M37.02 241 462 88 130 103 143 
M37.03 217  293 142 98 85 
O38.01 135 740 112 109 238 166 
O38.02 129 853 192 45 57 67 
O38.03 338 385 71 53 57 90 
 
 
CD3+ (%) Baseline IP R15 R30 R45 R60 
B01-1.1 79 83 83 84 82 83 
B01-1.2 78 76 82 83 82 82 
B01-1.3 84 81 82 83 84 84 
E02-1.1 72 74 80 79 79 75 
E02-1.2 78 67 77 81 80 80 
E02-1.3 78 72 75 78 82 79 
Z03-1.1 64 58 67 76 77 75 
Z03-1.2 61 54 66 68 67 67 
Z03-1.3  57 66 67 69 72 
G04-1.1 73 72 75 77 78 75 
G04-1.2 75 67 72 74 75 74 
G04-1.3 77 67 73 79 78 77 
P05-1.1 74 65 73 75 73 72 
P05-1.2 72 57 66 71 76 76 
P05-1.3 69 67 69 71 76 74 
P06-1.1 75 70 76 76 77 77 
P06-1.2 76 68 77 76 77 77 
P06-1.3 78 56 69 74 77 77 
G07-1.1 78 79 77 79 78 79 
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CD3+ (%) Baseline IP R15 R30 R45 R60 
G07-1.2 78 79 78 78 77 77 
G07-1.3 76 78 78 78 78 78 
R08-2.1 63 46 60 65 73 71 
R08-2.2 72 50 61 66 69 65 
R08-2.3 65 46 63 68 73 70 
R09-2.1 72 57 72 72 74 74 
R09-2.2 73 64 72 74 72 70 
R09-2.3 70 60 68 75 78 77 
W10-2.1 49 51 65 64 66 68 
W10-2.2 60 50 64 68 67 63 
W10-2.3 64 54 64 71 75 72 
S11-3.1 78 72 76 79 78 78 
S11-3.2 79 77 78 77 75  
S11-3.3 77 77 77 77 77 76 
T12-3.1 76 62 78 83 81 82 
T12-3.2 82 75 78 81 82 79 
T12-3.3 78 78 79 77 76 73 
C13-3.1 79 71 82 81 76  
C13-3.2 79 76 78 79  79 
C13-3.3 77 80 81 82 80 75 
W14-3.1 68 70 70 71 68  
W14-3.2 68 65 72 70 70 69 
W14-3.3 70 73 70 72 69 69 
X15-3.1 71 60 71 70 73 72 
X15-3.2 70 62 71 73 72 72 
X15-3.3 72 66 70 73 72 68 
Y16-3.1 74 59 73 73 74 70 
Y16-3.2 72 57 69 71 69 67 
Y16-3.3 75 71 72 73 70 70 
Z17-3.1 68 55 67 70 70 71 
Z17-3.2 69 57  70 71 68 
Z17-3.3 66 69 68 70 70 68 
A18.01 80 77 80 80 81 81 
A18.02 79 79 81 80 79 79 
A18.03 81 77 80 81 80 81 
B19.01 72 59 60 76 79 78 
B19.02 75 65 76 80 77 81 
B19.03 77 54 73 79 77 70 
D21.01 62 48 60 64 64 64 
D21.02 62 57 65 65 65 64 
D21.03 63 54 59 64 63 62 
E22.01 82 78 81 80 83 83 
E22.02 81 81 81 82 84 82 
E22.03 82 76 80 80 81 79 
J24.01 77 76 79 77 77 76 
J24.02 71 73 77 75 76 72 
J24.03 78 73 77 80 79 79 
K25.01 78 71 80 81 81 79 
K25.02 76 75 83 84 81 80 
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CD3+ (%) Baseline IP R15 R30 R45 R60 
K25.03 84 75 81 80 82 81 
M26.01 63 54 62 66 63 55 
M26.02 63 58 66 72 66 57 
M26.03 68 59 71 71 72 68 
P27.01 63 61 74 74 76 76 
P27.02 67 68 75 74 75 75 
P27.03 72 60 74 76 75 76 
R28.01 56 43 61 65 63 63 
R28.02 62 47 60 62 61 59 
R28.03 65 47 58 64 63 63 
Z29.01 61 60 68 67 67 59 
Z29.02 61 60 74 74  59 
Z29.03 58 40 54 68 69 69 
A30.01 68 69 74 72 71 74 
A30.02 71 61 75 75 74 73 
A30.03 71 59 72 74 73 70 
B31.01 72 71 75 76 74 72 
B31.02 75 61 76 77 77 74 
B31.03 70 66 77 77 76 74 
C32.01 62 52 64 65 62 63 
C32.02 64 45 61 65 64 62 
C32.03 64 45 63 67 66 61 
D33.01 71 76 77 77 76 71 
D33.02 76 65 74 76 78 77 
D33.03 75 67 74 76 74 75 
H34.01 72 74 75 76 73 74 
H34.02 68 67 70 69 68 67 
H34.03 67 55 66 69 69 70 
J35.01 69 58 72 72 70 65 
J35.02 70 52 70 72 70 69 
J35.03 72 51 61 65 64 63 
K36.01 67 68 73 72 71 72 
K36.02 71 68 76 75 72 73 
K36.03 72 66 76 73 75 76 
M37.01 0 58 58  63 65 
M37.02 69 55 80 69 68 68 
M37.03 71  59 67 70 70 
O38.01 75 56 77 76 67 72 
O38.02 76 56 64 81 80 77 








CD4+ (%) Baseline IP R15 R30 R45 R60 
B01-1.1 41 40 41 44 42 42 
B01-1.2 37 29 38 42 44 43 
B01-1.3 44 37 41 42 43 43 
E02-1.1 41 39 50 54 54 49 
E02-1.2 51 35 46 53 52 50 
E02-1.3 50 39 44 49 55 53 
Z03-1.1 32 25 32 44 47 45 
Z03-1.2 31 22 34 37 38 38 
Z03-1.3  26 35 36 39 41 
G04-1.1 46 42 45 51 52 51 
G04-1.2 50 40 44 49 47 48 
G04-1.3 48 36 42 49 50 52 
P05-1.1 39 29 37 37 37 38 
P05-1.2 35 23 28 32 37 39 
P05-1.3 32 29 32 33 38 39 
P06-1.1 44 40 44 46 47 46 
P06-1.2 46 37 45 46 48 47 
P06-1.3 50 28 40 44 47 48 
G07-1.1 45 43 41 41 45 44 
G07-1.2 45 40 43 42 45 45 
G07-1.3 44 40 42 46 47 45 
R08-2.1 38 22 34 40 48 49 
R08-2.2 44 24 34 42 43 42 
R08-2.3 38 24 35 42 47 45 
R09-2.1 42 27 41 43 46 45 
R09-2.2 40 34 40 42 41 38 
R09-2.3 39 29 36 43 45 45 
W10-2.1 30 30 42 41 45 46 
W10-2.2 38 32 42 43 42 43 
W10-2.3 42 33 41 48 48 49 
S11-3.1 50 44 48 51 49 51 
S11-3.2 49 46 49 49 47  
S11-3.3 49 47 49 49 48 48 
T12-3.1 38 29 43 46 44 45 
T12-3.2 45 39 43 45 45 45 
T12-3.3 42 43 45 43 43 39 
C13-3.1 48 38 52 52 45  
C13-3.2 49 43 47 50  49 
C13-3.3 46 50 52 53 51 45 
W14-3.1 40 33 36 39 40  
W14-3.2 41 30 38 41 42 41 
W14-3.3 45 42 44 45 44 42 
X15-3.1 44 32 49 48 51 49 
X15-3.2 43 35 48 51 50 48 
X15-3.3 45 40 47 49 48 46 
Y16-3.1 48 29 44 46 47 45 
Y16-3.2 45 29 42 46 44 43 
Y16-3.3 49 45 46 47 45 42 
Z17-3.1 39 24 34 37 40 39 
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CD4+ (%) Baseline IP R15 R30 R45 R60 
Z17-3.2 36 25  40 42 42 
Z17-3.3 36 36 39 39 40 40 
A18.01 39 31 37 41 43 41 
A18.02 39 36 40 41 40 40 
A18.03 38 32 41 47 48 47 
B19.01 38 26 28 42 48 47 
B19.02 41 29 44 49 47 49 
B19.03 43 22 40 51 50 44 
D21.01 42 26 36 41 43 43 
D21.02 40 35 42 42 43 41 
D21.03 39 28 34 43 43 41 
E22.01 48 26 37 44 46 46 
E22.02 44 39 36 39 45 47 
E22.03 45 25 37 45 49 48 
J24.01 49 42 52 51 53 49 
J24.02 31 41 49 49 51 47 
J24.03 47 33 43 47 47 50 
K25.01 38 30 41 43 42 43 
K25.02 34 27 40 44 43 43 
K25.03 44 30 37 40 40 41 
M26.01 37 31 37 43 41 34 
M26.02 36 31 39 48 43 34 
M26.03 42 33 45 47 46 44 
P27.01 42 38 53 54 55 54 
P27.02 45 47 54 53 54 57 
P27.03 50 39 49 52 52 52 
R28.01 34 24 39 44 42 44 
R28.02 38 27 38 39 40 39 
R28.03 42 26 35 39 41 41 
Z29.01 36 38 46 44 45 37 
Z29.02 35 36 44 45  36 
Z29.03 35 21 32 43 45 45 
A30.01 31 34 41 41 39 42 
A30.02 36 26 40 41 42 40 
A30.03 38 24 38 42 42 39 
B31.01 38 39 44 45 45 42 
B31.02 44 34 50 51 50 47 
B31.03 38 37 49 49 48 46 
C32.01 41 30 44 43 41 43 
C32.02 44 26 40 46 44 42 
C32.03 42 26 41 46 46 41 
D33.01 49 52 54 53 52 44 
D33.02 54 40 52 54 53 54 
D33.03 54 41 51 54 51 52 
H34.01 50 52 54 56 55 53 
H34.02 48 46 52 50 50 49 
H34.03 48 32 42 49 50 50 
J35.01 50 39 50 50 49 46 
J35.02 49 35 49 52 51 48 
189 
 
CD4+ (%) Baseline IP R15 R30 R45 R60 
J35.03 50 34 42 46 45 44 
K36.01 35 30 39 43 42 43 
K36.02 42 29 43 45 42 45 
K36.03 41 27 38 43 44 45 
M37.01 0 34 34  37 37 
M37.02 40 32 51 43 42 43 
M37.03 44  35 43 46 45 
O38.01 48 30 49 50 40 46 
O38.02 48 30 39 56 56 53 
O38.03 45 38 52 55 56 54 
 
 
CD8+ (%) Baseline IP R15 R30 R45 R60 
B01-1.1 34 40 38 37 37 37 
B01-1.2 39 44 40 38 35 37 
B01-1.3 36 41 39 38 38 38 
E02-1.1 29 32 28 25 23 27 
E02-1.2 27 31 29 28 28 28 
E02-1.3 27 31 29 29 27 26 
Z03-1.1 29 31 33 31 29 28 
Z03-1.2 29 31 32 30 26 30 
Z03-1.3  30 31 29 28 30 
G04-1.1 25 27 28 24 24 24 
G04-1.2 23 24 27 24 26 24 
G04-1.3 27 29 28 28 26 24 
P05-1.1 35 33 34 36 34 33 
P05-1.2 36 33 36 38 37 36 
P05-1.3 35 36 36 35 37 34 
P06-1.1 29 28 29 29 28 29 
P06-1.2 28 27 29 28 27 29 
P06-1.3 26 25 26 27 29 28 
G07-1.1 28 34 33 34 30 31 
G07-1.2 31 36 32 32 30 29 
G07-1.3 31 35 32 30 28 30 
R08-2.1 23 22 25 25 25 24 
R08-2.2 28 25 26 25 24 23 
R08-2.3 26 21 25 26 25 24 
R09-2.1 30 30 32 30 30 29 
R09-2.2 32 29 32 32 31 32 
R09-2.3 31 31 32 32 33 32 
W10-2.1 16 19 22 22 21 22 
W10-2.2 19 17 20 22 21 19 
W10-2.3 19 19 21 21 24 21 
S11-3.1 26 26 26 26 27 27 
S11-3.2 27 29 28 27 26  
S11-3.3 25 28 27 27 27 27 
T12-3.1 36 32 33 34 33 33 
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CD8+ (%) Baseline IP R15 R30 R45 R60 
T12-3.2 34 34 34 34 36 31 
T12-3.3 35 32 32 30 31 33 
C13-3.1 26 31 27 27 26  
C13-3.2 28 32 27 26  27 
C13-3.3 27 27 25 26 26 26 
W14-3.1 26 33 33 31 27  
W14-3.2 25 33 31 27 26 25 
W14-3.3 25 27 24 25 24 25 
X15-3.1 25 25 22 22 23 21 
X15-3.2 25 26 21 20 21 22 
X15-3.3 25 24 23 21 22 22 
Y16-3.1 26 27 27 26 25 25 
Y16-3.2 25 26 27 25 22 23 
Y16-3.3 25 24 25 24 24 25 
Z17-3.1 27 28 30 30 30 30 
Z17-3.2 30 29  26 27 25 
Z17-3.3 27 29 28 30 29 26 
A18.01 39 46 41 38 37 38 
A18.02 40 42 40 37 38 38 
A18.03 41 45 39 35 33 32 
B19.01 33 30 30 31 29 29 
B19.02 30 32 29 28 29 31 
B19.03 30 28 29 25 25 24 
D21.01 19 22 23 22 22 21 
D21.02 21 19 22 22 20 22 
D21.03 21 25 24 19 18 18 
E22.01 34 49 42 33 35 36 
E22.02 35 40 43 40 36 35 
E22.03 35 49 40 33 31 30 
J24.01 28 33 26 26 24 26 
J24.02 39 32 27 25 24 24 
J24.03 28 38 33 30 31 28 
K25.01 32 32 31 31 33 31 
K25.02 39 45 40 38 37 35 
K25.03 39 43 40 39 40 39 
M26.01 25 24 25 24 21 21 
M26.02 26 26 25 24 22 22 
M26.03 26 28 25 25 26 24 
P27.01 20 22 21 20 21 22 
P27.02 22 20 22 21 20 18 
P27.03 22 22 24 23 23 23 
R28.01 19 17 20 19 20 18 
R28.02 22 18 20 21 21 19 
R28.03 21 19 20 22 21 21 
Z29.01 21 19 20 21 20 20 
Z29.02 23 22 26 27  21 
Z29.03 20 17 19 24 22 23 
A30.01 34 34 31 32 33 30 
A30.02 34 34 34 32 31 32 
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CD8+ (%) Baseline IP R15 R30 R45 R60 
A30.03 34 35 32 32 30 30 
B31.01 33 30 29 29 28 29 
B31.02 30 27 28 27 27 28 
B31.03 32 30 28 28 29 28 
C32.01 21 21 20 21 19 19 
C32.02 21 17 20 19 19 19 
C32.03 22 19 21 20 20 19 
D33.01 21 21 22 23 22 24 
D33.02 20 24 21 20 22 22 
D33.03 20 24 21 21 22 23 
H34.01 20 22 19 20 17 19 
H34.02 19 21 17 18 19 17 
H34.03 18 21 21 19 18 19 
J35.01 18 17 19 20 19 18 
J35.02 19 16 19 19 18 18 
J35.03 20 16 18 17 18 18 
K36.01 28 38 34 27 25 26 
K36.02 25 39 33 30 27 25 
K36.03 29 36 36 28 30 31 
M37.01 0 22 22  26 26 
M37.02 26 21 28 25 26 25 
M37.03 25  22 23 23 23 
O38.01 23 23 25 23 24 22 
O38.02 25 23 24 22 22 21 
O38.03 22 28 26 24 21 20 
 
 
CD19+ (%) Baseline IP R15 R30 R45 R60 
B01-1.1 13 9 12 10 14 10 
B01-1.2 13 6 10 11 12 10 
B01-1.3 12 6 11 10 11 10 
E02-1.1 9 6 10 10 12 10 
E02-1.2 12 8 12 12 10 11 
E02-1.3 11 10 11 11 12 12 
Z03-1.1 11 6 8 12 13 12 
Z03-1.2 10 7 11 12 10 12 
Z03-1.3  9 12 12 13 13 
G04-1.1 17 12 14 15 14 17 
G04-1.2 17 15 15 18 16 17 
G04-1.3 15 11 13 16 16 16 
P05-1.1 12 8 9 10 10 11 
P05-1.2 10 6 9 11 10 10 
P05-1.3 10 9 11 10 12 13 
P06-1.1 15 11 14 15 15 16 
P06-1.2 15 10 14 16 16 17 
P06-1.3 15 11 14 15 15 15 
G07-1.1 19 16 16 17 18 17 
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CD19+ (%) Baseline IP R15 R30 R45 R60 
G07-1.2 18 15 17 18 21 19 
G07-1.3 21 15 17 19 19 18 
R08-2.1 14 11 13 15 16 17 
R08-2.2 17 10 13 14 15 15 
R08-2.3 15 12 13 17 15 16 
R09-2.1 20 13 15 17 18 17 
R09-2.2 20 15 20 19 20 20 
R09-2.3 19 12 13 16 16 17 
W10-2.1 10 13 15 17 18 20 
W10-2.2 17 13 17 18 18 18 
W10-2.3 16 11 13 16 15 17 
S11-3.1 16 13 15 15 15 16 
S11-3.2 15 14 16 17 19  
S11-3.3 15 13 16 17 16 17 
T12-3.1 10 6 9 10 12 10 
T12-3.2 10 9 10 10 9 10 
T12-3.3 9 11 10 11 10 11 
C13-3.1 9 8 11 11 10  
C13-3.2 9 9 11 10  8 
C13-3.3 8 8 10 10 9 11 
W14-3.1 28 15 23 24 25  
W14-3.2 27 18 21 24 24 23 
W14-3.3 26 20 24 24 27 26 
X15-3.1 13 12 16 15 15 16 
X15-3.2 13 13 18 18 19 15 
X15-3.3 15 14 16 16 17 19 
Y16-3.1 18 11 15 18 16 16 
Y16-3.2 16 10 16 16 15 14 
Y16-3.3 18 15 16 17 17 16 
Z17-3.1 13 7 12 13 13 15 
Z17-3.2 12 8  15 15 16 
Z17-3.3 13 14 18 18 16 16 
A18.01 15 9 10 13 14 13 
A18.02 13 10 14 15 14 14 
A18.03 8 7 11 13 12 12 
B19.01 13 10 10 10 13 11 
B19.02 11 8 13 12 13 13 
B19.03 10 7 10 12 11 10 
D21.01 29 20 27 26 27 26 
D21.02 28 20 25 25 25 24 
D21.03 27 12 17 24 25 26 
E22.01 15 10 15 16 15 15 
E22.02 13 12 12 13 12 14 
E22.03 14 7 13 14 15 16 
J24.01 17 13 16 16 17 16 
J24.02 9 11 13 14 15 16 
J24.03 14 9 11 10 11 13 
K25.01 13 8 12 12 11 12 
K25.02 10 8 10 11 11 13 
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CD19+ (%) Baseline IP R15 R30 R45 R60 
K25.03 11 8 9 10 10 10 
M26.01 14 9 11 14 15 15 
M26.02 14 9 14 20 19 15 
M26.03 14 9 13 15 16 15 
P27.01 10 9 13 13 13 12 
P27.02 12 14 17 18 16 16 
P27.03 11 9 12 10 11 12 
R28.01 22 14 23 23 25 24 
R28.02 23 13 22 24 25 24 
R28.03 24 12 19 22 23 26 
Z29.01 16 13 16 17 18 17 
Z29.02 13 10 16 20  16 
Z29.03 15 7 11 17 17 18 
A30.01 15 16 19 22 21 19 
A30.02 19 12 17 20 21 22 
A30.03 17 12 18 19 20 20 
B31.01 16 14 16 16 18 18 
B31.02 16 12 18 17 17 18 
B31.03 15 15 16 16 17 18 
C32.01 22 15 25 22 23 23 
C32.02 25 15 21 24 26 26 
C32.03 27 15 22 25 27 26 
D33.01 17 16 16 17 16 13 
D33.02 18 12 15 18 17 17 
D33.03 20 14 17 20 20 21 
H34.01 20 17 18 20 20 19 
H34.02 26 21 22 24 26 25 
H34.03 27 15 19 22 24 24 
J35.01 19 14 19 20 21 18 
J35.02 21 14 18 19 19 19 
J35.03 19 13 17 19 18 17 
K36.01 17 12 17 18 20 18 
K36.02 20 11 18 17 17 19 
K36.03 20 10 16 18 16 16 
M37.01 0 14 14  16 16 
M37.02 16 13 11 18 20 19 
M37.03 14  13 18 18 18 
O38.01 15 9 12 12 12 13 
O38.02 13 7 16 13 14 15 








NK Cells (%) Baseline IP R15 R30 R45 R60 
B01-1.1 7 7 5 4 3 6 
B01-1.2 7 17 7 5 6 7 
B01-1.3 4 12 8 7 5 5 
E02-1.1 17 18 10 10 7 11 
E02-1.2 10 23 9 7 9 8 
E02-1.3 8 17 12 9 6 7 
Z03-1.1 24 34 24 11 10 11 
Z03-1.2 28 38 23 21 21 22 
Z03-1.3  34 22 19 17 15 
G04-1.1 8 15 9 6 6 7 
G04-1.2 7 17 12 7 9 8 
G04-1.3 8 20 11 6 5 6 
P05-1.1 14 26 18 14 17 17 
P05-1.2 18 37 25 18 15 13 
P05-1.3 20 23 19 17 13 13 
P06-1.1 8 17 9 7 6 6 
P06-1.2 8 20 8 7 6 5 
P06-1.3 6 29 16 9 7 7 
G07-1.1 2 4 6 3 3 4 
G07-1.2 4 6 4 2 2 3 
G07-1.3 4 7 4 2 2 3 
R08-2.1 21 40 25 17 10 11 
R08-2.2 10 38 24 18 13 17 
R08-2.3 18 41 23 15 10 13 
R09-2.1 7 28 11 9 6 7 
R09-2.2 5 19 8 7 7 9 
R09-2.3 10 27 18 8 6 5 
W10-2.1 40 35 17 15 13 10 
W10-2.2 22 36 18 12 11 18 
W10-2.3 19 35 22 12 9 9 
S11-3.1 6 14 7 5 5 5 
S11-3.2 3 8 4 4 5  
S11-3.3 7 8 7 6 7 7 
T12-3.1 11 31 9 4 4 6 
T12-3.2 4 12 8 6 6 8 
T12-3.3 10 9 7 8 10 13 
C13-3.1 10 19 5 5 11  
C13-3.2 10 14 10 8  11 
C13-3.3 13 10 7 6 8 11 
W14-3.1 4 13 7 4 6  
W14-3.2 3 16 5 4 5 6 
W14-3.3 2 7 4 3 3 4 
X15-3.1 15 25 11 14 12 10 
X15-3.2 15 22 10 8 8 11 
X15-3.3 11 18 13 9 10 13 
Y16-3.1 8 29 11 8 10 14 
Y16-3.2 12 32 15 13 15 18 
Y16-3.3 7 13 11 9 13 13 
Z17-3.1 16 36 19 13 15 12 
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NK Cells (%) Baseline IP R15 R30 R45 R60 
Z17-3.2 17 34  13 11 13 
Z17-3.3 19 14 12 10 11 12 
A18.01 4 12 9 5 4 4 
A18.02 7 10 4 4 5 5 
A18.03 9 15 8 5 7 5 
B19.01 14 29 27 13 8 10 
B19.02 12 26 10 7 8 6 
B19.03 11 37 15 8 11 19 
D21.01 8 30 12 8 9 10 
D21.02 9 21 10 9 9 9 
D21.03 9 32 23 9 9 11 
E22.01 2 11 4 2 2 3 
E22.02 5 6 6 4 2 3 
E22.03 4 14 5 4 3 4 
J24.01 5 10 5 6 6 7 
J24.02 19 15 9 9 9 11 
J24.03 7 16 11 8 8 7 
K25.01 9 20 9 6 8 8 
K25.02 13 16 6 6 6 6 
K25.03 5 16 8 8 7 7 
M26.01 22 36 27 19 21 29 
M26.02 23 32 19 8 14 27 
M26.03 17 33 15 13 13 15 
P27.01 26 28 12 12 10 10 
P27.02 20 16 6 7 8 9 
P27.03 15 31 12 12 13 11 
R28.01 20 42 15 10 10 11 
R28.02 13 38 18 12 13 16 
R28.03 9 40 21 11 12 11 
Z29.01 22 26 14 14 13 23 
Z29.02 25 29 8 6  23 
Z29.03 24 52 32 15 13 12 
A30.01 16 13 6 6 8 6 
A30.02 9 25 7 5 4 4 
A30.03 12 29 8 5 6 10 
B31.01 11 11 7 5 6 8 
B31.02 7 25 5 4 5 6 
B31.03 13 17 6 5 5 6 
C32.01 15 30 10 11 13 14 
C32.02 10 37 16 10 8 11 
C32.03 9 38 13 6 6 11 
D33.01 11 6 8 6 7 15 
D33.02 4 22 8 4 4 5 
D33.03 4 18 8 4 6 4 
H34.01 5 8 5 4 4 5 
H34.02 5 12 6 5 5 6 
H34.03 5 26 12 7 6 5 
J35.01 11 27 8 7 8 15 
J35.02 8 34 10 9 10 11 
196 
 
NK Cells (%) Baseline IP R15 R30 R45 R60 
J35.03 8 33 20 14 16 18 
K36.01 13 19 7 8 7 7 
K36.02 6 20 5 7 8 6 
K36.03 6 22 7 7 7 6 
M37.01 0 25 25  21 17 
M37.02 13 29 9 12 9 12 
M37.03 13  24 15 11 10 
O38.01 8 33 10 10 20 14 
O38.02 8 35 17 5 6 6 
O38.03 17 22 8 5 6 8 
 
 
Neutrophils (cells/ul) Baseline IP R15 R30 R45 R60 
B01-1.1  2773 2985 3006 3386 4581 5263 
B01-1.2  3608 4535 3763 6118 7190 7746 
B01-1.3  2793 3040 2436 2399 2579 3013 
E02-1.1  5616 4457 5176 8486 9622 11063 
E02-1.2 3954 6875 4209 4114 4643 5488 
E02-1.3 3074 3294 3005 3293 3207 3711 
Z03-1.1 1597 2077 1521 1360 1813 2808 
Z03-1.2 3164 2941 2309 2744 2698 2567 
Z03-1.3  1130 1323 1525 1338 1449 
G04-1.1 3158 3622 3289 3279 3390 3769 
G04-1.2 4221 5236 5713 5483 5263 5548 
G04-1.3 4416 4787 3690 4616 4475 4371 
P05-1.1 6670 6399 6019 6333 7282 8448 
P05-1.2 3080 4087 2860 2906 3917 5150 
P05-1.3 2230 3738 4284 4355 4821 5232 
P06-1.1 2790 3649 3082 3120 3243 3599 
P06-1.2 3686 4522 3619 3542 3908 3859 
P06-1.3 3557 4202 2877 3091 3893 4854 
G07-1.1 3541 3243 3033 2866 3306 3367 
G07-1.2 2570 4025 3553 3509 3426 3648 
G07-1.3 3213 3760 2921 2715 3040 3018 
R08-2.1 4118 7188 6319 7930 8799 10210 
R08-2.2 3283 4560 4215 4270 5767 8090 
R08-2.3 2574 4253 3149 3637 4173 5495 
R09-2.1 2012 5309 4644 5475 5860 5918 
R09-2.2 3130  2077 2236 2253 2383 
R09-2.3 2155 3067 2514 2296 2526 2981 
W10-2.1 3311 3298 3365 4951 5663 6014 
W10-2.2 2938 3010 2090 2084 2586 3314 
W10-2.3 2754 3799 3062 3073 3281 3724 
S11-3.1 5554 8248 6489 6734 6109 6461 
S11-3.2 3634 5170 6072 6044 6355 -1 
S11-3.3 5483 6689 6092 6175 6358 6737 
T12-3.1 2197 4248 2875 2564 2979 2864 
T12-3.2 2356 2693 2842 3116 3514 3475 
197 
 
Neutrophils (cells/ul) Baseline IP R15 R30 R45 R60 
T12-3.3 2346 2140 2687 3244 3575 3881 
C13-3.1 3738 5074 3578  5415  
C13-3.2 3203 3722 4668 5544 5649  
C13-3.3 3813 3714 3845 4532 6197 6457 
W14-3.1 3369 4000 4082 2792   
W14-3.2 4046 6578 5121 5217 5641 6192 
W14-3.3 2708 4079 3805 3898 4233 4998 
X15-3.1 2894 4692 4929   8636 
X15-3.2 2836 4459 4460 6806 7125 7553 
X15-3.3 4111 4991 5159 6154 6961 7638 
Y16-3.1 3251 5910 4830 5850 5852 7334 
Y16-3.2 3317 4180 6006 6906 6769 7546 
Y16-3.3 3162 3233 3599 4774 6459 7324 
Z17-3.1 4960 8614 6880 7685 7837 8504 
Z17-3.2 4259 7459  7632 8481 9185 
Z17-3.3 7337 9943 10723 12175 11210 11588 
A18.01 3478 3872 3125 2934 2921 3115 
A18.02 2673 2582 2298 2239 2465 3227 
A18.03 5152 9275 7960 7496 7834 7987 
B19.01  8525 8845 8526 8270 9036 
B19.02 3725 4811 3344 3530 4346 4755 
B19.03 2519 5889 5944 8255 9031 10305 
D21.01 8079 9765 7770 7516 7553 7461 
D21.02 3892 3640 3185 3668 4015 4374 
D21.03 3404 6743 5530 5285 6448 6964 
E22.01 6179 9072 6768 7644 9606 9759 
E22.02 4154 4920 4481 4920 5506 6466 
E22.03 6374 9781 7480 8650 9736 11905 
J24.01 3386 3845 4466 5670 6053 7673 
J24.02 3294 3942 4182 5438 6656 8423 
J24.03 3431 4377 3570 5062 4215 5799 
K25.01 3629 7182 5862 5980 6322 6494 
K25.02 3352 4283 4404 4984 5395 5520 
K25.03 2736 3650 3431 4099 3631 4410 
M26.01 1866 3373 3878 4408 5814  
M26.02 1994 2098 2677 3307 5258 7259 
M26.03 1473 1853 1455 1870 1660 2954 
P27.01 5538 7392 6312 7391 8603 9129 
P27.02 5151 7403 7811 9039 10741 11106 
P27.03 4856 6100 4946 5198 4988 5206 
R28.01 2324 3462 3027 3719 4752 5445 
R28.02 1804 2677 2993 3631 5247 6245 
R28.03 1946 2825 2039 2246 1884 2472 
Z29.01 4785 7242 7690 10071 11880 14112 
Z29.02 4289 5292 4808 6840   
Z29.03 8619 12691 8940 8056 8567 8332 
A30.01 2989 8514 7997 -1 7805 6930 
A30.02 2552 5060 4877 5828 6286 6760 
A30.03 2661 4150 3990 5623 6296 6336 
198 
 
Neutrophils (cells/ul) Baseline IP R15 R30 R45 R60 
B31.01 3094 4614 5169 6312 7236 9145 
B31.02 3367 5686 4240 5685 6995 7997 
B31.03 3244 4688 4576 6396 8312 8953 
C32.01 2424 3306 3966 3259 4272 4619 
C32.02 2416 3816 2498 2554 2795 3092 
C32.03 2407 4067 2705 2976 3264 3239 
D33.01 4951 6384 5058 5860 7004 5838 
D33.02 3358 4739 3381 3856 4792 5173 
D33.03 4092 4964 3689 3882 4349 4498 
H34.01 1474 2635 2861 3650 4342 4826 
H34.02 1474 3004 3102 3864 4302 4602 
H34.03 2331 5376 3898 3784 4621 4752 
J35.01 3776 4836 4627 5867 6820 7323 
J35.02 2846 4400 4723 5573 5843 6421 
J35.03 2797 3976 3409 4410 5644 5783 
K36.01 1909 6625 6855 8030 8692 9570 
K36.02 3265 5535 4165 4719 4794 4963 
K36.03 3364 4831 3788 5498 6785 7450 
M37.01 4018 8812 9770  11219 11659 
M37.02 3422 5145 5705 6703 7645 8270 
M37.03 4342  6084 7387 8704 10448 
O38.01 2115 5641 5062 5809 6560 6178 
O38.02 2410 3495 2710 3485 4021 4392 
O38.03 1922 2470 2220 3006 3555 3823 
 
 
Monocytes (cells/ul) Baseline IP R15 R30 R45 R60 
B01-1.1 176 188 171 206 159 211 
B01-1.2 255 230 202 160 229 230 
B01-1.3 201 220 232 179 202 193 
E02-1.1 912 655 547 707 787 832 
E02-1.2 683 1425 721 683 625 744 
E02-1.3 661 624 530 543 504 661 
Z03-1.1 528 595 451 352 343 428 
Z03-1.2 638 1132 698 730 677 704 
Z03-1.3  605 445 380 390 360 
G04-1.1 462 442 427 393 400 470 
G04-1.2 479 585 578 540 621 608 
G04-1.3 533 581 450 496 561 440 
P05-1.1 563 675 713 731 688 816 
P05-1.2 507 686 498 470 506 503 
P05-1.3 436 488 490 536 561 533 
P06-1.1 696 705 548 585 603 737 
P06-1.2 745 896 718 684 735 698 
P06-1.3 888 1071 516 484 567 718 
G07-1.1 460 440 435 341 439 458 
G07-1.2 403 569 539 583 504 554 
G07-1.3 391 526 402 365 335 370 
199 
 
Monocytes (cells/ul) Baseline IP R15 R30 R45 R60 
R08-2.1 607 1041 579 545 473 536 
R08-2.2 531 760 443 462 466 566 
R08-2.3 478 845 493 445 428 517 
R09-2.1 460 864 628 504 479 480 
R09-2.2 459  417 344 383 437 
R09-2.3 510 612 545 400 378 317 
W10-2.1 308 465 250 302 368 421 
W10-2.2 259 376 245 235 234 268 
W10-2.3 294 391 288 248 268 396 
S11-3.1 641 791 684 598 564 632 
S11-3.2 711 1034 880 740 828  
S11-3.3 727 764 739 664 587 650 
T12-3.1 374 754 322 276 275 297 
T12-3.2 396 387 330 338 332 355 
T12-3.3 449 400 392 418 508 465 
C13-3.1 342 529 307  375  
C13-3.2 347 314 340 310 175  
C13-3.3 582 450 297 329 470 432 
W14-3.1 413 288 391 200   
W14-3.2 490 809 439 474 577 506 
W14-3.3 337 449 360 400 415 422 
X15-3.1 345 488 298   374 
X15-3.2 403 540 342 410 487 519 
X15-3.3 502 546 469 553 616 703 
Y16-3.1 470 614 359 374 354 409 
Y16-3.2 446 563 496 338 348 490 
Y16-3.3 333 464 433 432 422 388 
Z17-3.1 837 1406 730 742 709 673 
Z17-3.2 782 895  649 649 702 
Z17-3.3 968 1072 952 1003 959 1080 
A18.01 475 668 422 420 435 454 
A18.02 502 409 367 368 426 413 
A18.03 488 707 396 446 422 374 
B19.01  638 520 504 440 480 
B19.02 322 539 333 297 285 288 
B19.03 383 871 240 359 498 583 
D21.01 642 826 592 561 464 504 
D21.02 400 348 300 286 286 354 
D21.03 360 451 348 338 360 361 
E22.01 664 1176 620 510 480 566 
E22.02 442 412 396 393 385 448 
E22.03 826 1271 660 519 513 644 
J24.01 354 154 145 196 180 272 
J24.02 403 288 191 330 370 364 
J24.03 314 506 289 312 329 296 
K25.01 552 609 442 371 385 425 
K25.02 491 428 347 326 358 326 
K25.03 382 475 371 342 319 326 
M26.01 533 483 461 391 433  
200 
 
Monocytes (cells/ul) Baseline IP R15 R30 R45 R60 
M26.02 434 278 281 302 400 534 
M26.03 419 433 334 340 348 424 
P27.01 464 550 361 407 377 464 
P27.02 619 482 460 593 466 612 
P27.03 520 879 360 485 466 479 
R28.01 416 550 312 333 354 376 
R28.02 444 391 378 309 429 501 
R28.03 343 429 322 239 257 332 
Z29.01 1009 857 850 1181 1166 1327 
Z29.02 910 963 818 1058   
Z29.03 1241 2313 1392 1283 1079 1145 
A30.01 535 770 666  605 512 
A30.02 489 968 528 578 640 602 
A30.03 480 916 456 497 521 624 
B31.01 372 336 305 256 405 338 
B31.02 403 618 296 353 445 421 
B31.03 455 464 333 353 444 508 
C32.01 461 586 391 394 486 446 
C32.02 451 848 491 353 378 470 
C32.03 383 780 400 386 379 441 
D33.01 562 580 497 493 561 689 
D33.02 394 722 360 347 436 462 
D33.03 428 781 412 395 533 501 
H34.01 460 403 340 302 342 365 
H34.02 398 551 338 454 420 494 
H34.03 491 1445 671 490 544 507 
J35.01 291 385 297 262 308 338 
J35.02 301 514 262 259 255 303 
J35.03 302 348 348 314 370 362 
K36.01 1210 631 458 500 530 510 
K36.02 376 648 401 396 469 490 
K36.03 464 810 478 518 581 682 
M37.01 609 627 571  702 493 
M37.02 415 413 370 403 437 470 
M37.03 516  421 498 464 440 
O38.01 396 590 363 407 428 379 
O38.02 398 578 334 285 403 390 










Eosinophils (cells/ul) Baseline IP R15 R30 R45 R60 
B01-1.1 78 42 59 29 55 27 
B01-1.2 41 74 45 30 44 18 
B01-1.3 25 20 32 31 46 51 
E02-1.1 129 101 92 73 46 52 
E02-1.2 235 300 163 188 170 144 
E02-1.3 218 168 148 185 170 118 
Z03-1.1 101 56 37 32 25 23 
Z03-1.2 51 84 54 54 42 37 
Z03-1.3  40 25 23 24 21 
G04-1.1 68 77 76 66 57 67 
G04-1.2 120 69 85 67 73 76 
G04-1.3 163 273 156 154 125 118 
P05-1.1 88 117 107 119 84 95 
P05-1.2 189 255 164 151 166 111 
P05-1.3 78 59 77 47 57 44 
P06-1.1 829 828 706 702 650 672 
P06-1.2 729 711 616 554 540 482 
P06-1.3 483 571 319 286 277 274 
G07-1.1 221 205 174 160 189 183 
G07-1.2 199 230 217 211 192 195 
G07-1.3 233 234 176 165 173 207 
R08-2.1 145 318 178 168 126 71 
R08-2.2 845 1230 1020 823 719 515 
R08-2.3 452 509 290 245 192 182 
R09-2.1 142 163 138 117 84 53 
R09-2.2 101  77 69 79 83 
R09-2.3 125 68 66 39 44 48 
W10-2.1 484 601 450 489 465 460 
W10-2.2 446 472 326 313 285 273 
W10-2.3 490 309 394 322 212 352 
S11-3.1 187 142 90 110 91 80 
S11-3.2 158 188 62 60 62  
S11-3.3 87 91 91 75 51 62 
T12-3.1 105 123 74 48 45 52 
T12-3.2 86 70 75 42 61 50 
T12-3.3 133 76 95 71 54 62 
C13-3.1 132 126 74  68  
C13-3.2 112 57 82 72 49  
C13-3.3 92 96 66 67 65 50 
W14-3.1 77 58 44 28   
W14-3.2 75 103 69 59 55 50 
W14-3.3 66 46 70 64 55 54 
X15-3.1 106 74 50   40 
X15-3.2 85 71 30 16 26 18 
X15-3.3 124 84 67 95 70 48 
Y16-3.1 67 89 69 94 31 48 
Y16-3.2 62 53 67 53 35 58 
Y16-3.3 96 61 43 65 62 58 
Z17-3.1 573 740 500 456 480 353 
202 
 
Eosinophils (cells/ul) Baseline IP R15 R30 R45 R60 
Z17-3.2 706 630  371 352 351 
Z17-3.3 352 295 207 243 212 222 
A18.01 79 134 93 67 77 65 
A18.02 99 78 75 64 78 59 
A18.03 112 74 59 37 29 29 
B19.01  213 182 126 130 76 
B19.02 261 183 135 106 99 96 
B19.03 270 377 184 165 117 60 
D21.01 150 90 97 64 64 54 
D21.02 145 65 60 85 77 66 
D21.03 128 154 87 69 32 67 
E22.01 118 182 132 118 152 130 
E22.02 117 99 73 76 74 66 
E22.03 154 233 110 170 68 110 
J24.01 95 22 23 28 23 10 
J24.02 98 45 17 8 17 0 
J24.03 137 150 106 85 79 99 
K25.01 104 74 47 79 41 77 
K25.02 50 53 13 20 37 89 
K25.03 86 122 91 55 70 70 
M26.01 852 585 480 378 350  
M26.02 490 307 299 202 193 156 
M26.03 806 695 562 537 596 545 
P27.01 301 286 189 194 178 128 
P27.02 519 538 396 472 356 292 
P27.03 448 394 302 270 296 281 
R28.01 21 32 22 20 12 13 
R28.02 22 18 13 5 7 15 
R28.03 23 23 22 23 13 8 
Z29.01 365 306 200 165 115 134 
Z29.02 271 252 210 167   
Z29.03 116 130 84 64 76 53 
A30.01 117 44 59  38 34 
A30.02 103 88 53 45 41 34 
A30.03 108 134 86 58 63 64 
B31.01 124 110 121 64 63 44 
B31.02 78 124 69 38 36 49 
B31.03 124 96 58 41 51 32 
C32.01 178 134 88 82 78 68 
C32.02 71 96 50 37 30 44 
C32.03 87 125 69 60 58 39 
D33.01 193 143 145 162 116 193 
D33.02 122 125 80 83 86 77 
D33.03 104 118 87 71 98 91 
H34.01 156 86 129 94 89 45 
H34.02 168 157 94 90 72 72 
H34.03 185 307 183 165 141 117 
J35.01 186 208 191 162 167 160 
J35.02 112 126 83 94 75 82 
203 
 
Eosinophils (cells/ul) Baseline IP R15 R30 R45 R60 
J35.03 130 163 137 122 85 100 
K36.01 189 107 70 80 42 70 
K36.02 95 99 59 66 68 70 
K36.03 87 62 71 53 70 67 
M37.01 315 239 190  122 151 
M37.02 262 233 185 160 177 140 
M37.03 208  117 116 113 83 
O38.01 383 352 158 126 134 103 
O38.02 446 449 268 235 218 238 
O38.03 578 437 255 252 189 209 
 
 
Basophils (cells/ul) Baseline IP R15 R30 R45 R60 
B01-1.1 15 5 14 20 6 20 
B01-1.2 23 16 17 8 18 37 
B01-1.3 20 20 12 12 21 28 
E02-1.1 43 50 50 42 0 0 
E02-1.2 55 50 48 47 57 72 
E02-1.3 35 42 32 50 32 47 
Z03-1.1 26 25 25 22 21 23 
Z03-1.2 23 30 32 34 19 32 
Z03-1.3  30 25 20 21 21 
G04-1.1 34 26 11 26 26 22 
G04-1.2 19 39 23 15 22 23 
G04-1.3 28 44 30 27 40 25 
P05-1.1 18 27 16 34 28 0 
P05-1.2 24 20 0 17 6 30 
P05-1.3 10 13 14 34 21 22 
P06-1.1 37 16 46 39 34 51 
P06-1.2 32 52 55 43 30 29 
P06-1.3 43 82 35 33 32 37 
G07-1.1 25 31 17 28 24 24 
G07-1.2 26 22 12 6 24 13 
G07-1.3 25 22 28 10 22 22 
R08-2.1 33 64 53 69 53 12 
R08-2.2 45 50 30 27 0 20 
R08-2.3 36 38 46 23 43 38 
R09-2.1 26 29 35 29 46 38 
R09-2.2 0  30 22 31 18 
R09-2.3 30 34 44 34 13 29 
W10-2.1 28 50 25 40 30 39 
W10-2.2 5 27 14 10 16 9 
W10-2.3 25 19 24 28 33 28 
S11-3.1 62 24 36 28 33 62 
S11-3.2 0 0 26 43 53  
S11-3.3 32 36 42 33 26 18 
T12-3.1 17 66 41 28 14 17 
T12-3.2 22 44 22 33 36 30 
204 
 
Basophils (cells/ul) Baseline IP R15 R30 R45 R60 
T12-3.3 26 36 41 26 16 39 
C13-3.1 18 34 27  30  
C13-3.2 11 23 13 29 28  
C13-3.3 36 30 39 18 32 17 
W14-3.1 24 38 32 20   
W14-3.2 41 80 31 15 47 58 
W14-3.3 31 53 29 29 31 27 
X15-3.1 27 22 12   20 
X15-3.2 11 36 18 8 17 18 
X15-3.3 19 21 13 24 44 29 
Y16-3.1 24 20 28 16 23 38 
Y16-3.2 31 26 34 36 26 29 
Y16-3.3 26 18 18 36 26 29 
Z17-3.1 55 104 50 42 109 46 
Z17-3.2 60 76  72 55 12 
Z17-3.3 66 67 83 30 85 89 
A18.01 29 36 25 22 28 24 
A18.02 20 22 24 20 16 18 
A18.03 24 62 20 28 29 10 
B19.01  25 36 21 20 11 
B19.02 20 104 26 27 12 19 
B19.03 20 26 24 0 11 36 
D21.01 21 26 49 18 9 0 
D21.02 14 24 35 16 11 12 
D21.03 31 33 16 35 16 8 
E22.01 18 42 19 10 0 12 
E22.02 21 21 13 14 15 8 
E22.03 38 47 20 0 11 0 
J24.01 41 6 12 14 30 19 
J24.02 24 38 46 53 52 20 
J24.03 23 32 41 71 18 46 
K25.01 14 21 24 16 16 9 
K25.02 32 15 19 27 15 15 
K25.03 29 29 23 6 17 32 
M26.01 39 34 32 25 15  
M26.02 36 29 32 24 21 28 
M26.03 21 51 23 33 44 39 
P27.01 17 22 17 10 22 23 
P27.02 46 34 32 48 14 14 
P27.03 24 30 14 15 30 23 
R28.01 16 19 18 5 6 0 
R28.02 18 23 13 20 0 0 
R28.03 12 17 19 15 13 20 
Z29.01 26 10 20 25 0 0 
Z29.02 16 18 8 29   
Z29.03 35 56 36 42 33 0 
A30.01 27 44 0  29 25 
A30.02 19 18 20 30 16 26 
A30.03 29 42 29 29 32 24 
205 
 
Basophils (cells/ul) Baseline IP R15 R30 R45 R60 
B31.01 25 29 14 24 27 22 
B31.02 20 41 19 23 27 39 
B31.03 26 32 32 33 20 43 
C32.01 29 31 33 10 30 12 
C32.02 28 32 18 12 22 29 
C32.03 31 25 32 28 38 34 
D33.01 39 59 28 31 45 42 
D33.02 41 42 27 33 13 35 
D33.03 35 42 46 35 33 26 
H34.01 20 34 18 26 24 13 
H34.02 12 17 14 22 18 20 
H34.03 25 30 31 17 38 39 
J35.01 19 23 33 23 18 19 
J35.02 15 24 13 22 15 16 
J35.03 16 21 17 13 15 31 
K36.01 0 68 26 40 21 35 
K36.02 21 36 12 20 41 21 
K36.03 29 35 18 30 44 58 
M37.01 42 80 12  41 14 
M37.02 24 38 37 34 28 10 
M37.03 54  39 9 10 12 
O38.01 45 53 40 44 42 47 
O38.02 43 41 26 60 45 37 
O38.03 33 52 37 32 56 39 
 
 
Neutrophils (%) Baseline IP R15 R30 R45 R60 
B01-1.1 56.6 63.5 66.8 69.1 75.1 77.4 
B01-1.2 62.2 55.3 67.2 80.5 81.7 84.2 
B01-1.3 57 60.8 60.9 61.5 61.4 65.5 
E02-1.1 65.3 61.9 72.9 81.6 84.4 85.1 
E02-1.2 57.3 55 61.9 61.4 65.4 68.6 
E02-1.3 52.1 54.9 56.7 58.8 60.5 62.9 
Z03-1.1 36.3 33.5 37.1 42.5 51.8 62.4 
Z03-1.2 55.5 38.7 51.3 56 57.4 55.8 
Z03-1.3  22.6 37.8 46.2 44.6 48.3 
G04-1.1 55.4 56.6 60.9 64.3 65.2 67.3 
G04-1.2 67 68 74.2 74.1 72.1 73 
G04-1.3 62.2 54.4 61.5 68.9 67.8 70.5 
P05-1.1 75.8 71.1 73.4 74.5 78.3 79.7 
P05-1.2 52.2 41.7 45.4 51.9 61.2 69.6 
P05-1.3 45.5 57.5 61.2 65 67.9 70.7 
P06-1.1 37.7 44.5 46.7 48 48.4 49.3 
P06-1.2 45.5 43.9 46.4 49.2 52.1 53.6 
P06-1.3 50.1 41.2 49.6 56.2 61.8 65.6 
G07-1.1 56.2 52.3 52.3 52.1 54.2 55.2 
G07-1.2 50.4 55.9 57.3 56.6 57.1 57.9 
G07-1.3 51 51.5 53.1 54.3 56.3 53.9 
206 
 
Neutrophils (%) Baseline IP R15 R30 R45 R60 
R08-2.1 62.4 56.6 71 80.1 83.8 85.8 
R08-2.2 51.3 45.6 56.2 62.8 73 80.1 
R08-2.3 49.5 44.3 54.3 63.8 67.3 72.3 
R09-2.1 46.8 55.3 67.3 75 77.1 78.9 
R09-2.2 55.9  48.3 52 51.2 51.8 
R09-2.3 43.1 45.1 45.7 53.4 57.4 62.1 
W10-2.1 60.2 53.2 67.3 73.9 75.5 77.1 
W10-2.2 61.2 56.8 59.7 61.3 66.3 70.5 
W10-2.3 56.2 60.3 63.8 66.8 69.8 67.7 
S11-3.1 62.4 69.9 72.1 73.2 73.6 72.6 
S11-3.2 46 55 69 71.1 71.4  
S11-3.3 69.4 73.5 73.4 74.4 74.8 75.7 
T12-3.1 52.3 51.8 62.5 64.1 66.2 66.6 
T12-3.2 54.8 61.2 64.6 66.3 68.9 69.5 
T12-3.3 46 53.5 59.7 63.6 66.2 69.3 
C13-3.1 62.3 60.4 67.5  72.2  
C13-3.2 57.2 65.3 74.1 77 80.7  
C13-3.3 53.7 61.9 69.9 74.3 76.5 77.8 
W14-3.1 57.1 62.5 64.8 69.8   
W14-3.2 59.5 57.7 66.5 70.5 71.4 74.6 
W14-3.3 53.1 61.8 65.6 67.2 69.4 73.5 
X15-3.1 54.6 63.4 79.5   85.5 
X15-3.2 53.5 62.8 75.6 83 81.9 83 
X15-3.3 66.3 71.3 77 77.9 79.1 80.4 
Y16-3.1 53.3 59.7 70 75 76 77.2 
Y16-3.2 53.5 47.5 71.5 77.6 77.8 78.6 
Y16-3.3 49.4 53 59 66.3 73.4 75.5 
Z17-3.1 54.5 58.2 68.8 72.5 71.9 74.6 
Z17-3.2 50.1 59.2  74.1 77.1 78.5 
Z17-3.3 66.7 74.2 77.7 80.1 79.5 78.3 
A18.01 48.3 43.5 50.4 52.4 53.1 52.8 
A18.02 40.5 46.1 48.9 45.7 47.4 54.7 
A18.03 64.4 74.8 80.4 80.6 81.6 83.2 
B19.01 . 68.2 73.1 81.2 82.7 82.9 
B19.02 55.6 55.3 64.3 66.6 70.1 74.3 
B19.03 49.4 45.3 74.3 85.1 85.2 86.6 
D21.01 75.5 75.7 80.1 81.7 83 82.9 
D21.02 56.4 61.7 63.7 69.2 73 72.9 
D21.03 55.8 61.3 70 76.6 80.6 82.9 
E22.01 67.9 64.8 72 78 82.1 82.7 
E22.02 60.2 69.3 67.9 71.3 74.4 77.9 
E22.03 66.4 63.1 74.8 81.6 85.4 86.9 
J24.01 49.8 69.9 77 81 80.7 79.1 
J24.02 54 61.6 72.1 72.5 77.4 83.4 
J24.03 60.2 55.4 60.5 71.3 69.1 76.3 
K25.01 52.6 68.4 74.2 75.7 77.1 76.4 
K25.02 53.2 57.1 69.9 73.3 73.9 74.6 
K25.03 48 50.7 60.2 67.2 62.6 68.9 
M26.01 28.7 49.6 60.6 71.1 76.5  
207 
 
Neutrophils (%) Baseline IP R15 R30 R45 R60 
M26.02 39.1 43.7 58.2 68.9 76.2 78.9 
M26.03 27.8 32.5 38.3 45.6 41.5 53.7 
P27.01 64.4 67.2 73.4 76.2 77.5 78.7 
P27.02 56.6 66.1 73 74.7 78.4 79.9 
P27.03 60.7 60.4 68.7 67.5 67.4 68.5 
R28.01 44.7 54.1 68.8 75.9 77.9 82.5 
R28.02 41 58.2 69.6 74.1 79.5 81.1 
R28.03 49.9 48.7 55.1 59.1 57.1 61.8 
Z29.01 55 71 76.9 79.3 82.5 84 
Z29.02 52.3 58.8 64.1 69.8   
Z29.03 74.3 68.6 74.5 76 78.6 78.6 
A30.01 56.4 77.4 81.6  81.3 82.5 
A30.02 54.3 57.5 73.9 77.7 77.6 78.6 
A30.03 54.3 49.4 70 78.1 79.7 79.2 
B31.01 49.9 63.2 72.8 78.9 80.4 83.9 
B31.02 51.8 55.2 67.3 75.8 78.6 81.6 
B31.03 49.9 58.6 71.5 78 82.3 82.9 
C32.01 50.5 54.2 72.1 67.9 71.2 74.5 
C32.02 51.4 47.7 55.5 62.3 65 63.1 
C32.03 47.2 49 58.8 64.7 68 66.1 
D33.01 64.3 76 73.3 76.1 78.7 69.5 
D33.02 57.9 57.1 63.8 70.1 72.6 73.9 
D33.03 59.3 59.1 63.6 65.8 66.9 69.2 
H34.01 37.8 54.9 62.2 70.2 73.6 75.4 
H34.02 37.8 51.8 66 69 71.7 70.8 
H34.03 55.5 54.3 63.9 68.8 72.2 73.1 
J35.01 60.9 62.8 70.1 76.2 77.5 77.9 
J35.02 55.8 55.7 73.8 77.4 77.9 78.3 
J35.03 51.8 56 59.8 68.9 73.3 75.1 
K36.01 30.3 68.3 77.9 80.3 82 82.5 
K36.02 61.6 61.5 70.6 71.5 70.5 70.9 
K36.03 58 54.9 64.2 73.3 77.1 77.6 
M37.01 57.4 77.3 82.1  83.1 85.1 
M37.02 56.1 68.6 77.1 79.8 82.2 82.7 
M37.03 64.8  78 83 84.5 87.8 
O38.01 47 64.1 76.7 78.5 78.1 78.2 
O38.02 50.2 51.4 61.6 69.7 71.8 72 










Monocytes (%) Baseline IP R15 R30 R45 R60 
B01-1.1 3.6 4 3.8 4.2 2.6 3.1 
B01-1.2 4.4 2.8 3.6 2.1 2.6 2.5 
B01-1.3 4.1 4.4 5.8 4.6 4.8 4.2 
E02-1.1 10.6 9.1 7.7 6.8 6.9 6.4 
E02-1.2 9.9 11.4 10.6 10.2 8.8 9.3 
E02-1.3 11.2 10.4 10 9.7 9.5 11.2 
Z03-1.1 12 9.6 11 11 9.8 9.5 
Z03-1.2 11.2 14.9 15.5 14.9 14.4 15.3 
Z03-1.3  12.1 12.7 11.5 13 12 
G04-1.1 8.1 6.9 7.9 7.7 7.7 8.4 
G04-1.2 7.6 7.6 7.5 7.3 8.5 8 
G04-1.3 7.5 6.6 7.5 7.4 8.5 7.1 
P05-1.1 6.4 7.5 8.7 8.6 7.4 7.7 
P05-1.2 8.6 7 7.9 8.4 7.9 6.8 
P05-1.3 8.9 7.5 7 8 7.9 7.2 
P06-1.1 9.4 8.6 8.3 9 9 10.1 
P06-1.2 9.2 8.7 9.2 9.5 9.8 9.7 
P06-1.3 12.5 10.5 8.9 8.8 9 9.7 
G07-1.1 7.3 7.1 7.5 6.2 7.2 7.5 
G07-1.2 7.9 7.9 8.7 9.4 8.4 8.8 
G07-1.3 6.2 7.2 7.3 7.3 6.2 6.6 
R08-2.1 9.2 8.2 6.5 5.5 4.5 4.5 
R08-2.2 8.3 7.6 5.9 6.8 5.9 5.6 
R08-2.3 9.2 8.8 8.5 7.8 6.9 6.8 
R09-2.1 10.7 9 9.1 6.9 6.3 6.4 
R09-2.2 8.2  9.7 8 8.7 9.5 
R09-2.3 10.2 9 9.9 9.3 8.6 6.6 
W10-2.1 5.6 7.5 5 4.5 4.9 5.4 
W10-2.2 5.4 7.1 7 6.9 6 5.7 
W10-2.3 6 6.2 6 5.4 5.7 7.2 
S11-3.1 7.2 6.7 7.6 6.5 6.8 7.1 
S11-3.2 9 11 10 8.7 9.3  
S11-3.3 9.2 8.4 8.9 8 6.9 7.3 
T12-3.1 8.9 9.2 7 6.9 6.1 6.9 
T12-3.2 9.2 8.8 7.5 7.2 6.5 7.1 
T12-3.3 8.8 10 8.7 8.2 9.4 8.3 
C13-3.1 5.7 6.3 5.8  5  
C13-3.2 6.2 5.5 5.4 4.3 2.5  
C13-3.3 8.2 7.5 5.4 5.4 5.8 5.2 
W14-3.1 7 4.5 6.2 5   
W14-3.2 7.2 7.1 5.7 6.4 7.3 6.1 
W14-3.3 6.6 6.8 6.2 6.9 6.8 6.2 
X15-3.1 6.5 6.6 4.8   3.7 
X15-3.2 7.6 7.6 5.8 5 5.6 5.7 
X15-3.3 8.1 7.8 7 7 7 7.4 
Y16-3.1 7.7 6.2 5.2 4.8 4.6 4.3 
Y16-3.2 7.2 6.4 5.9 3.8 4 5.1 
Y16-3.3 5.2 7.6 7.1 6 4.8 4 
Z17-3.1 9.2 9.5 7.3 7 6.5 5.9 
209 
 
Monocytes (%) Baseline IP R15 R30 R45 R60 
Z17-3.2 9.2 7.1  6.3 5.9 6 
Z17-3.3 8.8 8 6.9 6.6 6.8 7.3 
A18.01 6.6 7.5 6.8 7.5 7.9 7.7 
A18.02 7.6 7.3 7.8 7.5 8.2 7 
A18.03 6.1 5.7 4 4.8 4.4 3.9 
B19.01  5.1 4.3 4.8 4.4 4.4 
B19.02 4.8 6.2 6.4 5.6 4.6 4.5 
B19.03 7.5 6.7 3 3.7 4.7 4.9 
D21.01 6 6.4 6.1 6.1 5.1 5.6 
D21.02 5.8 5.9 6 5.4 5.2 5.9 
D21.03 5.9 4.1 4.4 4.9 4.5 4.3 
E22.01 7.3 8.4 6.6 5.2 4.1 4.8 
E22.02 6.4 5.8 6 5.7 5.2 5.4 
E22.03 8.6 8.2 6.6 4.9 4.5 4.7 
J24.01 5.2 2.8 2.5 2.8 2.4 2.8 
J24.02 6.6 4.5 3.3 4.4 4.3 3.6 
J24.03 5.5 6.4 4.9 4.4 5.4 3.9 
K25.01 8 5.8 5.6 4.7 4.7 5 
K25.02 7.8 5.7 5.5 4.8 4.9 4.4 
K25.03 6.7 6.6 6.5 5.6 5.5 5.1 
M26.01 8.2 7.1 7.2 6.3 5.7  
M26.02 8.5 5.8 6.1 6.3 5.8 5.8 
M26.03 7.9 7.6 8.8 8.3 8.7 7.7 
P27.01 5.4 5 4.2 4.2 3.4 4 
P27.02 6.8 4.3 4.3 4.9 3.4 4.4 
P27.03 6.5 8.7 5 6.3 6.3 6.3 
R28.01 8 8.6 7.1 6.8 5.8 5.7 
R28.02 10.1 8.5 8.8 6.3 6.5 6.5 
R28.03 8.8 7.4 8.7 6.3 7.8 8.3 
Z29.01 11.6 8.4 8.5 9.3 8.1 7.9 
Z29.02 11.1 10.7 10.9 10.8   
Z29.03 10.7 12.5 11.6 12.1 9.9 10.8 
A30.01 10.1 7 6.8  6.3 6.1 
A30.02 10.4 11 8 7.7 7.9 7 
A30.03 9.8 10.9 8 6.9 6.6 7.8 
B31.01 6 4.6 4.3 3.2 4.5 3.1 
B31.02 6.2 6 4.7 4.7 5 4.3 
B31.03 7 5.8 5.2 4.3 4.4 4.7 
C32.01 9.6 9.6 7.1 8.2 8.1 7.2 
C32.02 9.6 10.6 10.9 8.6 8.8 9.6 
C32.03 7.5 9.4 8.7 8.4 7.9 9 
D33.01 7.3 6.9 7.2 6.4 6.3 8.2 
D33.02 6.8 8.7 6.8 6.3 6.6 6.6 
D33.03 6.2 9.3 7.1 6.7 8.2 7.7 
H34.01 11.8 8.4 7.4 5.8 5.8 5.7 
H34.02 10.2 9.5 7.2 8.1 7 7.6 
H34.03 11.7 14.6 11 8.9 8.5 7.8 
J35.01 4.7 5 4.5 3.4 3.5 3.6 
J35.02 5.9 6.5 4.1 3.6 3.4 3.7 
210 
 
Monocytes (%) Baseline IP R15 R30 R45 R60 
J35.03 5.6 4.9 6.1 4.9 4.8 4.7 
K36.01 19.2 6.5 5.2 5 5 4.4 
K36.02 7.1 7.2 6.8 6 6.9 7 
K36.03 8 9.2 8.1 6.9 6.6 7.1 
M37.01 8.7 5.5 4.8  5.2 3.6 
M37.02 6.8 5.5 5 4.8 4.7 4.7 
M37.03 7.7  5.4 5.6 4.5 3.7 
O38.01 8.8 6.7 5.5 5.5 5.1 4.8 
O38.02 8.3 8.5 7.6 5.7 7.2 6.4 
O38.03 9 9.6 7.8 6.4 6.7 7.7 
 
 
Eosinophils (%) Baseline IP R15 R30 R45 R60 
B01-1.1 1.6 0.9 1.3 0.6 0.9 0.4 
B01-1.2 0.7 0.9 0.8 0.4 0.5 0.2 
B01-1.3 0.5 0.4 0.8 0.8 1.1 1.1 
E02-1.1 1.5 1.4 1.3 0.7 0.4 0.4 
E02-1.2 3.4 2.4 2.4 2.8 2.4 1.8 
E02-1.3 3.7 2.8 2.8 3.3 3.2 2 
Z03-1.1 2.3 0.9 0.9 1 0.7 0.5 
Z03-1.2 0.9 1.1 1.2 1.1 0.9 0.8 
Z03-1.3  0.8 0.7 0.7 0.8 0.7 
G04-1.1 1.2 1.2 1.4 1.3 1.1 1.2 
G04-1.2 1.9 0.9 1.1 0.9 1 1 
G04-1.3 2.3 3.1 2.6 2.3 1.9 1.9 
P05-1.1 1 1.3 1.3 1.4 0.9 0.9 
P05-1.2 3.2 2.6 2.6 2.7 2.6 1.5 
P05-1.3 1.6 0.9 1.1 0.7 0.8 0.6 
P06-1.1 11.2 10.1 10.7 10.8 9.7 9.2 
P06-1.2 9 6.9 7.9 7.7 7.2 6.7 
P06-1.3 6.8 5.6 5.5 5.2 4.4 3.7 
G07-1.1 3.5 3.3 3 2.9 3.1 3 
G07-1.2 3.9 3.2 3.5 3.4 3.2 3.1 
G07-1.3 3.7 3.2 3.2 3.3 3.2 3.7 
R08-2.1 2.2 2.5 2 1.7 1.2 0.6 
R08-2.2 13.2 12.3 13.6 12.1 9.1 5.1 
R08-2.3 8.7 5.3 5 4.3 3.1 2.4 
R09-2.1 3.3 1.7 2 1.6 1.1 0.7 
R09-2.2 1.8  1.8 1.6 1.8 1.8 
R09-2.3 2.5 1 1.2 0.9 1 1 
W10-2.1 8.8 9.7 9 7.3 6.2 5.9 
W10-2.2 9.3 8.9 9.3 9.2 7.3 5.8 
W10-2.3 10 4.9 8.2 7 4.5 6.4 
S11-3.1 2.1 1.2 1 1.2 1.1 0.9 
S11-3.2 2 2 0.7 0.7 0.7  
S11-3.3 1.1 1 1.1 0.9 0.6 0.7 
T12-3.1 2.5 1.5 1.6 1.2 1 1.2 
T12-3.2 2 1.6 1.7 0.9 1.2 1 
211 
 
Eosinophils (%) Baseline IP R15 R30 R45 R60 
T12-3.3 2.6 1.9 2.1 1.4 1 1.1 
C13-3.1 2.2 1.5 1.4  0.9  
C13-3.2 2 1 1.3 1 0.7  
C13-3.3 1.3 1.6 1.2 1.1 0.8 0.6 
W14-3.1 1.3 0.9 0.7 0.7   
W14-3.2 1.1 0.9 0.9 0.8 0.7 0.6 
W14-3.3 1.3 0.7 1.2 1.1 0.9 0.8 
X15-3.1 2 1 0.8   0.4 
X15-3.2 1.6 1 0.5 0.2 0.3 0.2 
X15-3.3 2 1.2 1 1.2 0.8 0.5 
Y16-3.1 1.1 0.9 1 1.2 0.4 0.5 
Y16-3.2 1 0.6 0.8 0.6 0.4 0.6 
Y16-3.3 1.5 1 0.7 0.9 0.7 0.6 
Z17-3.1 6.3 5 5 4.3 4.4 3.1 
Z17-3.2 8.3 5  3.6 3.2 3 
Z17-3.3 3.2 2.2 1.5 1.6 1.5 1.5 
A18.01 1.1 1.5 1.5 1.2 1.4 1.1 
A18.02 1.5 1.4 1.6 1.3 1.5 1 
A18.03 1.4 0.6 0.6 0.4 0.3 0.3 
B19.01  1.7 1.5 1.2 1.3 0.7 
B19.02 3.9 2.1 2.6 2 1.6 1.5 
B19.03 5.3 2.9 2.3 1.7 1.1 0.5 
D21.01 1.4 0.7 1 0.7 0.7 0.6 
D21.02 2.1 1.1 1.2 1.6 1.4 1.1 
D21.03 2.1 1.4 1.1 1 0.4 0.8 
E22.01 1.3 1.3 1.4 1.2 1.3 1.1 
E22.02 1.7 1.4 1.1 1.1 1 0.8 
E22.03 1.6 1.5 1.1 1.6 0.6 0.8 
J24.01 1.4 0.4 0.4 0.4 0.3 0.1 
J24.02 1.6 0.7 0.3 0.1 0.2 0 
J24.03 2.4 1.9 1.8 1.2 1.3 1.3 
K25.01 1.5 0.7 0.6 1 0.5 0.9 
K25.02 0.8 0.7 0.2 0.3 0.5 1.2 
K25.03 1.5 1.7 1.6 0.9 1.2 1.1 
M26.01 13.1 8.6 7.5 6.1 4.6  
M26.02 9.6 6.4 6.5 4.2 2.8 1.7 
M26.03 15.2 12.2 14.8 13.1 14.9 9.9 
P27.01 3.5 2.6 2.2 2 1.6 1.1 
P27.02 5.7 4.8 3.7 3.9 2.6 2.1 
P27.03 5.6 3.9 4.2 3.5 4 3.7 
R28.01 0.4 0.5 0.5 0.4 0.2 0.2 
R28.02 0.5 0.4 0.3 0.1 0.1 0.2 
R28.03 0.6 0.4 0.6 0.6 0.4 0.2 
Z29.01 4.2 3 2 1.3 0.8 0.8 
Z29.02 3.3 2.8 2.8 1.7   
Z29.03 1 0.7 0.7 0.6 0.7 0.5 
A30.01 2.2 0.4 0.6  0.4 0.4 
A30.02 2.2 1 0.8 0.6 0.5 0.4 
A30.03 2.2 1.6 1.5 0.8 0.8 0.8 
212 
 
Eosinophils (%) Baseline IP R15 R30 R45 R60 
B31.01 2 1.5 1.7 0.8 0.7 0.4 
B31.02 1.2 1.2 1.1 0.5 0.4 0.5 
B31.03 1.9 1.2 0.9 0.5 0.5 0.3 
C32.01 3.7 2.2 1.6 1.7 1.3 1.1 
C32.02 1.5 1.2 1.1 0.9 0.7 0.9 
C32.03 1.7 1.5 1.5 1.3 1.2 0.8 
D33.01 2.5 1.7 2.1 2.1 1.3 2.3 
D33.02 2.1 1.5 1.5 1.5 1.3 1.1 
D33.03 1.5 1.4 1.5 1.2 1.5 1.4 
H34.01 4 1.8 2.8 1.8 1.5 0.7 
H34.02 4.3 2.7 2 1.6 1.2 1.1 
H34.03 4.4 3.1 3 3 2.2 1.8 
J35.01 3 2.7 2.9 2.1 1.9 1.7 
J35.02 2.2 1.6 1.3 1.3 1 1 
J35.03 2.4 2.3 2.4 1.9 1.1 1.3 
K36.01 3 1.1 0.8 0.8 0.4 0.6 
K36.02 1.8 1.1 1 1 1 1 
K36.03 1.5 0.7 1.2 0.7 0.8 0.7 
M37.01 4.5 2.1 1.6  0.9 1.1 
M37.02 4.3 3.1 2.5 1.9 1.9 1.4 
M37.03 3.1  1.5 1.3 1.1 0.7 
O38.01 8.5 4 2.4 1.7 1.6 1.3 
O38.02 9.3 6.6 6.1 4.7 3.9 3.9 
O38.03 12.3 8.4 6.9 5.6 3.7 3.8 
 
 
Basophils (%) Baseline IP R15 R30 R45 R60 
B01-1.1 0.3 0.1 0.3 0.4 0.1 0.3 
B01-1.2 0.4 0.2 0.3 0.1 0.2 0.4 
B01-1.3 0.4 0.4 0.3 0.3 0.5 0.6 
E02-1.1 0.5 0.7 0.7 0.4 0 0 
E02-1.2 0.8 0.4 0.7 0.7 0.8 0.9 
E02-1.3 0.6 0.7 0.6 0.9 0.6 0.8 
Z03-1.1 0.6 0.4 0.6 0.7 0.6 0.5 
Z03-1.2 0.4 0.4 0.7 0.7 0.4 0.7 
Z03-1.3  0.6 0.7 0.6 0.7 0.7 
G04-1.1 0.6 0.4 0.2 0.5 0.5 0.4 
G04-1.2 0.3 0.5 0.3 0.2 0.3 0.3 
G04-1.3 0.4 0.5 0.5 0.4 0.6 0.4 
P05-1.1 0.2 0.3 0.2 0.4 0.3 0 
P05-1.2 0.4 0.2 0 0.3 0.1 0.4 
P05-1.3 0.2 0.2 0.2 0.5 0.3 0.3 
P06-1.1 0.5 0.2 0.7 0.6 0.5 0.7 
P06-1.2 0.4 0.5 0.7 0.6 0.4 0.4 
P06-1.3 0.6 0.8 0.6 0.6 0.5 0.5 
G07-1.1 0.4 0.5 0.3 0.5 0.4 0.4 
G07-1.2 0.5 0.3 0.2 0.1 0.4 0.2 
G07-1.3 0.4 0.3 0.5 0.2 0.4 0.4 
213 
 
Basophils (%) Baseline IP R15 R30 R45 R60 
R08-2.1 0.5 0.5 0.6 0.7 0.5 0.1 
R08-2.2 0.7 0.5 0.4 0.4 0 0.2 
R08-2.3 0.7 0.4 0.8 0.4 0.7 0.5 
R09-2.1 0.6 0.3 0.5 0.4 0.6 0.5 
R09-2.2 0  0.7 0.5 0.7 0.4 
R09-2.3 0.6 0.5 0.8 0.8 0.3 0.6 
W10-2.1 0.5 0.8 0.5 0.6 0.4 0.5 
W10-2.2 0.1 0.5 0.4 0.3 0.4 0.2 
W10-2.3 0.5 0.3 0.5 0.6 0.7 0.5 
S11-3.1 0.7 0.2 0.4 0.3 0.4 0.7 
S11-3.2 0 0 0.3 0.5 0.6  
S11-3.3 0.4 0.4 0.5 0.4 0.3 0.2 
T12-3.1 0.4 0.8 0.9 0.7 0.3 0.4 
T12-3.2 0.5 1 0.5 0.7 0.7 0.6 
T12-3.3 0.5 0.9 0.9 0.5 0.3 0.7 
C13-3.1 0.3 0.4 0.5  0.4  
C13-3.2 0.2 0.4 0.2 0.4 0.4  
C13-3.3 0.5 0.5 0.7 0.3 0.4 0.2 
W14-3.1 0.4 0.6 0.5 0.5   
W14-3.2 0.6 0.7 0.4 0.2 0.6 0.7 
W14-3.3 0.6 0.8 0.5 0.5 0.5 0.4 
X15-3.1 0.5 0.3 0.2   0.2 
X15-3.2 0.2 0.5 0.3 0.1 0.2 0.2 
X15-3.3 0.3 0.3 0.2 0.3 0.5 0.3 
Y16-3.1 0.4 0.2 0.4 0.2 0.3 0.4 
Y16-3.2 0.5 0.3 0.4 0.4 0.3 0.3 
Y16-3.3 0.4 0.3 0.3 0.5 0.3 0.3 
Z17-3.1 0.6 0.7 0.5 0.4 1 0.4 
Z17-3.2 0.7 0.6  0.7 0.5 0.1 
Z17-3.3 0.6 0.5 0.6 0.2 0.6 0.6 
A18.01 0.4 0.4 0.4 0.4 0.5 0.4 
A18.02 0.3 0.4 0.5 0.4 0.3 0.3 
A18.03 0.3 0.5 0.2 0.3 0.3 0.1 
B19.01  0.2 0.3 0.2 0.2 0.1 
B19.02 0.3 1.2 0.5 0.5 0.2 0.3 
B19.03 0.4 0.2 0.3 0 0.1 0.3 
D21.01 0.2 0.2 0.5 0.2 0.1 0 
D21.02 0.2 0.4 0.7 0.3 0.2 0.2 
D21.03 0.5 0.3 0.2 0.5 0.2 0.1 
E22.01 0.2 0.3 0.2 0.1 0 0.1 
E22.02 0.3 0.3 0.2 0.2 0.2 0.1 
E22.03 0.4 0.3 0.2 0 0.1 0 
J24.01 0.6 0.1 0.2 0.2 0.4 0.2 
J24.02 0.4 0.6 0.8 0.7 0.6 0.2 
J24.03 0.4 0.4 0.7 1 0.3 0.6 
K25.01 0.2 0.2 0.3 0.2 0.2 0.1 
K25.02 0.5 0.2 0.3 0.4 0.2 0.2 
K25.03 0.5 0.4 0.4 0.1 0.3 0.5 
M26.01 0.6 0.5 0.5 0.4 0.2  
214 
 
Basophils (%) Baseline IP R15 R30 R45 R60 
M26.02 0.7 0.6 0.7 0.5 0.3 0.3 
M26.03 0.4 0.9 0.6 0.8 1.1 0.7 
P27.01 0.2 0.2 0.2 0.1 0.2 0.2 
P27.02 0.5 0.3 0.3 0.4 0.1 0.1 
P27.03 0.3 0.3 0.2 0.2 0.4 0.3 
R28.01 0.3 0.3 0.4 0.1 0.1 0 
R28.02 0.4 0.5 0.3 0.4 0 0 
R28.03 0.3 0.3 0.5 0.4 0.4 0.5 
Z29.01 0.3 0.1 0.2 0.2 0 0 
Z29.02 0.2 0.2 0.1 0.3   
Z29.03 0.3 0.3 0.3 0.4 0.3 0 
A30.01 0.5 0.4 0  0.3 0.3 
A30.02 0.4 0.2 0.3 0.4 0.2 0.3 
A30.03 0.6 0.5 0.5 0.4 0.4 0.3 
B31.01 0.4 0.4 0.2 0.3 0.3 0.2 
B31.02 0.3 0.4 0.3 0.3 0.3 0.4 
B31.03 0.4 0.4 0.5 0.4 0.2 0.4 
C32.01 0.6 0.5 0.6 0.2 0.5 0.2 
C32.02 0.6 0.4 0.4 0.3 0.5 0.6 
C32.03 0.6 0.3 0.7 0.6 0.8 0.7 
D33.01 0.5 0.7 0.4 0.4 0.5 0.5 
D33.02 0.7 0.5 0.5 0.6 0.2 0.5 
D33.03 0.5 0.5 0.8 0.6 0.5 0.4 
H34.01 0.5 0.7 0.4 0.5 0.4 0.2 
H34.02 0.3 0.3 0.3 0.4 0.3 0.3 
H34.03 0.6 0.3 0.5 0.3 0.6 0.6 
J35.01 0.3 0.3 0.5 0.3 0.2 0.2 
J35.02 0.3 0.3 0.2 0.3 0.2 0.2 
J35.03 0.3 0.3 0.3 0.2 0.2 0.4 
K36.01 0 0.7 0.3 0.4 0.2 0.3 
K36.02 0.4 0.4 0.2 0.3 0.6 0.3 
K36.03 0.5 0.4 0.3 0.4 0.5 0.6 
M37.01 0.6 0.7 0.1  0.3 0.1 
M37.02 0.4 0.5 0.5 0.4 0.3 0.1 
M37.03 0.8  0.5 0.1 0.1 0.1 
O38.01 1 0.6 0.6 0.6 0.5 0.6 
O38.02 0.9 0.6 0.6 1.2 0.8 0.6 










IgG (mg/dl) Baseline IP R15 R30 R45 R60 
B01-1.1 685 725 678 673 664 685 
B01-1.2 678 731 685 677 689 670 
B01-1.3 656 726 675 648 656 656 
E02-1.1 952 1037 1000 973 955 986 
E02-1.2 1000 1088 1023 992 953 998 
E02-1.3 984 1006 967 934 899 921 
Z03-1.1 1323 1362 1318 1281 1278 1341 
Z03-1.2 1272 1361 1306 1234 1312 1240 
Z03-1.3 1267 1328 1252 1210 1231 1234 
G04-1.1 1040 1124 1105 1034 1050 1048 
G04-1.2 1069 1094 1055 1012 1009 1032 
G04-1.3 1091 1261 1131 1085 1014 1017 
P05-1.1 1151 1096 1077 1069 1080 1083 
P05-1.2 1124 1300 1175 1573 1114 1143 
P05-1.3 1195 1166 1145 1172 1122 1119 
P06-1.1 1105 1107 1118 1069 1146 1129 
P06-1.2 1099 1153 1088 1076 1061 1064 
P06-1.3 1029 1349 951 992 978 970 
G07-1.1 949 929 916 926 965 981 
G07-1.2 971 1044 966 941 983 997 
G07-1.3 911 989 926 929 875 910 
R08-2.1 1287 1347 1281 1249 1244 1275 
R08-2.2 1163 1359 1289 1233 1242 1264 
R08-2.3 1222 1380 1252 1249 1228 1258 
R09-2.1 1230 1318 1281 1244 1190 1179 
R09-2.2 1169 1336 1187 1160 1175 1175 
R09-2.3 1294 1436 1368 1325 1267 1255 
W10-2.1 1477 1561 1406 1441 1418 1423 
W10-2.2 1365 1543 1387 1298 1355 1317 
W10-2.3 1445 1557 1474 1398 1430 1309 
S11-3.1 663 745 662 626 630 640 
S11-3.2 568 568 548 521 529  
S11-3.3 655 684 626 607 624 624 
T12-3.1 1166 1276 1130 1086 1112 1066 
T12-3.2 1005 1124 1149 1018 1049 1069 
T12-3.3 1175 1169 1163 1152 1149 1160 
C13-3.1 1169 1279 1109 1074 1254 1228 
C13-3.2 1107 1107 979 1066 927 950 
C13-3.3 1265 1202 1064 1067 1122 1235 
W14-3.1 1052 1091 1100 1030 1075 1103 
W14-3.2 945 1105 1010 971 976 914 
W14-3.3 1093 1096 1025 1027 1073 1117 
X15-3.1 1086 1181 1061 991 1010 1016 
X15-3.2 994 1053 937 1029 1016 968 
X15-3.3 1050 1090 1025 1033 1005 1027 
Y16-3.1 973 1058 1016 986 939 994 
Y16-3.2 989 1067 955 1016 1032 1029 
Y16-3.3 1105 1140 1082 1175 1158 1244 
Z17-3.1 1260 1326 1240 1270 1279 1240 
216 
 
IgG (mg/dl) Baseline IP R15 R30 R45 R60 
Z17-3.2 1138 1155 1102 1086 1099 1154 
Z17-3.3 1338 1323 1302 1354 1336 1388 
A18.01 1150 1159 1100 1091 1085 1074 
A18.02 1041 1088 1011 968 989 976 
A18.03 1032 1076 998 966 1004 972 
B19.01 967 1080 986 986 981 953 
B19.02 1038 1060 976 931 910 918 
B19.03 910 938 894 883 858 855 
D21.01 1094 1210 1103 1037 1080 1031 
D21.02 1169 1227 1107 1099 1093 1088 
D21.03 1151 1258 1163 1118 1118 1127 
E22.01 1123 1225 1115 1077 1071 1141 
E22.02 1141 1209 1195 1138 1141 1149 
E22.03 1076 1279 1205 1130 1142 1190 
J24.01 1046 1104 1038 1068 1033 1052 
J24.02 1073 1097 995 1001 1053 1079 
J24.03 988 1059 1011 938 938 915 
K25.01 934 973 866 848 851 846 
K25.02 834 902 778 780 770 796 
K25.03 820 851 764 751 766 743 
M26.01 1215 1235 1178 1158 1144 1189 
M26.02 1218 1248 1172 1142 1199 1142 
M26.03 1071 1131 1110 1035 1011 1144 
P27.01 1429 1399 1315 1297 1312 1353 
P27.02 1314 1393 1289 1298 1298 1304 
P27.03 1250 1343 1292 1234 1253 1244 
R28.01 1121 1172 1082 1038 1038 1038 
R28.02 1106 1118 1091 1065 1065 1085 
R28.03 1011 1077 1011 985 1002 1014 
Z29.01 1181 1169 1127 1158 1167 1161 
Z29.02 1151 1124 1056 1130  1160 
Z29.03 1113 1153 1068 1014 1095 1080 
A30.01 1619 1643 1484 1558 1795 1546 
A30.02 1757 1789 1643 1640 1643 1666 
A30.03 1618 1775 1634 1600 1655 1575 
B31.01 940 953 856 868 886 873 
B31.02 938 1022 945 889 883 895 
B31.03 936 954 871 843 864 846 
C32.01 1200 1117 1106 1109 1187 1171 
C32.02 1317 1429 1348 1299 1276 1333 
C32.03 1227 1374 1255 1227 1207 1272 
D33.01 808 791 761 808 810 905 
D33.02 784 844 768 751 736 724 
D33.03 759 811 755 735 726 738 
H34.01 1046 1066 1074 1033 1025 1051 
H34.02 1152 1253 1087 1051 1056 1072 
H34.03 1047 1218 1123 1090 1058 1060 
J35.01 779 873 775 765 756 775 
J35.02 775 861 825 796 750 746 
217 
 
IgG (mg/dl) Baseline IP R15 R30 R45 R60 
J35.03 718 801 762 721 738 750 
K36.01 1061 1127 1046 1046 1014 1030 
K36.02 1007 1228 1018 971 974 1026 
K36.03 1034 1148 970 954 988 1017 
M37.01 1520 1537 1446  1637 1579 
M37.02 1385 1616 1443 1368 1380 1431 
M37.03 1398  1424 1359 1316 1316 
O38.01 1187 1146 1168 1154 1217 1160 
O38.02 1171 1331 1219 1173 1179 1231 
O38.03 1107 1241 1143 1154 1140 1145 
R39.01 1168 1207 1187 1162 1151 1085 
       
       
 
IgM (mg/dl) Baseline IP R15 R30 R45 R60 
B01-1.1 203 211 197 200 194 201 
B01-1.2 189 197 180 179 192 178 
B01-1.3 188 204 190 185 184 191 
E02-1.1 51 50 51 48 52 50 
E02-1.2 49 47 45 44 45 46 
E02-1.3 38 41 40 44 36 37 
Z03-1.1 123 122 115 116 115 114 
Z03-1.2 111 114 107 103 107 112 
Z03-1.3 102 110 104 98 104 100 
G04-1.1 93 94 87 87 85 82 
G04-1.2 84 87 82 77 79 78 
G04-1.3 102 107 94 93 93 103 
P05-1.1 168 159 159 156 163 157 
P05-1.2 167 182 162 164 153 156 
P05-1.3 169 164 162 165 164 157 
P06-1.1 127 126 116 115 130 126 
P06-1.2 125 128 119 117 117 117 
P06-1.3 117 126 105 109 104 102 
G07-1.1 143 139 140 138 140 140 
G07-1.2 143 147 140 135 139 151 
G07-1.3 140 139 133 127 122 126 
R08-2.1 115 117 109 107 106 106 
R08-2.2 103 114 109 106 103 106 
R08-2.3 92 103 96 94 89 92 
R09-2.1 105 105 104 101 100 95 
R09-2.2 96 107 95 96 94 94 
R09-2.3 122 136 131 121 118 119 
W10-2.1 170 175 164 163 162 163 
W10-2.2 162 176 156 152 148 147 
W10-2.3 169 172 164 158 155 143 
S11-3.1 39 46 37 38 37 37 
S11-3.2 30 30 28 22 28  
S11-3.3 57 66 61 63 60 60 
218 
 
IgM (mg/dl) Baseline IP R15 R30 R45 R60 
T12-3.1 194 216 196 181 184 179 
T12-3.2 178 194 202 170 188 183 
T12-3.3 197 190 185 187 186 186 
C13-3.1 116 124 110 106 122 117 
C13-3.2 113 108 99 106 91 92 
C13-3.3 123 115 103 98 103 124 
W14-3.1 71 73 74 67 70 75 
W14-3.2 62 71 62 62 62 62 
W14-3.3 79 83 75 74 79 81 
X15-3.1 72 80 67 64 66 66 
X15-3.2 59 62 60 62 60 59 
X15-3.3 64 66 65 60 61 63 
Y16-3.1 89 127 120 115 113 113 
Y16-3.2 114 118 104 114 117 117 
Y16-3.3 118 115 113 122 124 125 
Z17-3.1 208 230 206 207 210 199 
Z17-3.2 182 180 172 174 167 180 
Z17-3.3 196 190 190 191 199 201 
A18.01 75 81 74 70 66 75 
A18.02 62 67 56 58 58 58 
A18.03 60 56 56 51 55 58 
B19.01 67 72 68 67 64 66 
B19.02 76 74 68 68 65 66 
B19.03 80 79 72 72 71 74 
D21.01 40 44 39 40 40 40 
D21.02 41 41 37 37 38 38 
D21.03 38 41 38 37 35 36 
E22.01 95 104 94 86 89 95 
E22.02 93 88 88 87 85 88 
E22.03 76 85 79 76 73 79 
J24.01 146 152 141 141 143 143 
J24.02 145 143 128 132 138 139 
J24.03 134 148 138 131 128 129 
K25.01 82 84 77 75 74 75 
K25.02 71 75 64 65 64 66 
K25.03 68 69 67 57 62 60 
M26.01 112 113 107 105 106 109 
M26.02 115 116 108 107 114 111 
M26.03 101 111 105 95 97 106 
P27.01 204 203 185 191 191 196 
P27.02 206 216 193 196 204 199 
P27.03 186 197 187 182 187 187 
R28.01 101 102 96 84 94 94 
R28.02 100 97 93 92 94 94 
R28.03 91 97 89 88 87 86 
Z29.01 65 62 63 64 65 63 
Z29.02 70 70 63 66  70 
Z29.03 70 75 70 63 74 65 
A30.01 181 171 158 166 190 165 
219 
 
IgM (mg/dl) Baseline IP R15 R30 R45 R60 
A30.02 188 184 171 166 169 178 
A30.03 175 188 182 173 180 170 
B31.01 74 74 67 68 67 69 
B31.02 73 77 71 69 66 69 
B31.03 73 76 67 66 68 64 
C32.01 131 119 118 116 121 121 
C32.02 147 158 146 138 138 144 
C32.03 132 146 137 132 131 133 
D33.01 90 84 83 84 86 95 
D33.02 88 95 89 86 83 84 
D33.03 83 92 83 82 82 80 
H34.01 103 101 96 92 92 95 
H34.02 108 114 103 99 95 98 
H34.03 102 112 109 105 99 99 
J35.01 118 130 120 115 113 121 
J35.02 114 130 123 114 117 116 
J35.03 112 123 115 109 110 111 
K36.01 128 131 121 123 116 121 
K36.02 116 136 111 110 108 113 
K36.03 117 133 113 108 118 117 
M37.01 101 102 94  108 104 
M37.02 84 96 85 83 83 83 
M37.03 95  92 91 88 87 
O38.01 214 201 208 205 214 206 
O38.02 206 234 208 206 206 204 
O38.03 195 208 190 194 195 196 
       
       
 
Oxidative Burst (%) Baseline IP R15 R30 R45 R60 
B01-1.1 100 99 97 98 94 99 
B01-1.2 99 97 98 99 100 99 
B01-1.3 96 95 96 95 96 96 
E02-1.1 99 98 98 100 100 100 
E02-1.2 99 98 96 95 95 97 
E02-1.3 95 98 96 99 94 99 
Z03-1.1 93 96 97 97 98 97 
Z03-1.2 97 95 95 95 96 95 
Z03-1.3  93 94 90 92 94 
G04-1.1 97 71 93 100 97 97 
G04-1.2 94 98 99 99 97 97 
G04-1.3 98 98 98 97 98 98 
P05-1.1 99 100 100 100 97 97 
P05-1.2 99 97 99 99 99 99 
P05-1.3 97 100 100 99 100 100 
P06-1.1 100 97 97 98 99 99 
P06-1.2 96 99 99 99 99 98 
P06-1.3 99 98 99 99 99 99 
220 
 
Oxidative Burst (%) Baseline IP R15 R30 R45 R60 
G07-1.1 99 98 99 98 98 96 
G07-1.2 95 98 98 98 99 99 
G07-1.3 98 98 98 98 98 98 
R08-2.1 100 100 99 100 100 100 
R08-2.2 90 99 99 99 99 100 
R08-2.3 100 97 97 98 98 99 
R09-2.1 99 100 99 100 100 100 
R09-2.2 92 83 85 85 90 93 
R09-2.3 94 94 91 89 87 92 
W10-2.1 100 100 99 100 100 100 
W10-2.2 93 97 93 95 98 96 
W10-2.3 98 98 96 96 97 96 
S11-3.1 95 96 97 98 97 97 
S11-3.2 96 97 92 95 96  
S11-3.3 93 91 92 87 86 95 
T12-3.1 93 96 97 96 97 97 
T12-3.2 98 99 94 98 97 97 
T12-3.3 94 92 96 98 98 97 
C13-3.1 95 93 94 95 96 77 
C13-3.2 96 98 94 92   
C13-3.3 97 90 93 98 98 95 
W14-3.1 94 93 93 95 76  
W14-3.2 96 97 95 94 95 94 
W14-3.3 94 96 97 98 95 97 
X15-3.1 94 93 96 97  94 
X15-3.2 94 94 94 94 94 92 
X15-3.3 94 94 99 93 94 99 
Y16-3.1 97 97 96 97 95 97 
Y16-3.2 97 98 22 96 97 97 
Y16-3.3 97 95 100 98 99 100 
Z17-3.1 95 97 100 99 98 99 
Z17-3.2 96 98  98 98 97 
Z17-3.3 97 97 96 97 98 97 
A18.01 90 94 96 95 98 93 
A18.02 86 89 88 97 92 94 
A18.03 97 98 98 99 99 99 
B19.01 90 100 99 98 99 97 
B19.02 97 93 98 88 97 89 
B19.03 97 95 97 95 97 96 
D21.01 94 93 95 94 98 95 
D21.02 97 92 93 88 92 91 
D21.03 95 97 96 97 97 97 
E22.01 84 93 93 90 83 95 
E22.02 90 87 92 98 85  
E22.03 93 96 93 96 96 95 
J24.01 89 91 93 93 90 91 
J24.02 84 83 90 90 95 96 
J24.03 93 97 92 95 96 94 
K25.01 92 96 97 97 96 94 
221 
 
Oxidative Burst (%) Baseline IP R15 R30 R45 R60 
K25.02 93 96 96 98 95 98 
K25.03 95 94 95 98 94 98 
M26.01 91 96 95 98 96 96 
M26.02 97 97 96 98 98 98 
M26.03 99 98 98 98 99 99 
P27.01 93 95 95 95 96 93 
P27.02 98 99 100 98 100 99 
P27.03 98 100 98 99 98 100 
R28.01 87 84 91 90 83 91 
R28.02 92 83 88 86 90 91 
R28.03 92 94 93 94 93 92 
Z29.01 93 93 95 94 98 93 
Z29.02 99 98 97 99   
Z29.03 100 100 100 99 99 99 
A30.01 99 99 100 99 99 100 
A30.02 89 92 95 95 90 98 
A30.03 93 97 94 100 94 91 
B31.01 98 98 99 99 99 99 
B31.02 86 93 91 91 88 96 
B31.03 96 92 93 93 91 99 
C32.01 98 98 99 99 100 99 
C32.02 82 87 83 83 84 83 
C32.03 95 94 93 93 96 95 
D33.01 100 99 99 99 98  
D33.02 86 94 95 92 94 91 
D33.03 93 83 97 92 94 90 
H34.01 98 98 99 99 99 99 
H34.02 85 92 93 90 93 94 
H34.03 92 100 97 94 94 97 
J35.01 100 99 100 99 99 99 
J35.02 93 93 96 99 98 96 
J35.03 91 92 96 96 97 95 
K36.01 99 99 97 98 100 99 
K36.02 86 85 89 89 82 86 
K36.03 86 87 89 91 94 89 
M37.01 97 100 99  99 99 
M37.02 72 82 80 82 83 85 
M37.03 92  94 86 93 98 
O38.01 98 100 99 100 99 100 
O38.02 96 96 97 94 96 98 








    Visit 1     
    Heart Rate   Time (min) in Heart Rate Zones 











B01-1 176 74 122 21.6 13.9 12.9 6.3 0.0 
E02-1 178 90 136 15.3 9.0 14.2 15.7 0.5 
Z03-1 181 67 130 19.7 9.4 14.9 10.3 0.6 
G04-1 191 68 133 21.5 6.9 11.2 10.0 5.8 
P05-1 195 90 145 12.4 7.8 10.6 15.1 8.4 
P06-1 217 39 125 22.9 4.0 6.5 9.3 12.5 
G07-1 166 77 116 30.4 17.9 6.1 0.9 0.0 
R08-2 202 91 156 1.1 6.8 17.8 19.6 9.3 
R09-2 204 116 163 0.3 2.0 17.1 19.7 16.4 
W10-2 182 85 133 10.2 23.5 12.0 7.7 0.7 
S11-3 222 79 132 18.8 19.1 8.6 11.8 3.5 
T12-3 200 84 154 1.5 13.3 19.0 12.2 15.5 
C13-3 210 93 135 15.5 22.7 9.1 10.3 4.4 
W14-3 218 95 151 1.2 13.7 21.1 17.8 7.6 
X15-3 217 82 152 2.9 13.5 17.9 14.2 13.6 
Y16-3 193 82 131 24.1 11.5 11.3 11.6 3.4 
Z17-3 196 81 143 7.0 22.2 10.3 11.1 10.6 
A18-04 200 45 141 9.3 7.5 7.8 8.0 11.5 
B19-04 201 68 157 1.3 4.4 14.1 14.3 10.1 
D21-04 192 73 142 6.8 10.9 11.2 12.6 2.8 
E22-04         
J24-05 193 75 142 12.2 20.7 4.9 14.2 9.3 
K25-05 191 41 132 22.8 16.1 3.2 9.3 9.4 
M26-05 240 73 146 11.2 20.9 6.3 12.3 11.2 
P27-05 218 80 146 1.8 25.4 12.2 12.2 9.4 
R28-05 199 74 136 22.7 12.9 4.3 10.8 11.2 
Z29-05 194 79 141 14.6 20.8 4.1 7.3 15.8 
A30-06 236 85 146 13.2 15.9 6.4 5.7 18.6 
B31-06 239 85 140 8.6 25.7 6.8 11.9 5.8 
C32-06 201 96 146 10.0 19.9 7.7 3.2 19.1 
D33-06 187 79 135 15.3 21.1 6.9 8.8 7.2 
H34-06 193 96 143 1.3 31.1 6.3 14.8 6.5 
J35-06 185 66 125 31.5 8.9 3.8 14.7 1.9 
K36-06 192 77 141 12.0 16.7 12.1 2.7 15.7 
M37-06 191 79 147 4.5 20.1 13.5 5.1 16.0 





    Visit 2     
    Heart Rate   Time (min) in Heart Rate Zones 











B01-1 180 66 102 34.9 2.2 0.3 3.5 2.3 
E02-1 179 76 100 35.2 2.5 0.5 4.6 1.0 
Z03-1 196 87 139 8.3 8.8 11.7 8.8 4.7 
G04-1 187 78 122 14.7 7.3 5.2 4.9 1.3 
P05-1 196 84 131 17.0 6.4 6.0 7.9 5.7 
P06-1 204 99 147 7.4 5.1 5.4 7.3 8.7 
G07-1 167 86 111 21.2 6.4 4.9 1.6 0.0 
R08-2 190 102 138 20.5 4.8 5.2 15.0 6.8 
R09-2 198 104 128 25.5 7.1 4.5 8.9 6.1 
W10-2 169 79 105 38.2 6.2 6.0 3.5 0.0 
S11-3 227 81 130 31.2 4.7 1.9 21.9 3.4 
T12-3 203 86 145 8.6 24.8 2.8 3.7 20.5 
C13-3 202 85 136 23.4 11.3 3.2 17.0 6.7 
W14-3 200 100 148 1.6 24.7 13.5 5.0 16.2 
X15-3 196 111 151 7.5 18.3 8.1 4.8 22.5 
Y16-3 226 27 131 31.1 4.4 1.5 15.5 9.7 
Z17-3 205 72 148 6.8 21.7 6.9 4.2 21.4 
A18-04 190 93 138 8.5 15.4 8.2 7.0 4.5 
B19-04 215 100 150 5.5 8.7 8.3 11.2 9.3 
D21-04 195 73 131 18.5 8.6 4.9 4.9 7.0 
E22-04 161 44 99 27.6 7.7 7.0 2.5 0.0 
J24-05 191 105 164 1.0 1.5 12.6 23.9 14.7 
K25-05 189 78 154 5.0 9.0 9.9 12.8 18.2 
M26-05 222 77 156 4.1 5.7 14.6 17.3 12.4 
P27-05 225 97 160 2.5 4.5 11.5 21.6 14.0 
R28-05 190 71 157 2.0 6.0 12.9 21.8 11.2 
Z29-05 191 96 160 1.8 5.7 9.4 22.1 14.1 
A30-06 199 82 135 8.5 21.1 17.1 5.7 2.7 
B31-06 192 90 142 2.5 18.6 23.0 8.6 2.4 
C32-06 232 100 141 12.9 14.4 10.3 11.0 7.7 
D33-06 181 75 115 36.2 13.2 4.0 1.9 0.4 
H34-06 190 92 143 2.6 10.6 33.4 7.6 1.7 
J35-06 176 70 119 26.4 19.3 7.8 2.6 0.1 
K36-06 191 36 118 20.0 19.3 12.9 1.9 1.9 
M37-06 191 77 144 5.5 18.7 13.1 4.2 14.3 





    Visit 3     
    Heart Rate   Time (min) in Heart Rate Zones 











B01-1 173 70 146 0.9 5.4 10.1 7.7 0.0 
E02-1 171 73 127 9.4 5.8 4.6 5.1 0.0 
Z03-1 191 76 148 1.0 7.2 7.1 5.5 3.9 
G04-1 195 99 139 10.7 7.9 10.9 9.0 5.0 
P05-1 204 87 168 0.3 0.0 4.8 10.5 8.7 
P06-1 204 93 144 10.2 11.0 3.6 6.9 11.2 
G07-1 176 89 110 35.0 2.0 1.0 6.4 0.0 
R08-2 211 84 124 20.0 7.3 5.0 6.1 3.8 
R09-2 217 109 149 10.2 10.3 5.1 5.0 17.5 
W10-2 196 85 118 25.2 11.6 5.4 3.9 2.6 
S11-3 239 69 130 31.2 5.6 3.3 12.6 5.6 
T12-3 193 38 140 5.0 23.1 13.2 4.0 12.6 
C13-3 240 45 136 32.2 8.4 0.6 0.3 18.2 
W14-3 212 64 133 10.7 17.6 13.4 10.9 5.4 
X15-3 233 82 155 0.8 23.3 10.3 1.4 22.9 
Y16-3 197 53 131 27.8 9.4 3.4 13.0 5.3 
Z17-3 196 74 141 13.7 17.8 5.9 8.0 12.0 
A18-04 198 138 175 0.0 0.2 5.2 17.0 34.6 
B19-04 192 96 166 0.0 1.2 13.5 27.1 15.1 
D21-04 205 88 163 0.9 5.3 14.1 16.3 19.5 
E22-04 192 56 148 5.3 8.9 19.0 15.4 7.3 
J24-05 192 77 140 5.6 8.0 16.2 5.5 3.4 
K25-05 180 48 125 11.5 14.1 7.8 4.1 0.7 
M26-05 180 72 142 5.8 4.0 13.5 14.8 0.5 
P27-05 217 80 143 6.3 5.5 15.1 8.0 3.3 
R28-05 195 78 142 4.0 9.1 14.8 5.8 4.3 
Z29-05 197 100 162 1.4 2.0 5.4 21.2 8.3 
A30-06 194 51 127 23.8 5.9 4.6 8.0 6.7 
B31-06 179 100 140 5.8 14.2 13.1 14.4 0.4 
C32-06 193 74 138 15.0 9.6 6.6 8.6 8.8 
D33-06 168 78 99 36.6 7.5 5.0 1.2 0.0 
H34-06 187 41 136 6.4 14.2 15.0 10.7 2.8 
J35-06 215 67 123 24.9 7.8 8.6 6.0 2.2 
K36-06 178 27 110 28.5 8.7 7.9 4.3 0.4 
M37-06 224 76 154 1.0 16.2 7.6 11.0 13.5 
038-06 176 42 111 30.3 7.9 6.5 5.2 0.1 
 
